Clinical multi-parameter purification of human central memory T cells for adoptive therapy

Jeannette Bet

Vorsitzender: Univ.-Prof. Dr. P. A. Knolle
Prüfer der Dissertation: 1. Univ.-Prof. Dr. D. Busch
                                      2. Univ.-Prof. Dr. M. Groll

Die Dissertation wurde am 03.07.2014 bei der Technischen Universität München eingereicht und durch die Fakultät für Medizin am 19.11.2014 angenommen.
Publications:

**Bet, J. et al.** *Direct ex vivo clinical-grade multi-parameter purification and characterization of human central memory T cells for adoptive therapy*  
(manuscript in preparation)

Parts of this thesis were previously published:


Contents
1. Summary .............................................................................................................................................. 5
2. List of Abbreviations ............................................................................................................................. 6
3. Introduction ........................................................................................................................................... 8
   3.1 T cell-mediated immunity ............................................................................................................... 8
       3.1.1 Antigen-recognition and function of T cells .............................................................................. 8
       3.1.2 T cell development ............................................................................................................... 9
       3.1.3 The course of a T cell-mediated immune response ..................................................................... 10
       3.1.4 T cell subset differentiation .................................................................................................... 11
       3.1.5 Distinct immunological roles of T cell subpopulations ............................................................ 14
       3.1.6 The role of T cells in controlling malignant diseases ............................................................... 15
3.2 Adoptive T cell therapy ..................................................................................................................... 17
       3.2.1 Early developments in adoptive cellular therapy ...................................................................... 17
       3.2.2 Genetically re-directed T cells for adoptive immunotherapy ................................................. 20
       3.2.3 Chimeric antigen receptor-engineered T cells ......................................................................... 21
       3.2.4 Finding the ideal T cells for adoptive therapy ....................................................................... 22
3.3 Purification of T cell populations ....................................................................................................... 24
       3.3.1 Methods for human T cell isolation .......................................................................................... 24
       3.3.2 Comparison of different strategies for cell separation .............................................................. 25
       3.3.3 Principle of the reversible Streptamer Technology .................................................................. 26
       3.3.4 Fab-Streptamers and serial enrichment .................................................................................. 28
       3.3.5 Clinical isolation of T cell subpopulations ............................................................................. 29
3.4 Current needs for clinical cell processing and adoptive transfer of T cells ............................................ 30
4. Aim of this thesis .................................................................................................................................... 31
5. Results .................................................................................................................................................. 32
   5.1 Ex vivo Streptamer staining for phenotypic markers on human PBMCs ........................................... 32
       5.1.1 Clones and mutations of Fab fragments ................................................................................... 32
       5.1.2 Evaluation of Fab Streptamer stainings ................................................................................... 34
   5.2 Reversibility of Fab Streptamer stainings .......................................................................................... 42
       5.2.1 Critical parameters for reversibility of Fab fragments .............................................................. 42
       5.2.2 Development of an assay for testing reversibility of Fab fragments ........................................ 44
       5.2.3 Evaluation of anti-human Fab fragments for reversibility ....................................................... 48
   5.3 Streptamer-based selection of ex vivo human PBMCs using nano-sized paramagnetic microbeads .................................................................................................................................................. 56
5.4 Development of a pre-clinical multi-parameter purification protocol using larger magnetic microbeads

5.4.1 Optimal parameters for magnetic microbead selections

5.4.2 Sequential positive magnetic enrichment over two parameters

5.4.3 Sequential positive magnetic enrichment of central memory T cells

5.4.4 CD45RA depletion

5.4.5 Sequential selection of CD8 and CD4 central memory T cells

5.5 A Streptamer technology-based protocol for the selection of human TCM in compliance with GMP-manufacturing of cell products

5.6 Further developments in TCM purification

5.6.1 Centrifugation-free purification of central memory T cells out of PBMCs

5.6.2 Transfer of the Streptamer-based TCM purification protocol to an affinity-based non-magnetic cell selection technology

5.6.3 Whole blood purification process without the need for prior density gradient centrifugation

6. Discussion

6.1 Advantages of central memory T cells for adoptive T cell therapy

6.2 Central memory T cell subset selection

6.3 Advantages of reversible reagents for positive selections

6.3.1 Reversible reagents improve multi-parameter positive selections

6.3.2 Circumventing problems caused by remaining sort markers

6.4 Generation of Fab Streptamer reversibility

6.5 Optimization of positive magnetic selection with larger magnetic microbeads

6.6 Clinical applications for Streptamer-based TCM purification

6.7 Clinical trial using Streptamer-enriched TCM for immune reconstitution of post HPCT patients

7. Material and Methods

7.1 Material

7.1.1 Equipment

7.1.2 Chemicals and reagents

7.1.3 Media and buffers

7.1.4 Antibodies and conjugates

7.1.5 Cells

7.1.6 Software

7.2 Methods

7.2.1 Ficoll density centrifugation and determination of cell numbers

7.2.2 Cryopreservation of human lymphocytes and cell lines
7.2.3 Activation of T lymphocytes ................................................................. 114
7.2.4 *In vitro* cultivation and expansion of T lymphocytes ...................... 114
7.2.5 Fab expression and purification .......................................................... 114
7.2.6 T lymphocyte-mediated kill assay (Chromium release assay) ........... 115
7.2.7 Antibody and *Streptamer* staining with subsequent FACS analysis .... 116
7.2.8 MACS sorting ...................................................................................... 116
7.2.9 Magnetic microbead sorting ................................................................. 116

8. Acknowledgements ................................................................................. 118
9. Bibliographie .......................................................................................... 120
1. Summary

**Background:** Adoptive transfer of primary or genetically modified T cells is a promising treatment for malignant or chronic infectious diseases. Inefficient engraftment, limited persistence and protectivity of *in vitro* expanded cells often still impair therapeutic success. Different T cell subpopulations (for example central memory and effector memory) are not equally suitable for patient treatment, and optimal functionality and longevity of transferred cells are crucial for therapeutic efficacy. Recent studies indicate that antigen-specific central memory T cells are capable of giving rise to long-term persistent T cell responses and have an excellent safety profile. Therefore, this T cell subset seems to have clear advantages for adoptive immunotherapy. However, direct isolation of central memory T cells was so far hampered by the lack of clinical multi-parameter selection platforms.

**Results:** We developed a three-step serial magnetic selection procedure based on the fully reversible *Streptamer* technology targeting CD3⁺, CD62L⁺ and CD45RA⁻ central memory T cells. We established isolation of human central memory T cells in a closed system using equipment and consumables that have been previously approved for clinical use and present a GMP-compliant protocol to manufacture purified T cell products for the use in patients. We validated phenotype and function of purified subsets, which can then be used directly for adoptive transfer or further modified *in vitro*. We have further tested new tools for a faster purification of central memory T cells e.g. a column for the removal of reagents.

**Conclusion:** We demonstrate that central memory T cells can be purified to high purities and with high yields under GMP-compliant conditions using a fully reversible serial enrichment procedure. This procedure can in principle be adapted to select cell subsets based on any constellation of cell surface markers, and may provide a means of ensuring more defined T cell products for adoptive cellular therapy.
## 2. List of Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIDS</td>
<td>acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>APC</td>
<td>antigen presenting cells</td>
</tr>
<tr>
<td>ATMP</td>
<td>advanced therapeutic medicinal product</td>
</tr>
<tr>
<td>CAR</td>
<td>chimeric antigen receptor</td>
</tr>
<tr>
<td>CD</td>
<td>cluster of differentiation</td>
</tr>
<tr>
<td>CDR</td>
<td>complementarity determining region</td>
</tr>
<tr>
<td>CMV</td>
<td>cytomegalovirus</td>
</tr>
<tr>
<td>CTL</td>
<td>cytotoxic T lymphocyte</td>
</tr>
<tr>
<td>DC</td>
<td>dendritic cell</td>
</tr>
<tr>
<td>DLI</td>
<td>donor lymphocyte infusion</td>
</tr>
<tr>
<td>EBV</td>
<td>Epstein-Barr-virus</td>
</tr>
<tr>
<td>FACS</td>
<td>fluorescent activated cell sorting</td>
</tr>
<tr>
<td>GMP</td>
<td>good manufacturing practice</td>
</tr>
<tr>
<td>GvHD</td>
<td>graft-versus-host disease</td>
</tr>
<tr>
<td>HIV</td>
<td>human immunodeficiency virus</td>
</tr>
<tr>
<td>HLA</td>
<td>human leukocyte antigen</td>
</tr>
<tr>
<td>hr/hrs</td>
<td>hour/hours</td>
</tr>
<tr>
<td>IFNγ</td>
<td>interferon gamma</td>
</tr>
<tr>
<td>IL-2</td>
<td>interleukin-2</td>
</tr>
<tr>
<td>mAb</td>
<td>monoclonal antibody</td>
</tr>
<tr>
<td>MACS</td>
<td>magnetic-activated cell sorting</td>
</tr>
<tr>
<td>MHC</td>
<td>major histocompatibility complex</td>
</tr>
<tr>
<td>min</td>
<td>minute/minutes</td>
</tr>
<tr>
<td>nm</td>
<td>nanometer</td>
</tr>
<tr>
<td>PBL</td>
<td>peripheral blood lymphocyte</td>
</tr>
<tr>
<td>PBMC</td>
<td>peripheral blood mononucleated cell</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PE</td>
<td>phycoerythrin</td>
</tr>
<tr>
<td>PI</td>
<td>propidium iodide</td>
</tr>
<tr>
<td>rpm</td>
<td>rounds per minute</td>
</tr>
<tr>
<td>ScFv</td>
<td>single-chain variable fragment</td>
</tr>
<tr>
<td>T&lt;sub&gt;CM&lt;/sub&gt;</td>
<td>central memory T cell</td>
</tr>
</tbody>
</table>
TCR  T cell receptor
T_E  effector T cell
T_EM  effector memory T cell
T_EMRA  effector memory CD45RA-positive T cell (terminally differentiated)
TIL  tumor-infiltrating lymphocyte
T_REG  regulatory T cell
T_SCM  memory stem cell (T cell)

Logical operators
+  set union
\cap  intersection / cut set
3. Introduction

3.1 T cell-mediated immunity

T cells are part of the adaptive immune system. The highly specific recognition of a large spectrum of ligands encoded or expressed by different pathogens is a unique feature of adaptive immunity in contrast to innate immunity [4]. Another hallmark of adaptive immunity is the ability to generate a life-long immunologic memory through formation of memory B and T cells, which protect individuals upon clearance of infection or following vaccination [5, 6]. Both, the adaptive and innate branch of the immune system, cooperate in a complex network of interactions. The immunological role of T cells is multilayered and involves both effector and regulatory functions. T cells patrol tissues in search of infected or degenerated cells and in the optimal case destroy those cells or control the activity of other immune cells. The immune system has evolved side-by-side with pathogens, the cause of infections, and is therefore highly adapted to protect the host through various specialized mechanisms. The infusion of a patient with specific T cells has meanwhile developed into a very promising treatment for some virus infections. Similarly, a protective but less well understood role is assigned to T cells in the context of malignant diseases. Although certain subsets of T cells have been described that infiltrate the tumor microenvironment and support tumor growth, the exploitation of anti-tumor immunity through adoptive transfer of tumor-reactive effector T cells is regarded as a potentially curative therapy for some cancers. Some important parameters that determine persistence and functionality of infused T cells are believed to be cell-intrinsic features linked to the cell phenotype. Therefore, the efficacy of T cell-based therapies might be improved by understanding the differential role of T cell subsets and by developing strategies to efficiently purify well-defined cell populations.

3.1.1 Antigen-recognition and function of T cells

T and B lymphocytes- are equipped with specialized receptors capable of binding an enormous variety of ligands. The T and B lymphocyte antigen receptors are generated during their development by somatic recombination, a gene rearrangement process through which defined gene fragments are nearly randomly combined from different gene sets [7]. Thus, a broad repertoire of diverse immune receptors is produced.

T cell receptors (TCRs) are heterodimeric cell surface structures, usually consisting of membrane-anchored α and β subunits. The major histocompatibility complex (MHC) is capable to present short
peptide fragment (8-12 amino acids) derived from protein degradation. TCRs recognize peptide-MHC complexes as their ligand. Thereby, recognition of both the peptide fragment as well as the relevant MHC molecule is required for T cell activation, and is termed MHC restriction [8].

Two main groups of functionally distinct T cells are characterized by the class of MHC molecules that they recognize. CD8⁺ T cells usually recognize epitopes presented by MHC class I molecules, which are expressed in all tissues on all nucleated cells. CD4⁺ T cells recognize antigen in the context of MHC class II molecules, which are expressed in a more restricted manner by professional antigen presenting cells of the innate and adaptive immune system, namely dendritic cells (DCs), macrophages, and B cells. The structure and generation of peptide-MHC complexes is similar but not identical for the two classes of MHC. The most important difference is the origin of the presented peptide, which they display on the cell surface. Peptides presented by MHC molecules originate either from the cytosol (MHC class I) or from vesicles with content taken up from the extracellular space (MHC class II) [9]. Therefore, CD8⁺ T cells mainly take over the role of inspecting the content of nucleated cells and thus detect foreign proteins of viruses and intracellular pathogens as well as mutated proteins in cancerous cells. However, exceptions from these strict presentation pathways have been reported. Under defined circumstances, presentation of extracellular antigens by MHC class I as well as MHC class II presentation of cytosolic antigen can play an essential role in generating a potent T cell response.

CD8⁺ and CD4⁺ molecules function as co-receptors of the TCR. By co-binding to the same MHC molecule as the respective TCR, they enhance T cell binding and signaling. Mature CD4⁺ and CD8⁺ T lymphocytes also differ in their effector functions. CD4⁺ T cells, also termed T helper cells, control the activity and maintenance of other immune cells. They induce maturation and activation of B cells or innate immune cells, for example. However, some CD4⁺ T cells with cytotoxic activity have also been reported [10]. A substantial fraction of CD8⁺ cells on the other hand are predestined to become cytotoxic effectors capable of killing target cells upon activation [11] (see chapter 3.1.3 for a detailed description of T cell cytotoxicity).

### 3.1.2 T cell development

Like all blood cells, T lymphocytes arise from multipotent hematopoietic stem cells in the bone marrow. During their development, they undergo rigorous positive and negative selection events in the thymus. Selection of T cells is based on their respective TCR. This is essential both to ensure a repertoire of T cells capable of binding to self-MHC and delete potentially harmful cells that might attack healthy tissue. Roughly 95% of T cells do not withstand thymic selection. During positive selection, TCRs are screened for their capability to bind self-MHC within a defined affinity range. Those that do not bind sufficiently to self-MHC die by neglect [12]. Subsequent negative selection compels T cells that respond too strongly to self-MHC into apoptosis in order to delete potentially
autoreactive cells. After thymic selection, mature T lymphocytes become part of the lymphatic system and bloodstream as naïve T cells, which continually circulate through the lymphatic tissues in the search for foreign antigen. Their state is defined as naïve until activation through the first encounter with their cognate peptide-MHC complex.

At least two different signals are necessary to activate naïve T cells. This process is called ‘priming’. ‘Signal one’ is the binding of the peptide-MHC complex through the TCR. ‘Signal two’ is determined by the ligation of co-stimulatory molecules of the B7 protein family through co-stimulatory receptors of which CD28 is best characterized. Furthermore, secreted cytokines, often termed “signal three” are needed for the expansion phase of an immune response.

### 3.1.3 The course of a T cell-mediated immune response

The innate immune system is generally the first branch to respond to pathogen encounter resulting in activation of antigen presenting cells (APCs) which leads to initiation of the adaptive immune response. A typical T cell-mediated immune response can be subdivided into three consecutive phases: priming, expansion, and contraction. Initiation takes place when activated professional APCs provide the cognate TCR epitope plus co-stimulation to a naïve pathogen-specific cell (priming). With the support of secreted cytokines, rapid clonal expansion and differentiation into effector cells is initiated upon repetitive encounter with the respective antigen. Driven by cytokines, activated T cells can give rise to thousands of daughter cell bearing identical pathogen-specific TCRs (expansion phase). The expanding clones together guarantee a large pool of effector cells, usually reaching a peak in cell numbers around 7-10 days after initial antigen encounter. Subsequently, many of these cells undergo apoptosis upon clearance of the infection, leaving only a small fraction of pathogen-specific long-living memory T cells (contraction phase). Clonal expansion and consecutive contraction are closely linked to differentiation into subsets with distinct function (chapter 3.1.5).

Once developed into effector cells, T cells respond to antigen without strict dependency on co-stimulatory signals just by triggering of the T cell receptors [13-15]. Activated CD4+ T cells provide help to B cells for the differentiation into antibody producing plasma cells. CD8+ T cells combat infected cells through formation of close contacts with their respective target cell [16, 17]. Effector proteins of CD8+ T cells, which are released at the site of interaction with the target cell, are, for example, perforin and proteins of the granzyme family. Perforin multimerizes to form a lytic pore in the target cell membrane. Through these pores, protein degrading granzymes as well as ions and water can enter and ultimately lyse the target cell. Beyond that, other, perforin-independent mechanisms of target cell killing have been described: the induction of apoptosis upon binding of the receptor Fas-ligand (CD178) to the Fas molecule (CD95). Furthermore, a pathway of cell-mediated death distinct from Fas receptor-induced apoptosis is known to be activated by the antimicrobial protease granulysin.
Besides these mechanisms, direct effector functions of cytokines, such as antiviral effects of interferons, have been described [19, 20]. CD8+ T cells play a particularly important role in the control of viral infections. However, not all viruses can enter and infect dendritic cells, the most specialized cells in priming of T cells directly. Therefore, dendritic cell mediated cross-priming ensures activation of virus-specific cytotoxic T cells by presentation of extracellular antigens through MHC class I. This mechanism is a requirement for the induction of cytotoxic immunity through all peptide-based vaccinations and plays a particularly important role in engaging tumor immunity against most tumors, some of which can impair dendritic cell function [21-23]. Taken together, the role of T cells is to patrol the tissues, to kill pathogen infected cells or cancer cells (CD8+) upon activation, or they help to augment or dampen the activity of other components of the immune system in response to a specific antigen (CD4+). T cells are essential for sustained protection, which gets altered during (therapeutic) suppression of the immune system or in some immune deficiencies. Patients suffering from the acquired immune deficiency syndrome (AIDS), which destroys CD4+ T cells, have a higher prevalence for some cancers, e.g. lung cancer [24]. Further, individuals without a functional T cell compartment because of a genetic disorder often suffer from severe bacterial, viral, or fungal infections [25]. Similarly, upon allogeneic hematopoietic stem cell transplantation, recovery of a functional T cell system can take many months and therefore infections or reactivation of latent chronic infections can cause severe disease [26-28]. In line with this, long term suppression of the immune system to avoid rejection of organ transplants is associated with an increase in cancer incidence, for example following kidney transplantation [29].

3.1.4 T cell subset differentiation

T cell differentiation is associated with changes in phenotype, metabolism, life-span, proliferative capacity, and function. How and when fate decisions are made and how subsets differentiate has been thoroughly investigated throughout the last decades. It has been shown that a single naïve T cell precursor is capable of giving rise to all antigen-experienced subsets, namely effector, central memory, and effector memory T cells [30, 31]. For the diversification of T cells out of naïve precursor T cells, different models have been suggested. According to the linear differentiation model, naïve T cells develop first into effector T cells, a subset of which then continue to develop into memory T cells. The model of progressive differentiation on the other hand describes a differentiation progressing from slowly proliferating memory subsets to rapidly proliferating subsets with decreased differentiation plasticity. Corresponding to the latter model, differentiation largely depends already on early signals, postulating that memory T cells might already be detectable during an immune response before the contraction phase [32, 33]. There is indeed evidence for the occurrence of memory T cells based on lineage markers as early as day 4 in infections of mice with Listeria monocytogenes [34]. Furthermore, T cells of the memory compartment represent an earlier stage of differentiation than their effector
counterparts. Presumably, central memory T cells (T_{CM}) are generated very early from naïve precursors during the course of an infection before the effector memory compartment is established [35]. Similarly, an early stage of differentiation for the memory compartment in contrast to the effector compartment has been stated, when patients with infections with persistent viruses were monitored [36]. Only recently some groups have shed light on the kinetics of differentiation on a single-cell level, providing strong evidence that naïve precursor cells can give rise to subsets that are associated with a high capacity for self-renewal validated by serial transplantation of donor-derived cells [37]. Central memory precursor cells, which arise early from naïve T cells followed by effector memory and effector precursors, uniquely reveal the capacity to differentiate into all but naïve subsets and are associated with a high capacity for self-renewal, which is verified by adoptive transfer of single cells and in vivo fate mapping of single cells [38, 39].

Recently, a multi-potent pool of memory stem cells (T_{SCM}) characterized by an even less differentiated phenotype among memory cells and increased proliferative capacity and survival has been described in mice and later in humans. Human T cells with a T_{SCM} phenotype were found within a T cell compartment which is characteristic for naïve T cells but have phenotypic and functional properties distinct from those of naïve or memory T cells like high expression of CD95, increased proliferation capacity, and more efficient reconstitution of immunodeficient hosts [40-42]. Furthermore, in a pre-clinical study in a humanized mouse model, T_{SCM} mediated superior anti-tumor responses [41]. Compared with other memory T cell subsets, T_{SCM} conferred superior immune responses against tumors and better proliferative capacity upon adoptive transfer in mice [42]. Like naïve T cells, T_{SCM} were found to be capable of differentiating into T_{CM}, T_{EM}, and T_{E} subsets as well as maintaining themselves by homeostatic proliferation. Although T_{SCM} were further hypothesized to be responsible for the maintenance of the memory T cell pool based on these findings, it remains unverified whether this memory subset arises in T cell responses to every antigen, like other memory subsets. However, serial adoptive transfer experiments on the single-cell level and subsequent re-expansion of single T_{CM}-derived T cells has led to the revelation of true stemness for an epitope-specific immune response in the T_{CM} compartment [43]. Therefore repetitive transfusion of single cells of the T_{CM} pool over three generations of mice was conducted revealing that the T_{CM} subset possesses essential traits of regular tissue stem cells. These findings challenge the suggested role of the T_{SCM} subset as a source for sustaining long-term memory. These findings have tremendous impact on the development of new therapies, especially adoptive T cell therapy, through identification of most suitable candidates for adoptive transfer to provide a durable and functionally diverse immune response. The functional attributes associated with stem cell-like memory T cells, high proliferative capacity and continuous self-renewal, can be most suitable for the adoptive transfer of low numbers of T cells with long-term in vivo survival. Thus, re-transfers of short-term effector cells could be avoided [44]. Particularly naïve and central memory T cells, which reveal highest capacity of diversification, have been thoroughly investigated for their in vivo behavior upon adoptive transfer. Both subsets have been
shown to possess the ability to fully reconstitute the whole subset diversity of the T cell compartment [45, 46].

Along this line, the in vivo survival of T_{CM}S upon adoptive transfer has been investigated and proven to be superior to the one of T_{EM}S (and T_{E}s) in animal models and patients, and has proven more successful for T_{CM} [47-50].

Memory T cells change the expression of many surface molecules as they differentiate from naïve T cells. Some of these surface markers are expressed differentially between the two memory subsets T_{CM} and T_{EM}. Changes occur mainly in the surface molecules L-selectin (CD62L) and CD45. While naïve T cells exclusively express the RA splice variant of the tyrosine phosphatase CD45 (CD45RA), memory cells are mostly found to express the variant CD45RO. Molecules of the CD45 family act by modulating signaling in T cells. Further, T_{CM}S can be phenotypically segregated from T_{EM} subsets by the characteristic expression of the markers CCR7 and CD62L (lymph node homing receptor). The combination of both characteristics allows discrimination of short-lived effector T cells from naïve, effector memory and central memory T cells [51, 52]. Thus, the surface molecules CD45RO and CCR7 (or CD62L) together with a T cell marker (either CD3 or CD4 and CD8) can strictly segregate T_{CM} from all other subsets.

The abovementioned findings argue that T_{CM} can be of superior quality for adoptive T cell therapy (see chapter 3.2.4) [32]. Fig. 1.1 illustrates chosen aspects of T cell differentiation with respect to their grade of differentiation and phenotype. It is obvious that precisely defined, functional subsets can only be characterized by a combination of at least two markers.
Fig. 1: Changes in phenotype and characteristics during T cell differentiation.

The relative expression levels of classical effector proteins (perforin and IFNγ), homing receptors (CCR7 and CD62L), the signaling molecule CD45RA and Interleukin-2 are displayed dependent on the grade of T cell differentiation [36]. The progressive differentiation model is represented in the order of T cell subsets. With regard to the characteristics of less differentiated T cell subsets, aspects like self-renewal and multipotency are believed to be associated with higher therapeutic efficacy.

### 3.1.5 Distinct immunological roles of T cell subpopulations

As previously described, we distinguish at least between naïve, effector, effector memory, and central memory T cell subsets, all of which can be associated with distinct activation requirements and a characteristic phenotype composed of a combination of cell surface markers suggesting a division of labor between the subsets. Compared to naïve T cells, memory subsets are maintained at higher frequencies, have been shown to respond to a specific antigen or epitope without the requirement for co-stimulation and interact more efficiently with dendritic cells in *in vitro* cultures [52-55].

Effector T cells are associated with one or multiple immediate effector functions and a relatively short lifespan in the absence of specific antigen. Survival of these cells is dependent on the availability of antigen-dependent signals and cytokines [56]. Memory subsets are long-lived and are maintained mainly by cytokines. Central memory T cells can be distinguished from effector memory T cells as follows: CD45RO⁺ CD62L⁺ T cells (all T cells are CD3⁺) are referred to as central memory T cells,
whereas CD45R0+ CD62L− CD3+ cells are defined as effector memory T cells. These subpopulations can be found in the CD4+ and in the CD8+ T cell pool alike. Based on differential expression of the homing receptor CD62L, there are two subpopulations of long-lived T cells, which can survive long-term without antigen re-encounter: **effector memory T cells (CD62L low)** on the one hand respond to an eventual antigen re-encounter very rapidly without the need for prior clonal expansion or differentiation and preferentially reside in non-lymphoid “peripheral” tissues. **Central memory T cells (CD62L high)** preferentially migrate to lymphoid organs such as lymph nodes and spleen, where they search for their specific antigen. In particular, central memory T cells proliferate vigorously upon antigen re-encounter and upon further differentiation provide a rapid source for newly generated effector and memory T cell subsets.

The contribution of effector memory and central memory T cells in long-lasting protective immunity may differ depending on the pathogen. For example, it has been reported that long-lasting protection against the fast-replicating intracellular pathogen *Listeria monocytogenes* (*L.m.*) strongly depends on the presence of antigen-specific effector memory T cells at the time point of infection; recruitment of newly generated effector cells from central memory T cells seems to take too long. Nevertheless, it has been observed that robust recall responses could be obtained originating from previously induced *L.m.*-specific central memory T cells, suggesting that this T cell compartment serves as a source for robust recall expansion providing large numbers of armed effector cells [48]. Thus, it is assumed that effector memory T cells are crucial for the control of fast-replicating pathogens. On the other hand, persisting protection against slowly-replicating pathogens like Cytomegalovirus (CMV) can be reconstituted by adoptive transfer of central memory derived T cells in various animal models. In a study in non-human primates, antigen-specific CD8+ effector T cell clones derived from isolated CMV-specific T_EM or T_CM subsets were cultured for 8 weeks and adoptively transferred. While T_EM-derived clones survived for only a short duration, failed to home to lymphoid organs, and did not reacquire phenotypic characteristics of memory T cells, T_CM-derived clones persisted long-term after transfer, migrated to niches of T cell memory, reacquired their respective phenotypic properties, and responded to antigen challenge [47].

### 3.1.6 The role of T cells in controlling malignant diseases

Adaptive cellular immunity is a potent effector arm of the immune system, which is also able to combat cancer cells [57]. Three mechanisms collectively termed immunoediting have been described that mark the interaction—that is control and shaping of malignant cells—between T cell immunity and tumor growth: (1) Elimination: immunosurveillance suppresses tumor outgrowth. (2) Equilibrium: control of tumor cell mass by immune cells. (3) Escape: outgrowth of a selected part as a result of co-evolution between immune system and tumor development [58].
Direct evidence of the protective role of T cells towards tumors was derived from animal experiments. Tumors in immunodeficient (lacking T cells) and wild-type mice were chemically induced and the presence or absence of T cells was found to be critical for tumor outgrowth after induction. A publication in 1964 reported already that the transfer of lymphocytes could inhibit outgrowth of a chemically induced sarcoma in the rat [59].

Evidence for immunoediting was conclusively conducted when tumors from immunodeficient mice were found to be more immunogenic compared to tumors outgrown in wild-type mice [60, 61]. Furthermore, in immunodeficient mice, some malignancies like carcinogen-induced sarcomas, occurred faster and with an increased incidence with respect to wildtype mice with a normal immune system [62]. These findings provide direct evidence for the shaping of tumor immunogenicity under the pressure of the immune system. Tumor growth in an immunocompetent individual can proceed very slowly over decades in humans resulting in an expanding tumor with reduced immunogenicity and/or the ability to escape or suppress the immune system. Higher cancer incidences, e.g. lung cancer, are also associated with the occurrence of acquired immunodeficiency (AIDS) in patients [24].

Co-localization of T lymphocytes and tumor cells and infiltration of tumor sites by lymphocytes provide more insights into the role of T cells in malignant diseases: among cancer patients, clinical prognoses often are significantly better when tumor-associated lymphocytes occur within the tumor, so-called tumor-infiltrating lymphocytes (TILs). TILs have become clinically relevant prognostic markers in many cancers including colorectal cancer, gastric cancer, urothelial carcinoma, ovarian cancer and breast cancer. Not all tumor-associated immune cells correlate with a positive prognosis though and a growing number of immune escape mechanisms have been described, for example the recruitment of immune suppressor cells to the tumor site, an immune-inhibiting tumor microenvironment or other mechanisms that lead to either accumulation of immune cells associated with a negative prognosis for patients or the escape from being recognized by beneficial immune cells. Remarkably, factors like CD8+ T cell frequency, T\textsubscript{REG} phenotype and ratio between subsets of lymphocyte determine in several samples over good or poor prognosis. Some TIL compositions of cell types might be associated with suppression of micrometastasis in patients [63-68]. Once again, different roles are attributed to subsets of T lymphocytes and ongoing research is producing more insights into their functional interaction.
3.2 Adoptive T cell therapy

The far-reaching immunologic function of T cells can be transferred from one individual to another by a strategy termed ‘adoptive T cell transfer’ which harnesses the regenerative potential, protective re-expansion and effector cell differentiation of T cells. T cells isolated from the patient can be expanded and/or manipulated \textit{in vitro} and re-infused into the patient. This strategy is termed autologous transfer of T cells as opposed to the allogeneic approaches, where the T cell donor is distinct from the patient. Adoptive therapy is a form of immune therapy, which is curably applied to treat chronic diseases like some viral infections and certain cancers (transfer of cytotoxic T cells) \[69\] as well as Graft-versus-host disease (GvHD) (transfer of immunosuppressive T\textsubscript{REG}s) \[70, 71\]. Adoptive T cell therapy has been explored in clinical trials for over two decades now. The following section will cover early developments in the field of adoptive T cell therapy, selected clinical trials using various antigen-specific T cells as well as giving an overview on further developments and demands including the composition of such T cell products for therapeutic applications and mechanisms to increase safety.

3.2.1 Early developments in adoptive cellular therapy

3.2.1.1 Donor lymphocyte infusion

The first cornerstone in adoptive T cell therapy has been laid even before the existence of T cells was discovered, with the first bone marrow transplantation following sublethal whole body irradiation in 1959: three grafts from their respective identical twins where transplanted to patients suffering from leukemia. The grafts were transplanted from the patients’ respective twin donors to the patients as a procedure designed to heal the leukemia which resulted in the remission of the leukemia for up to 6 months \[72\]. Unfortunately, the leukemia relapsed in all patients. A different approach consisting in the transfer of stem cells between HLA identical individuals that was initially designed to reconstitute the patient’s immune cells after intense chemoradiotherapy resulted in high success rates as a treatment for hematological malignancies \[73\]. Up to the present, although it is associated with many possible complications, the described procedure termed allogeneic hematopoietic stem cell transplantation (HSCT) is the most commonly applied form of adoptive immunotherapy and is used as a standard treatment for hematological malignancies. T lymphocytes, which naturally occurred as part of the graft and which were therefore transplanted along with the graft, could later be identified as the responsible element mediating an anti-tumor effect in patients and the term graft-versus-leukemia effect (GvL effect) was coined describing this effect.

Nonetheless, this remarkable anti-leukemic effect is just one side of a two-faced medal. On the downside, severe cases of graft-versus-host disease (GvHD) occurred, a T cell-mediated allo-reactive
effect found in form of pathology in skin, gut, liver, lung and bone marrow. Analysis of leukemia relapse rates showed a 2.5 times lower incidence of relapse in allogeneic-marrow recipients with GvHD than in recipients without it stressing the association of both the GvL and the GvHD effect [74]. The in vitro depletion of T cells from the stem cell graft prior to transplantation has been tried with success to increase safety by reducing the risk of GvHD for non-autologous settings [72]. Comparison of patients who received transplants with or without prior T cell depletion again showed a higher risk of tumor recurrence in the T-cell depleted group. [75]. In a GvHD mouse model, Chen et al. succeeded in identifying naïve T cells as the mainly responsible subset for GvHD. Thus, dissection of GvL from GvHD could potentially be accomplished by depletion of the naïve subset [76]. Taken together, infusion of T cells along with the stem cell graft increases the anti-tumor effect drastically and has meanwhile become standard in allogeneic settings where donor and patient are distinct despite the risk of severe GvHD. For this form of treatment, T lymphocytes are obtained from the stem cell donor. The procedure is termed donor lymphocyte infusion (DLI) and can be seen as an early form of adoptive T cell therapy [77]. Thus, transplantation of donor T cells along with an allogeneic hematopoietic stem cell graft provided clinical proof that donor-derived immune cells can respond to host tumor cells after bone marrow transplantation in leukemia patients. Further investigations revealed that this effect is mainly T cell-mediated and T cells isolated from transplanted patients were shown to have tumor-specific activity. Further investigation revealed an important role for minor histocompatibility antigens as targets in some settings responsible for GvL which is a milestone in beginning to dissect GvL from GvHD [78].

### 3.2.1.2 Tumor-infiltrating lymphocytes

A breakthrough in adoptive cellular therapy (ACT) was made when Rosenberg et al. showed in 1986 that infusion of naturally occurring tumor-infiltrating lymphocytes (TILs) induced tumor remission in a remarkable fraction of mice, a result that could so far not be achieved by transfer of cultured lymphocytes [79]. Soon, the first T cells with known specificity for tumor-associated antigens (TAAs) from tumor infiltrates could be isolated. In that way, tumor infiltrates were harnessed as a source for T lymphocytes that are specific for tumor antigens and were therefore recruited to the tumor site. Subsequently, TIL therapy was combined with administration of high doses of intravenous IL-2 [80] and innovative lymphodepleting regimens; a strategy, which has been proven successful in about 50% of melanoma patients enrolled in a study in 2002 [81, 82]. Especially lymphodepleting preconditioning of recipients showed improved clinical effects presumably in consequence of depletion of immunosuppressive regulatory T cells or other subsets possibly competing with donor cells for cytokines and antigen-presenting cells [83, 84]. It is still unclear whether TAA-specific T cells, which as auto-antigens also underlie tolerance providing mechanisms, contribute to the tumor protective capacity assigned to TILs. In addition, TILs often show signs of exhaustion such as limited
functionality, self-renewal and proliferation due to chronic antigen exposure [85]. However, clinical results were not always reproducible and highly diverse between studies [86, 87]. Consequently, attempts to transfer TILs with a defined anti-tumor specificity were conducted by stimulation of TILs with antigens obtained from tumor biopsies. Cells were co-cultivated with tumor cells to selectively grow out tumor-specific cells from the cell culture. Surprisingly, those cultured TILs could not yield better clinical results so far [88].

### 3.2.1.3 Transfer of antigen-specific T cells

For the treatment of chronic viral infections, adoptive transfer of T cells with defined antigen specificity proved very effective. In 1992, for the first time, cytomegalovirus (CMV)-specific CD8+ T cell clones were successfully transferred to patients upon *in vitro* propagation. All patients had previously undergone allogeneic bone marrow transplantation and suffered from an increased risk of CMV reactivation, a life-threatening disease in immunocompromised people. Infusion of donor-derived CMV-specific CTLs reconstituted protective immunity against CMV reactivation [89]. Other studies using CTLs specific for antigens of EBV [90] and HIV [91] have provided further evidence for the efficacy, persistence and safety of adoptively transferred virus-specific T cell clones. Newer data indicate that low numbers of transferred T cells can already be sufficient to confer protective immunity towards CMV in recipients of allogeneic stem cell transplantation [92, 93]. For the last two decades, adoptive transfer of antigen-specific T cells has yielded promising results for chronic viral infections and some tumors, especially when the number of host cells competing for cytokines was reduced by lymphodepletion [81].

For the treatment of malignant diseases, advances in adoptive T cell therapy are needed. Since our knowledge on tumor-associated antigens (TAAs) has vastly improved, efforts were made to expand and transfer cells with known antigen specificity. Nonetheless, it is still difficult to isolate high-avidity tumor-specific T cells and gain access to suitable TCRs directed against these self-antigens [94]. Self-antigen specific T cells with high avidity are usually deleted in the thymus by negative selection (central tolerance). Because of the sometimes extremely low frequencies or complete absence of tumor-specific T lymphocytes in the patients and low *in vivo* response rates of such cells [95], it was sought to generate T cells of a defined specificity by genetic redirection of specificity. There are two principle strategies to impose a defined specificity on T cells: transgenic TCRs or synthetic CARs. Both strategies rely on the discovery of suitable target antigens.

A prerequisite of transgenic TCRs is the isolation of cDNA sequences for TCR α and β chains for the transduction of T cells with viral vectors. TCR gene sequences are usually obtained from tumor-reactive T cells e.g. upon isolation from tumor-infiltrating lymphocytes. Novel, MHC multimer-based single cell sorting and single cell PCR amplification enables the isolation of TCR sequences directly
ex vivo, e.g. from peripheral blood without the need for tissue biopsies or long expansion procedures in vitro [3].

The design and development of anti-tumor CARs requires the gene sequence of a single chain variable fragment (scFv) derived from a tumor antigen-specific antibody. Thus, the discovery of suitable tumor antigens is a prerequisite for obtaining TCRs or CARs of defined tumor-specificity for T cell therapies.

As a source for T cells, the reasonable approach was to use peripheral blood mononucleated cells (PBMCs) containing all functional subsets of T cells in contrast to using surgically removed tumor infiltrates containing partly functionally impaired T cells. Furthermore, not all tumors have lymphocyte infiltrates and are therefore not accessible by TIL-based approaches.

### 3.2.2 Genetically re-directed T cells for adoptive immunotherapy

The first report of genetically engineered T cells adoptively transferred to patients with metastatic melanoma originates from Morgan et al. in 2006: a transgene encoding the TCR which recognizes the melanoma-specific tumor antigen MART-1 was retrovirally introduced into peripheral blood lymphocytes (PBLs) that were expanded and adoptively transferred to patients with metastatic melanoma. 2 of 15 patients responded by complete tumor remission. Furthermore, adoptively transferred cells could be detected up to 20 months post transfer [96]. This was the first evidence in patients that tumor recognition can be established de novo in lymphocytes via introduction of a transgenic TCR. Transgenic TCRs are generally expressed in the same cell compartment as native TCRs. Therefore, mispairing of endogenous and transgenic TCR chains can occur, creating unpredictable and potentially toxic specificities [97]. Various strategies have been developed to overcome this problem [98]. An inherent limitation of TCR gene therapy is the HLA-restricted nature of antigen recognition by TCRs. TCRs recognize antigen in the context of a human leukocyte antigen (HLA) molecule, which is the human analogue to the MHC molecule. Often, through genomic instability, tumors escape the immune system by acquisition of escape mechanisms such as manipulation of antigen processing and antigen presentation to T cells or down-regulation of HLA class I altogether [99]. In such settings it could be beneficial to target tumor stromal cells, which are vital for sustaining tumor growth. Stromal cells are also less prone to immune escape because of their higher genetic stability compared with tumor cells. In addition, stromal cells are known to cross-present exogenous antigens on MHC class I molecules, a process which allows targeting tumor epitopes on stromal cells with re-directed T cells [21, 100]. Modifications in vectors and amino acid sequence enable the expression of TCRs in T cells at high levels. So far, a number of clinical trials have demonstrated the efficacy of TCR transgenes in adoptive T cell transfer. Two recent studies treating patients with metastatic melanoma or synovial cell carcinoma yielded clinical response rates of 28% and 79% [101-103].
3.2.3 Chimeric antigen receptor-engineered T cells

Another strategy to redirect tumor or other specificity of T cells is independent of HLA presentation: chimeric antigen receptors (CARs). The relative resistance of CARs towards a number of immune evasion mechanisms involving peptide processing and HLA expression renders them an attractive alternative to transgenic TCRs. CARs are artificial one-peptide chain antigen receptors usually containing intracellular and trans-membrane domains derived from TCRs (CD3ζ domain) and the antigen-specific fragment of an immunoglobulin (single-chain variable fragment). Thus, the CAR molecule combines HLA-independent antigen recognition (taken from immunoglobulins) with intrinsic effector functions and signaling of T cells in a single fusion protein [104]. As a result, CAR-transduced T cells are equipped with an antigen-specificity in addition to their native TCR. Structurally, CARs are built with a Fc hinge region as spacer domain between single-chain variable fragment (ScFv) and transmembrane domain, thus enabling increased expression levels through dimerization. According to a general classification, first generation CARs carry no additional co-stimulatory molecules in the intracellular signaling domain. Second generation CARs have either CD28, CD27, 41BB or OX40 as co-stimulatory domains and third generation CARs carry a combination of at least two co-stimulatory domains. It has been demonstrated that insertion of the co-stimulatory domain CD28 [105] or CD27 [106] in the CAR molecule results in increased persistence and anti-tumor effect of transferred T cells. For 41BB and CD80, it has been shown that constitutive expression of these co-stimulatory ligands on tumor-infiltrating T cells can lead to enhanced anti-tumor activity [107]. Unlike engineered TCRs, CARs are artificial molecules and potentially confer immunogenicity. Advances in design will be necessary to completely eliminate this problem. Second and third generation CARs with increased co-stimulation have yielded dramatic impact in the field of adoptive therapy of patients with hematologic malignancies. [108, 109]. In these trials, T cells were engineered to express CARs specific for the lineage-specific antigens CD19 or CD20, both of which are overexpressed in the respective B cell malignant diseases that patients suffered from. In other studies, CARs directed against the CE7R and GD2, both tumor antigens of neuroblastoma, have been tested demonstrating clinical responses in some cases [110, 111].

It is now more and more accepted that effective clinical response rates are associated with in vivo engraftment and persistence of transferred T cells as well as migration to the respective tumor sites [112, 113]. It is therefore of particular interest to conduct trials comparing the in vivo persistence of transferred cells. Functional subsets of the T cell compartment, however, are not equally suitable to achieve the desired in vivo persistence and migratory capacity. Following the discovery of diverse differentiation properties of T cell subsets, it is now appreciated that some subsets are superior in terms of their capacity to persist and reconstitute functional immunity upon transfer.
Fig. 1.2: The structure and organization of T cell receptor (TCR) and chimeric antigen receptor (CAR).

Organization of extracellular, transmembrane and intracellular domains of TCR/CD3 complex and CAR. TCRs are heterodimers which are associated with the extra- and intracellular subunits of CD3 (γ-ζ). ζ is a signaling domain which is also used in chimeric antigen receptor for the same purpose. In contrast, V_H and V_L are antibody-derived. Therefore, CARs can recognize antigenic structures in their native form while TCRs recognize small peptide fragments presented in a binding groove of major histocompatibility (MHC) molecules.

3.2.4 Finding the ideal T cells for adoptive therapy

Application of lymphodepleting regimens along with infusion of T cells has demonstrated increased persistence of T cells and as a consequence increased antitumor efficacy. Nevertheless, clinical results often lack efficacy and persistence, even when very high numbers of T cells are administered to patients. Retrospective analysis correlated in vivo persistence with therapeutic outcome. One obvious parameter is the lack of uniformity in given T cell products, which, in most trials, underlie large variation [114]. Therefore, it appears consequent to isolate T cells of a defined specificity and with optimal characteristics regarding longevity and safety. One strategy is the selection of an ideal subset of T cells with the intrinsic capacity for long-term survival upon transfer along with the ability to give rise to potent effector responses and to infiltrate sites of infection or tumor tissue. However, the ideal subset for successful and sustained persistence of adoptively transferred T cells is still controversially discussed, and may depend on the clinical indication. As described in detail in chapter 3.1.6, the less differentiated central memory T cell subset, characterized by longer telomeres, the general capacity for self-renewal and differentiation, expression of homing receptors and secretion of growth factors,
revealed better persistence both in non-human primates and in patients [47, 49, 115]. In recent CAR-engineered T cell studies, retrospective analysis for the TCM content positively correlates with objective clinical responses. Since started in 2005, the trend of selecting a subset of T cells for adoptive transfer has been increasingly adopted [116]. It has been clearly shown that T cells transferred at early stages of differentiation confer superior anti-tumor efficacy. In mouse models, the anti-tumor response of naïve T cells could exceed the response of TCM [45, 50, 116, 117]. In contrast to TCMs, naïve T cells are of unknown and potentially harmful specificity and are therefore believed to be the main mediators for graft-versus-host toxicities in allogeneic transplantation [118]. A means of ensuring a pre-defined T cell specificity is the selection of virus-specific T cell clones for introduction of a transgene, thus generating bi-specific cells of defined specificity [119]. It has been shown in a clinical trial applying CAR-transduced T cells targeting neuroblastoma that, indeed, bi-specific T cells persisted longer than CAR-specific T cell clones lacking virus specificity and therefore have a shortage of co-stimulation through engagement of their natural epitope [111]. Thus, it seems relevant to this field to develop a selection protocol for isolation of long-lived antigen-experienced memory T cells.

Most recent attempts in ACT aim at further dissecting the role of CD8+ and CD4+ T cells in adoptive transfer settings to find the optimal composition of a functional cell product.

It could be demonstrated that purified CD8+ TILs were in principle sufficient to mediate tumor regression [69]. However, when infusion of CD8+ enriched TILs was compared to infusion of unselected TILs, the CD8+ enriched T cells were not more potent therapeutically [120]. Furthermore, it has been demonstrated that in some cases CD8+ cytotoxic T cells even rely on CD4+ T cell help to infiltrate virus-infected tissue [121]. In contrast, complete remission in a melanoma patient has been observed upon transfer of tumor-specific CD4+ T cell clones alone [122]. The selection of suitable CD4+ subsets however might depend on further distinction of subsets of the CD4+ compartment since not only different subsets of T helper cells but also regulatory T cells, which might dampen an immune response, constitute the CD4+ compartment. The first pre-clinical studies attempting to pre-select a defined composition of naïve and memory CD4+ and CD8+ T cells and examine their in vivo behavior are currently conducted. Preliminary data on persistence and therapeutic efficacy of genetically modified tumor-reactive human T cells in immunodeficient Nod/Scid/gc−/− mice with engrafted tumors confirmed a distinct behavior and efficacy of defined compositions of subsets of CD4+ and CD8+ T cells. Lowest numbers of transferred CD19-CAR T cells were capable of eradicating tumors in these mice [123].

The definition of an ideal T cell subset for adoptive therapy may therefore be extended to not only one subset of cytotoxic T cells but to a combination of subsets of both functional T cell types (CD4+ and CD8+).
3.3 Purification of T cell populations

3.3.1 Methods for human T cell isolation

T lymphocytes can be visualized and isolated by a number of methods. The common base of visualization and separation methods is the labeling of cell-surface proteins (antigens) with specific probes, ultimately distinguishing labeled from unlabeled cells. Components of the cell surface to be labeled are on the one hand phenotypic markers characterizing functional subsets of T cells e.g. CD4; CD8, adhesion molecules, αβTCR etc. and on the other hand the respective TCR for its specificity. Moreover, the number of parameters that can be addressed by cell sorting is constantly expanding and includes not just surface antigens but also intracellular proteins, DNA, cell viability just to name a few.

The separation of cells out of a heterogeneous mixture of cells or directly from the blood is referred to as cell sorting. In general, there are two major technologies available for cell sorting: the fluorescence activated cell sorting (FACS) where light emission by fluorescent dyes is detected and magnetic-activated cell sorting (MACS), which harnesses the behavior of magnetic and para-magnetic particles in a magnetic field [124]. Magnetic particles have to be specifically bound to the cell surface and magnetically labeled cells can be retained in a magnetic field either directly using tubes, bags or flasks or indirectly using magnetic columns, depending on the nature and size of magnetic particles. Sorting by FACS however requires a more sophisticated fluidics and electronic appliance for the purpose of charging droplets –containing the scattered single cells- to be charged and electrostatically deflected from a stream.

Independent of the technology, there are two general strategies for isolation of a desired target population: target cells can be isolated either by positive or by negative enrichment. Positive enrichment is the selection of labeled cells for downstream applications, whereas in negative enrichment unwanted cells are labeled leaving the unlabeled target cells behind for further use. Each strategy is associated with specific advantages. Positive enrichment yields better purities of the target population and can, therefore, be applied even for very small target populations. Negatively enriched cells are obtained as so-called untouched cells without the risk for activation or damaging of the target cells but not all target populations can be accessed by negative enrichment [125].

For FACS and MACS, the enrichment strategy can be either positive or negative depending on the availability of reagents. For negative enrichment, also non-magnetic fluorescent-independent strategies have been developed e.g. unwanted cells are cross-linked to red blood cells, and subsequently separated from the target cells by density gradient centrifugation [126, 127]. All these technologies are based on the principle of specific antigen-binding mediated either by monoclonal antibodies specific for phenotypic markers or by particular TCR ligands, since by the sole means of monoclonal antibody labeling it is not possible to visualize and separate T cells based on their TCR specificity. The
groundwork for visualization and isolation of T cell specificity has been laid by Altman et al., who for the first time made soluble peptide-MHC tetramers that stably bind to the respective TCRs and can be combined with fluorescent or magnetic labels [128].

![Diagram](image)

Fig. 1:3: Positive cell selection using magnetic microbeads and a strong hand-held permanent magnet.

1) A mixture of cells is mixed with specific labeling microbeads to magnetically label a desired target fraction. 2) In a strong magnetic field, labeled cells are held back. 3) Unlabeled cells can be transferred in a separate tube. Washing of the cells improves the purity of the target cell population.

3.3.2 Comparison of different strategies for cell separation

The negative enrichment strategy can in principle target cells that are characterized by one or a combination of two or more markers depending on the nature of the cell mixture and the availability of antibodies. Purities of the target cell population, however, are significantly lower compared to positively enriched populations. Positive enrichment can target cells characterized by more than one markers currently mainly with FACS, which works with parallel detection of different dyes at the same time. Positive MACS enrichment can only be conducted with one specificity at a time, since cells are either magnetic (labeled) or not (unlabeled). Since the labels remain stably bound to the cell surface, clinical use of both technologies depends on the availability of clinically approved labeling reagents at present. Especially for fluorescent dyes, the nature of the reagents poses regulatory issues and is suspected to be associated with immunogeneicity. Another issue with FACS sorting is the limitation that most sorters cannot be transferred into a closed, sterile system. However, the advantages of magnetic cell selection over FACS are: (i) less training of personnel is required, since protocols are easier to follow and time of labor is shorter, (ii) the method enables fast high-throughput sorts and cell numbers can be scaled up without a direct correlation to the required sorting time, (iii) recovery rate of target cells exceeds those of other isolation methods since the need for specialized equipment can be minimalized, (iv) magnetic selection can be performed in an affordable closed system, a feature that is mandatory in good manufacturing practice, (v) the first
magnetic selection reagents are in clinical use for ten years now and second-generation reagents are easier to receive approval for by the regulatory authorities.

As already mentioned, positive MACS enrichment is limited to select cells based on one surface marker (A) or a population of single-positive cells of different markers (A+B) but not a target population characterized by combinatorial expression of markers (A∩B). Though recent advances in MACS technology were made by application of different-sized magnetic beads that can be differentiated by the strength of the magnetic field and used for two-step positive enrichment [129], the described strategy is limited to very few iterations (two positive enrichment steps). To accomplish isolation of populations characterized by combinatorial expression of markers (A∩B), serial steps of positive enrichment would have to be aligned and only if magnetic labels can be removed from the cells, a second positive selection step for a different marker with the same magnetic particle will be possible.

3.3.3 Principle of the reversible Streptamer Technology

Reversible TCR ligands were initially introduced to the field by Knabel et al. in 2002 as an advance of the aforementioned peptide-MHC (pMHC) multimer technology by Altman et al. [128]. Since multimerization of pMHC monomers is crucial to achieve stable binding to the TCR, it was hypothesized that pMHCs would spontaneously dissociate from the cell surface in their monomeric state. Consequently, the interaction of monomers with the respective backbone molecules (for multimerization) was designed in such a way that targeted disassembly of multimers into pMHC monomers and free backbone would become possible [130].

The concept of reversibility is based on the avidity gain resulting from the interaction with multipe pMHC molecule and the TCRs at the same time. The reversible pMHC monomers have rapid off-rates due to their relatively low binding affinity towards the TCR. However, to stably bind to the cell surface the monomers must be multimerized to establish a sufficient binding. The pMHC molecule is multimerized over an oligo-Streptactin backbone and therefore capable of binding several TCRs at the same time resulting in a higher avidity and stronger binding. Multimerization is mediated by strep-tag/streptactin interaction. Strep-tag is a nine amino acid long peptide initially made as a tool for affinity chromatography [131]. pMHC molecules are genetically fused with a strep-tag sequence bearing a high affinity towards Strepavidin or Streptactin, both of which can serve as the molecular backbones for multimerization. Streptactin is an engineered form of the streptavidin with a 10-fold enhanced binding affinity towards Strep-tag [132, 133]. This new family of pMHC multimers uses the strep-tag/streptactin interaction and can be disrupted by addition of a strong competitor, which binds to the active binding sites of the streptactin backbone with a $10^6$-fold higher affinity as compared to strep-tag.
The vitamin D-biotin is such a competitor, which has an intrinsic $10^6$-fold higher affinity towards streptactin. In the presence of D-biotin, it binds to the streptactin and, as a consequence, multimers are disrupted into monomers, because streptag is displaced from streptactin. Those monomers dissociate spontaneously from the cell leaving quasi untouched cells behind.

Recently, the reversible Streptamer technology has been extended not just to a broad series of complex TCR ligands but to a continuously growing list of phenotypic markers. These Streptamers targeting basically any surface antigen are termed Fab-Streptamers. They harness the broadly available variety of surface antigens, which can be targeted by specific monoclonal antibodies. Fab-Streptamers are built analogous to pMHC-Streptamers [130]. Their respective antigen-recognizing part is made of the variable Fab fragment of a monoclonal antibody and a strep-tag peptide for the multimerization with a Streptactin backbone.

Similar to the pMHC monomers, reversibility requires an optimal affinity of Fab fragments for monomers in order for them to dissociate spontaneously from the antigen but still bind stably in their multimeric form as a result of several antigens being bound at the same time (increased avidity). Fab monomer affinity can be reduced, if necessary, by insertion of point mutations in the variable region of the antibody fragment [1].

Reversible selection reagents can overcome unwanted changes of the cell population caused by remaining surface markers like premature activation, cross-linking or blockade of receptors causing functional impairments, and the entrance of cells in the state of anergy and exhaustion or even premature cell death.

Issues of clinical relevance, which can be avoided by the use of reversible labels, are potential toxicity and immunogenicity of remaining sort-markers or potential allergic reactions. Lastly, the comparably difficult process to receive approval for non-removable sort-markers is of economic interest.

From a regulatory point-of-view, cell selections using reversible Streptamers have been classified as ‘minimally manipulative’ to the cells. The status of cell products manufactured with Streptamers without further cell culture and/or genetic modification is therefore the status of non-advanced therapeutic medicinal products (non-ATMPs). Reversible Fab-Streptamers transfer the distinct advantage of negative enrichment –untouched target cells- to the more stringent positive enrichment, thus making the most of both general strategies [1]. This might have tremendous implementations on cell separation, both for research use and clinical T cell therapy.
28

Fig. 1.4: Principle of reversible cell labeling with Streptamer-coated magnetic microbeads.
Recombinant Fab fragments are derived from parental antibodies and expressed as fusionproteins with the nine amino acid long streptag peptide. 1) A target cell is stably labeled with Streptamer-coated magnetic microbeads. 2) Upon addition of the competitor D-biotin, the whole Streptactin-coated microbead is released from the surface of the target cell. 3) Spontaneous dissociation ensues the disruption of the multimer. Cells can subsequently be washed and may be labeled again with a different Multimer or antibody.

3.3.4 Fab-Streptamers and serial enrichment

Streptactin-covered magnetic beads can be used for direct, positive magnetic enrichment. The streptactin on the magnetic particles serves as a molecular backbone for Fab-multimers. Fab monomers are assembled to form a multimeric complex because they are fused to a strep-tag peptide which is moderately affinity towards streptactin. D-biotin is used to competitively bind and saturate the binding sites of the streptactin backbone thus, leaving low-affinity Fab monomers on the cell surface, which dissociate spontaneously. Cells are no longer magnetically labeled and can be eluted in a magnetic field after one round of positive enrichment. As a result, quasi untouched cells of high purity are separated from the Streptactin-covered magnetic beads. Residual soluble reagents (Fab monomers and D-biotin) can be removed by washing the cells by conventional centrifugation. Now, the quasi untouched cells can undergo another round of positive selection with a different Fab-multimer bead complex. In this way, this novel technology allows for the first time access to some therapeutically relevant T cell subpopulations such as T\textsubscript{REGS} and T\textsubscript{CM}, that require a constellation of markers for purification and were so far not accessible by minimally manipulating enrichment strategies.

Besides enabling serial positive enrichment in a closed system, the main advantage of this novel technology is its applicability to basically any surface antigen. So far, the rapid translation of
preclinical findings to a clinically applicable sort protocol has been difficult, for only a handful of T cell marker-specific monoclonal antibodies are approved for GMP-use by the regulatory authorities at present. With reversible Fab reagents being classified as minimally manipulating reagents, it is now possible to quickly develop suitable Fabs for virtually any newly found application.

### 3.3.5 Clinical isolation of T cell subpopulations

The first clinical-grade cell separation technology was the magnetic bead-based cliniMACS system [134]. It is based on the use of nanometer sized biotinylated super-paramagnetic particles with an average diameter of around 150 nm [135]. Other clinically available, general strategies for T cell isolation include functional isolation based on genetic screening [49, 136] and FACS-sorting [137]. One can argue that, among clinically available cell separation technologies, immunomagnetic separation is the best developed one at present. It is currently the only available method to generate large numbers of cells directly *ex vivo* without the need for *in vitro* expansion.

Direct clinical enrichment of defined cell populations based on surface markers has so far been limited to single parameters (marker). Human clinical trials using magnetic bead isolation of either CD4 or CD8 T cells prior to transfer of T cells have been conducted for both cancer and anti-viral therapies [69, 138]. Clinical cell isolation of CD34+ cells and peptide-MHC multimer+ cells have been conducted in clinical phase II and III studies [139-141].

A more precisely defined subset using more than one marker, however, so far required the combination of negative and positive selections in a serial fashion. For example, CD25 positive enrichment has been used in combination with CD8 and CD19 depletion for the isolation of TREGs to be administered to patients to prevent GvHD after stem cell transplantation [70]. A novel GMP-grade monoclonal antibody specific for human CD62L has recently been introduced; an advance, which made clinical-grade isolation of human memory T cell subsets possible. Clinical-grade isolation protocols using this CD62L-targeting antibody have recently been published by Wang et al.[142] and Terakura et al. [119]. The first clinical application of GMP-grade reversible HLA-streptamers originates from Schmitt et al. demonstrating evidence for clearance of CMV viremia upon transfer of CMV specific T cells in acute leukemia patients with recurrent CMV infection who have undergone allogeneic stem cell transplantation [92].
3.4 Current needs for clinical cell processing and adoptive transfer of T cells

Isolation of a defined cell product characterized by multiple cell surface markers still remains a major hurdle in cell processing from a regulatory point-of-view. Some practical challenges for the generation of well-defined T cell products as a therapeutic regimen still remain [143]. Isolation of T cell subsets must comply to GMP-standards [144]. It is mandatory in order to meet with regulations for clinical applications in most countries to conduct cell selections in a sterile and closed system. Negative and positive cell sorting using magnetic particles are directly applicable for clinical use because those are directly feasible in a closed system.

Isolation of central memory T cells, which are not further genetically modified or in vitro cultivated can retain the status of non-advance therapy medicinal products (non-ATMPs). According to the European commission, cells that are defined as non-ATMPs must not be substantially altered as a result of their processing. This includes ex vivo expansion or activation of cells. By producing non-ATMPs for personalized medicine it is possible to be flexible enough to rapidly translate novel findings of current research into clinically feasible applications.

Further requirements for isolation protocols are simplicity, reproducibility and minimal processing time to ensure economic feasibility for incorporation into human clinical trials.

Another general problem for T cell therapy is the poor access to clinical trials to a broad range of patients. Keeping the costs and level of complexity of the cell separation process as low as possible will be crucial in overcoming this limitation.

One key element of user-friendliness, simplicity and reproducibility is the automation of the cell purification process. Since there is currently no platform available, on which serial magnetic enrichment can be conducted, the automation of this process remains to be developed.
Adoptive transfer of primary or genetically engineered T cells is currently emerging as a promising strategy to treat tumors or chronic infectious diseases, as shown in several clinical trials. Unimpaired functionality and longevity of transferred cells are crucial for therapeutic efficacy. The ideal subset for successful and sustained persistence of adoptively transferred T cells therapies is still controversial as different T cell subpopulations (e.g. central memory and effector memory) are not equally suitable for patient treatment. Recent efforts to elucidate the contribution of different subsets to the efficacy and safety of adoptive T cell therapy have led to the proposition that selection and physical isolation of the most suitable T cell subset for adoptive transfer might help enhance the clinical response on the one hand and eliminate unwanted side effects on the other hand. Therefore, a better understanding of how subset compositions interfere with diversity in clinical response rates and the occurrence of side effects could make this approach more predictable. Studies suggested that antigen-specific central memory T cells (T<sub>CM</sub>) are most capable of giving rise to long-term persistent T cell responses, and thus seem to be most suitable for providing protective immunity in vivo upon adoptive transfer while minimizing the risk for T cell related toxicities.

The aim of this thesis was to develop a novel serial three-step enrichment protocol for the clinical isolation of CD62L<sup>+</sup>CD45RA<sup>-</sup>CD45RO<sup>+</sup>/CD45RA- memory T cells. The recently developed reversible Fab Streptamer technology can bypass this general problem by enabling serial positive purification via multiple surface markers.

The aim of this thesis was to develop a novel serial three-step enrichment protocol for the clinical isolation of CD62L<sup>+</sup>CD45RA-CD45RO<sup>+</sup> central memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells using CD3, CD8, CD4, CD45RA, CD45RO and CD62L Fab-Streptamers coupled to magnetic particles. First, the respective Fab proteins were generated and their staining properties were compared to conventional monoclonal antibody staining. Then, after determining the main parameters that influence reversibility, a novel assay to evaluate regent reversibility was developed for quality assessment of Fab proteins. Next, magnetic selection protocols for the use with reversible Streptamers were developed. To establish serial positive magnetic selection, magnetic particles of different sizes needed to be evaluated. Critical parameters that influence purity and cell recovery during the serial enrichment process were optimized to finally establish a three-step purification process with highest efficiency and the capacity to minimally influence the functionality of extracted cells. Finally, the technique was adapted to a GMP compliant procedure using equipment and consumables previously approved for the clinical use.
5 Results

5.1 Ex vivo Streptamer staining for phenotypic markers on human PBMCs

Current strategies for clinical purification of T cells based on phenotypic antigens use paramagnetic beads enabling direct positive enrichment. Stable labeling of target cells is generally based on “irreversible” high affinity monoclonal antibody staining. Antibody conjugates are available in a covalently bound form featuring fluorophores, which enable detection by flow cytometry, or with paramagnetic particles, which enable separation in a magnetic field. However, remaining antibodies and particles on the cell surface of purified cells can interfere with their functional integrity. We hypothesized that (i) multiparameter cell sorting by serial positive enrichment could be achieved if the complete cell label could be removed after each separation step before entering the next purification cycle and (ii) that cells, which have undergone reversible serial positive enrichment, would be functionally unimpaired. Therefore, we generated reversible staining reagents for the purpose of cell surface labeling and specific cell separation of central memory T cells including αCD3, αCD4, αCD8, αCD62L, αCD45RO, and αCD45RA based on existing antibody fragments.

5.1.1 Clones and mutations of Fab fragments

It has been recently demonstrated that the Streptamer technology, which was originally designed for reversible staining of T cell receptors using MHC-Multimers, can be transferred to create a broad spectrum of reversible antibody-like staining probes. Therefore, low-affinity antibody-derived Fab-fragments were generated, which stain like parental antibodies when multimerized via Strep-tag and Strep-Tactin, but can subsequently be removed entirely from the target cell population by targeted monomerization. Multimerization of Fab-fragments becomes possible via genetic fusion of the heavy chain of the Fab fragments to a OneSTrEP-tag sequence (Strep-tag), and subsequent co-expression together with the light chain in the periplasm of E. coli. The relatively high binding affinity of Strep-tag to Strep-Tactin ensures binding to multiple sites of tetrameric Strep-Tactin molecules, which is used as a backbone for multimerization. In some cases, the generation of Fab-fragments from dimeric parental antibodies is already enough to obtain a fully reversible reagent. However, in most cases the Fab-fragments are still of too high binding affinity to support reversibility of staining within a reasonable time frame. In that case, we have succeeded in the past for several examples of Fab-fragments to reduce the binding affinity without losing specificity by single amino acid exchange in
regions aside from the complementarity determining region (CDR). For the present thesis work, Stage cell therapeutics provided me with various mutated Fab fragments and plasmids relevant for $T_{CM}$ purification. Table 5.1 gives a detailed overview of all Fab proteins that have been used. For some proteins, a large number of different mutations or expression batches of the same plasmid have been made. Every batch required careful individual testing after the protein had been purified. As a first step in this evaluation, purified Fab-fragments were multimerized with a fluorophore-conjugated Strept-Tactin for analysis of antigen-specific surface stainings by flow cytometry.

<table>
<thead>
<tr>
<th>Specificity</th>
<th>Mutation</th>
<th>Plasmid</th>
<th>sequence</th>
<th>conc. [ug/mL] staining</th>
<th>Reversibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD4</td>
<td>H918</td>
<td>ok</td>
<td></td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CD8</td>
<td>C85Sheavy</td>
<td></td>
<td></td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CD62L</td>
<td>wt</td>
<td></td>
<td></td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CD62L</td>
<td>86</td>
<td></td>
<td></td>
<td>yes</td>
<td>yes</td>
</tr>
<tr>
<td>CD62L</td>
<td>87</td>
<td></td>
<td></td>
<td>no</td>
<td>-</td>
</tr>
<tr>
<td>CD62L</td>
<td>88</td>
<td></td>
<td></td>
<td>no</td>
<td>-</td>
</tr>
<tr>
<td>CD62L</td>
<td>89</td>
<td></td>
<td></td>
<td>no</td>
<td>-</td>
</tr>
<tr>
<td>CD62L</td>
<td>cys</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD45RO</td>
<td>wt</td>
<td>p1641</td>
<td>ok</td>
<td>163</td>
<td>yes</td>
</tr>
<tr>
<td>CD45RO</td>
<td>L11Sheavy</td>
<td>p1642</td>
<td>ok</td>
<td>121</td>
<td>yes</td>
</tr>
<tr>
<td>CD45RO</td>
<td>wt</td>
<td>p1643</td>
<td>ok</td>
<td>188</td>
<td>yes</td>
</tr>
<tr>
<td>CD45RO</td>
<td>L11Sheavy</td>
<td>p1644</td>
<td>ok</td>
<td>88</td>
<td>no</td>
</tr>
<tr>
<td>CD45RO</td>
<td>L11Aheavy</td>
<td>p1643</td>
<td>ok</td>
<td>70</td>
<td>no</td>
</tr>
<tr>
<td>CD45RO</td>
<td>104Aheavy</td>
<td>p1643</td>
<td>ok</td>
<td>90</td>
<td>no</td>
</tr>
<tr>
<td>CD45RO</td>
<td>Y37Alight</td>
<td>p1643</td>
<td>ok</td>
<td>30</td>
<td>no</td>
</tr>
<tr>
<td>CD45RO</td>
<td>Y41Alight</td>
<td>p1643</td>
<td>ok</td>
<td>60</td>
<td>no</td>
</tr>
</tbody>
</table>

Table 0.1: Overview of different Fab-fragments for the formation of Streptamer-based reagents

All recombinant Fab fragments that were used in this thesis work are listed in this table. The heavy chain of Fab fragments from parental antibodies is genetically fused to the OneSTrEP-tag sequence (Strep-tag) and expressed together with the light chain in the periplasm of E. coli. Mutations are indicated by the amino acid residue that has been exchanged by mutagene

is

PCR. Some purified Fab proteins have been provided by Stage cell therapeutics, Göttingen, as indicated. For all others, I received the expression vector and derived recombinant proteins by myself. For detailed information on 'staining' and 'reversibility' see following sections.
5.1.2 Evaluation of Fab Streptamer stainings

To demonstrate that Fab-Streptamer staining is identical to conventional antibody staining, both techniques have been used on multiple donor-derived PBMCs from healthy volunteers. Fab fragments were multimerized with PE- or APC-conjugated *Strep*-Tactin for analysis by flow cytometry. We used fresh PBMCs from healthy blood donors and employed control stainings with commercially available antibodies to test the ability of Fab-Streptamers to stably and specifically stain cells in the same way that antibodies do.

CD3-specific recombinant Fab proteins were derived from the OKT3 antibody clone. CD3-specific Fab-Streptamers using PE-conjugated *Strep*-Tactin were incubated with PBMCs at a ratio of 0.75 µg *Strep*-Tactin per 10^6 cells. Fig. 5.1a shows specific CD3-staining for one representative donor and a control without the specific Fab-fragment to exclude unspecific fluorescence by the *Strep*-Tactin backbone. Variations in CD3-frequencies are based on inter-individual differences between donors. We have performed CD3-specific Fab Streptamer stainings in 5 individual experiments using PBMCs from a different donor each time. Control stainings with a commercially available mAb-conjugate for flow cytometry served as positive controls for CD3 frequencies in a respective donor. We could show in independent experiments that CD3 frequencies determined by Streptamer staining and frequencies from antibody staining are equal (Fig. 5.1b). CD3 Fab-Streptamers can specifically stain CD3^+ cells in the same amount of time (20 minutes) under the same experimental conditions as commercial monoclonal antibodies.

![Fig. 0.1: CD3-specific Fab-Streptamer staining of human PBMCs](image)

Multimers of CD3-specific Fab fragments were generated at a ratio of 0.2 µg Fab and 0.75 µg (PE-labeled) Streptactin (ST) per 10^6 cells. All steps were conducted at 4°C. a. CD3 Streptamers of the OKT3 parental antibody clone specifically stain a subset of human living lymphocytes (pre-gated). ‘ST only’ indicates the control staining using PE-labeled *Strep*-Tactin without recombinant Fab protein. Numbers in dot plots indicate gate frequency. b. CD3 Streptamer stainings (black dots) and respective control stainings using the commercially available UCHT1 clone (red dots) performed on blood PBMCs from 5 different healthy donors.
The same strategy was applied to test the performance of CD4-specific Fab-Streptamers. Using different fluorescent dye-conjugates of antibody and Streptamer for flow cytometry enabled us to perform simultaneous staining with CD4 Fab-Streptamers and a CD4-specific mAb. Thereby, we confirm that CD4 Fab-Streptamers specifically stain the same subset of cells as commercial anti-CD4 antibodies. Controls include samples stained with just dye-conjugated backbone without Fab protein and monoclonal antibody staining alone. A small fraction of cells were only positive in one of the two staining strategies. This might be due to some cells with very low CD4 surface expression, which could be stained differently with multivalent Fab-Streptamers and bivalent parental antibodies bringing out minimal differences in binding avidity of the two clones. Indeed, CD4 Streptamers were derived from a different parental antibody clone (OKT4) than control antibodies (13B8.2). However, conventional CD4+ T cells are characterized by a high relative expression of CD4. This population is not affected by these small staining differences and appears double stained in both strategies (Fig. 5.2a). To account for naturally occurring scattering in the CD4+ frequencies between donors, we performed multiple individual stainings with CD4 antibodies and Streptamers. (Fig. 5.2b). The frequency of CD4+ PBMCs among living lymphocytes is identical for both, Streptamer and antibody stainings in n=5 donors respectively.

**Fig. 0.2: CD4-specific Fab Streptamer stainings of fresh PBMCs**

Streptamers of CD4-specific Fab fragments were generated as described for CD3 Streptamers a. CD4 Streptamers specifically stain the CD4+ subset of human living lymphocytes (pre-gated) as verified by the double staining using the commercially available CD4 mAb clone 13B8.2 and the OKT4-derived Fab Streptamers. Numbers in dot plots indicate gate frequency. b. CD4 Streptamer (black dots) and mAb stainings (red dots) performed on 5 different healthy donors.

CD3 and CD4 Fab-Streptamers were generated using an equivalent of 0.75 µg Strep-Tactin of dye-conjugated Strep-Tactin backbone. For previously evaluated Fabs this amount has been found to be optimal for the staining of up to 5x10^6 cells without causing a considerable unspecific background. However, the amount of recombinant Fab protein had to be determined for each protein meaning each specificity or mutation and every single expression batch. Therefore, titrations of Fab protein amounts
for multimerization were performed as a standard before new batches of protein expressions were used for further experiments. This type of Streptamer staining and titration testing has become part of the quality control for every new recombinant Fab protein batch in the meantime.

For CD8 Fab evaluation we first titrated the amount of Fab reagent per $10^6$ fresh PBMCs over a fixed amount of dye-conjugated backbone (0.75 µg Strept-Tactin), thereby changing the Strept-Tactin-to-Fab ratio in each titration step. Further, we tested different Streptamer-to-cell ratios for a given Strept-Tactin-to-Fab ratio to answer the question how both ratios as variable parameters contribute to Streptamer staining intensities. We show a series of CD8 Streptamer stainings with varying Strept-Tactin-to-Fab ratios in Fig. 5.3. Staining intensities drop significantly when less Fab protein is used during Streptamer formation. Ideally, the Streptamer staining should depict a similar population of cells to be CD8$^+$ positive as compared to staining with a conventional antibody. In order to reach this, we had to choose a slightly different Strept-Tactin-to-Fab ratio of 0.75 µg: 0.1 µg for CD8 Fab Streptamers. Two Strept-Tactin-to-Fab ratios were chosen (one too low and one optimal) to test the second parameter Streptamer-to-cell ratio. Increasing amounts of Streptamer reagent were added on a per cell basis. Our data show that increasing the Streptamer-to-cell ratio cannot compensate for a poorly chosen Strept-Tactin-to-Fab ratio. Variations following changes in Streptamer-to-cell ratios are less abundant than changes in the Strept-Tactin-to-Fab ratios. We conclude from these data that the latter parameter is crucial for the constitution of Fab Streptamers and that a certain minimum of binding sites on the Strept-Tactin backbone must be engaged during multimerization in order to establish an adequate staining intensity.
Fig. 0.3: Titration of CD8 Streptamer multimerization

0.75 µg (PE-conjugated) Strep-Tactin was multimerized with increasing amounts of recombinant CD8-specific Fab protein and stainings were performed on 10^6 fresh PBMCs per sample. The multimerized staining reagents were further titrated over 3 different Strep-Tactin: Fab ratios (shown for 10 ng and 0.1 µg Fab). All stainings were performed under the previously stated conditions.

Again, we used simultaneous stainings for evaluation of the specificity of CD8 Streptamer stainings. Co-stainings with two different CD8-specific monoclonal antibodies are shown in Fig. 5.4a. As expected, the mAb staining with the same clone from which the CD8 Fab is derived (OKT8) resulted in a dimmer CD8 staining and lower frequency of CD8^+ cells when applied simultaneously with the corresponding Streptamer. In contrast, a brighter staining intensity in simultaneous use of both reagents resulted from mAb staining with a different clone. We therefore continued to use the B.11 clone for all following stainings. The resulting CD8 frequencies of Streptamer stained PBMCs and antibody stained PBMCs are alike in n=9 donors (Fig. 5.4b). We conclude that CD8 Streptamer staining and mAb staining yield uniform frequencies. This uniformity holds true for all pairs for different donor material.

Fig. 0.4: Simultaneous CD8 Fab-Streptamer and mab staining and CD8 frequencies in healthy individuals

CD8-specific Fab Streptamers were made at a ratio of 0.1 µg Fab and 0.75 µg (PE-labeled) Strep-Tactin per 10^6 cells. a. CD8 Streptamers of the OKT8 parental antibody clone specifically stain CD8^+ living lymphocytes (pre-gated). Specificity is verified by double stainings with Streptamers and commercially available mAb clones (OKT8 and B9.11). ‘ST only’ indicates the control staining using PE-labeled Strep-Tactin without recombinant Fab protein. b. CD3 Streptamer stainings (black dots) and stainings with the commercial anti-CD8 B9.11 mAb (red dots) performed on blood PBMCs from 9 different healthy donors respectively.

For evaluation of a CD62L Fab, as shown for CD8 Fabs, we also performed titrations of the Strep-Tactin-to-Fab ratio. Fig. 5.5 displays a representative titration experiment with the unmutated CD62L Fab protein over a fixed amount of 0.75 µg PE-conjugated Strep-Tactin. An antibody control staining using the same fluorophore (PE) is included (brown graph). Based on the staining intensities of Streptamer stainings we decided to use a Strep-Tactin-to-Fab ratio of 0.75 µg: 0.2 µg per 10^6 cells (orange graph). Streptamers made with this ratio yielded the brightest staining equal to the control mAb staining in staining intensity.
Apart from the unmutated CD62L Fab, a total of 5 different mutated CD62L Fab proteins were tested at different Strept-Tactin-to-Fab ratios with Fab contents ranging from 10 ng to 20 µg (100-fold increase as compared to standard). The mutated proteins were made as part of a panel of CD62L Fabs with different affinities for evaluation. Since neither the standard ratio nor an increase in Fab content during multimerization could establish proper Streptamer stainings for the 5 mutated CD62L Fabs, representative Streptamer stainings of all Fab proteins at the standard Strept-Tactin-to-Fab ratio of 0.75 µg: 0.2 µg per 1x10^6 cells are shown in Fig. 5.6a. The poor stainings with mutated CD62L Fab proteins are not a consequence of a particularly low CD62L expression in one individual donor but showed the same unsatisfactory staining on donor-PBMCs from other individuals. Only the CD62L wildtype (wt) Fab compares to the antibody control in staining performance as verified by stainings with 6 different donor-derived PBMCs (Fig. 5.6b). Confirmation of specificity of the CD62L Streptamer staining was obtained by simultaneous stainings with CD62L Streptamers and commercially available antibodies (Fig. 5.6c). In conclusion, the CD62L Fab wt Fab stains CD62L^+ lymphocytes like the commercially available mAb clone LT-TD 180.

![CD62L Fab](image)

**Fig. 0.5:** Titration of CD62L Streptamer multimerization

Stainings were performed on 10^6 fresh PBMCs using CD62L-specific Streptamers or phycoerythrin-(PE)-conjugated anti-CD62L monoclonal antibody. For multimerization 0.75 µg (PE-conjugated) Strept-Tactin was multimerized with increasing amounts of recombinant CD62L-specific Fab protein and stainings were performed under the previously stated experimental conditions.
Fig. 0.6: CD62L-specific Streptamer stainings using a panel of mutated and unmutated Fabs

Fab-Streptamers were made as described for CD3 and other Fab-Streptamers. a. Different mutated and an unmutated CD62L Streptamer of the parental antibody clone DREG56 were used to stain a subset of living lymphocytes (pre-gated). b. CD62L Streptamer stainings and mAb stainings using the commercially available anti-CD62L clone LT-TD 180 were performed on different healthy donor PBMCs (n=6). c. CD62L Streptamer specificity is verified by double staining with Streptamers and the commercially available mAb clone LT-TD 180.

For human CD45RO, only one antibody clone (UCHL1) has so far been successfully generated and commonly used. Plasmids for expression of recombinant CD45RO fusion proteins with the OneSTrEP-tag sequence in *E. coli* were kindly provided by Dr. Stefan Dreher. Functionally assembled Fab fragments were purified following protein expression by affinity chromatography using a Strep-Tactin protein purification column. First, we tried to address the question, which CD45RO Fab-Streptamers stain like parental antibodies. In Fig. 5.7a we show the staining performance of a panel of unmutated and mutated Fab fragments multimerized in the presence of PE-labeled Strep-Tactin. Notably, the specimens p1641 wt and p1643 wt as well as their mutated forms p1642 L11Sheavy and p1644 L11Sheavy show very good surface staining of human PBMCs. Further mutations were made based on the specimen p1643 wt apart from L11Sheavy. Those mutations p1643 L11Aheavy, p1643
40

104Aheavy, p1643 Y37Alight, p1643 Y41Alight, p1642 55Aheavy and p1644 55Aheavy do not show sufficient surface staining. 0.2 µg Fab-fragment was used for multimerization with 0.75 µg StrepTactin. This ensures an approximately equimolar ratio between Fab fragments and free Streptag binding sites on the backbone. All Fab fragments were then multimerized with a different Fab: Strep-Tactin ratio increasing the amount of Fab fragments to ensure that variations in protein concentration are compensated for. Titrations using up to 100-fold higher Fab concentrations could not compensate for the lack in staining intensities for some mutated CD45RO Fabs. To confirm these data at least 2 replicates of Streptamer stainings were made using each mutant on different donor-PBMCs each time. For the 4 Fabs with good staining, PBMCs from 3 donors were analyzed using either Streptamers or the commercially available UCHL1 clone for flow cytometry (Fig. 5.7b). With the exception of one mutated CD45RO, which showed a drop in staining intensity on one donor compared to the mAb control, the other 3 CD45RO Fabs stained equal CD45RO-positive frequencies. The same 4 CD45RO Fabs were then simultaneously stained with the commercial mAb to verify specificity of the staining. Both Fab Streptamers and mAbs are based on the same antibody clone UCHL1, and as expected, both strategies yielded very good surface staining of an identical subset of cells (Fig. 5.7c).

One CD45RO Fab-fragment (p1643 wt) with superior yield in protein expression was selected to test the performance of a Fab protein aliquot, which had been frozen (-80°C) and thawed 10 times side by side with an aliquot which was stored at –80°C and was never opened before. We could not detect any significant differences in Streptamer stainings (Fig 5.7d), indicating a remarkable stability towards freezing-thawing cycles of these Fab fragments.

In summary, we could show that Streptamer staining is fast and robust and can substitute conventional antibody staining after careful evaluation of parameters including Strep-Tactin-to-cell ratio during multimerization and Streptamer-to-cell ratio during staining. Other parameters, which can affect Streptamer surface staining were found to be temperature, staining time, cell concentration and volume. This is not surprising, as the very same parameters are also known to affect staining with commercially available antibodies. However, just like with commercial antibodies variations in these parameters showed only mild effects on the staining intensity Fab Streptamer stainings.
Fig. 0.7: Multimer staining of CD45RO+ cells using a panel of mutated and unmutated CD45RO Streptamers

Multimers of CD45RO specific Fab fragments were newly generated prior to each experiment using 0.2 µg Fab and 0.75 µg phycoerythrin (PE)-labeled StrepTactin/10^6 cells. a. CD45RO specific Fab Streptamers of the same parental antibody clone stain the CD45RO+ subset of human PBMCs in their unmutated form or when the point-mutation L11S is introduced in the heavy chain of the variable region in the Fab fragment. b. 4 CD45RO Fab Streptamers were tested on 3 donors to compensate for variations in the frequency of CD45RO expression. Each dot represents a different healthy donor. c. The specificity of the 4 functional Fab Streptamers was verified by simultaneous staining with the commercially available
5.2 Reversibility of Fab Streptamer stainings

The Streptamer technology should enable serial positive enrichment, thus enrichment of cell subsets defined by simultaneous expression of more than one phenotypic antigen like it is the case for central memory T cells. The most crucial step for sequential positive enrichment is the full reversibility of the Streptamer reagent following each selection step. So far, we have verified the specificity of all single components necessary for TCM selection by Streptamer stainings and flow cytometry. Next, we needed to develop a flow cytometry-based protocol to test the efficiency of reversibility of surface bound Fab/Strep-Tactin backbone components from the cells.

5.2.1 Critical parameters for reversibility of Fab fragments

The protocol for testing full reversibility of Streptamer stainings is based on stainings of fresh PBMCs with Fab Streptamers as described in the previous chapter. Multimerization of Fab proteins with fluorescent dye-conjugated Strep-Tactin allows direct visualization of Streptamer-stained cells via flow cytometry. When D-biotin is added, the signal is lost because the dye-conjugated Strep-Tactin is disrupted from the multimer complex and therefore also from binding to the cell surface. Depending on the binding affinity of Fab monomers, subsequently also the Fab molecules will dissociate. This step was so far not directly verifiable with current methods. Both kinetics (backbone disruption and Fab dissociation) are important for evaluation of Fab performance and are depicted in Fig. 5.8a. We used a fully reversible CD62L Streptamer staining to illustrate the general strategy of reversibility testing. A schematic view of all necessary steps on a single-cell level (above) and obtained flow cytometry data from the removal process (below) are shown. Fab-Streptamer stained samples are indicated by grey graphs overlaid with controls for Fab-unspecific background/autofluorescence (empty graphs). After the backbone is removed from the previously stained cells it is crucial to test for remaining Fab monomers on the cell surface. We developed a simple test by re-staining washed cells (to remove d-biotin and soluble Fab fragments in the cell supernatant) with a fresh fluorophore-coupled but unmultimerized Strep-Tactin backbone. The absence of any fluorescence signal after re-staining with unbound Strep-Tactin indicates full Fab dissociation. In order to control for effective removal of D-biotin, we included an additional control staining adding pre-multimerized Fab Streptamers; minute amounts of D-biotin are enough to disassemble at least a fraction of the Streptamers, which can be detected by a reduced staining intensity. This strategy turned out to be a highly sensitive test for detection of any remaining surface-bound Fab monomers. Similar to the experiments described above to optimize conditions for Streptamer staining, we needed to identify the
most relevant parameters for efficient reversibility. **Fig. 5.8b** gives an overview on the most important parameters which were tested. As a first step, we attempted to determine the optimal concentration, total quantity and duration for D-biotin incubation. After that, we focused on controlling the washing of the cells to provide enough time and optimal conditions for Fab dissociation. Parameters that have been tested were specifically total wash volume, temperature, time and the number of wash repetitions. By repetitive washing, the reagent concentration in the supernatant is strongly reduced. This procedure seems to improve Fab dissociation in some cases by changing the equilibrium of the binding kinetics. Furthermore, we determined the detection limit of Strep-Tactin re-staining, which plays an important role in controlling the extent of Fab dissociation.

**Fig. 0.8: Developing an assay to measure Fab Strep-tamer reversibility**

A schematic view on the single-cell level and a fully reversible CD62L Fab-Streptamer staining (histograms) is shown to reveal all necessary steps in the process of reagent removal including Strep-Tactin re-staining to control Fab, Strep-Tactin, and D-biotin removal (a). For a detailed protocol on testing Streptamer reversibility see section below. Critical parameters for reversibility are highlighted underneath the relevant steps of the process (b).

Next, we sought to identify the sensitivity and detection limit of Strep-Tactin re-staining as described above. By titrating in decreasing amounts of monomeric Fab-StreptagIII, we found that Fab concentrations 100-fold lower than to the initial staining conditions could still be detected. For $10^6$
PBMCs, this threshold is equivalent to 2 ng of unbound Fab (Fig. 5.9). For most Fabs, 20 ng is the minimum amount required to establish any visible staining on $10^6$ cells. For a few Fab-Streptamers also smaller amounts of 10 ng Fab and slightly below can still promote some staining (see Fig. 5.3 for reference), a concentration that still exceeds the detection limit of the re-staining assay by a factor of 5.

![unbound CD45RO Fab](image)

**Fig. 0.9:** Detection limit of *Strep*-Tactin staining for unbound Fab proteins

$10^6$ fresh PBMCs were incubated with the indicated amounts of CD45RO Fab protein for 20 minutes before addition of a 0.75 µg *Strep*-Tactin equivalent of PE-conjugated unmultimerized *Strep*-Tactin. After 20 minutes, all samples were analyzed by flow cytometry.

### 5.2.2 Development of an assay for testing reversibility of Fab fragments

Taking into account the previously stated parameters, we started out by testing different concentrations of D-biotin ranging between 1 µM and 10 mM to remove *Streptamer* staining from freshly stained PBMCs to determine the necessary amount of D-biotin for targeted *Streptamer* disruption. It is advantageous at this point to determine the lowest necessary D-biotin concentration, since it can become laborious to remove D-biotin afterwards. D-biotin has a $10^6$-fold higher affinity towards *Strep*-Tactin compared to the Fab fusion protein. For this reason, a 20-minute-incubation period is believed to exceed the necessary time to replace all binding sites by far. In **Fig. 5.10a** a representative titration of the D-biotin concentration is shown. Concentrations of 100 µM or more remove a previously established *Streptamer* staining in all experiments. There is a clear titration effect showing that even very low D-biotin concentrations can affect the staining intensity without completely removing the staining. Although the kinetics of Fab displacement from the backbone by D-biotin are not expected to depend on Fab specificity, differences in surface antigen-expression can lead to differences in the amounts of accumulated Fab-*Streptamer* before D-biotin is applied, which might affect the measurement. Therefore, we performed titrations of the D-biotin concentration in independent experiments on different donor PBMCs using CD45RO, CD4 and CD8 Fab specificities.
Independently of Fab specificities, we were able to determine a threshold concentration of 100 µM D-biotin for the successful removal of Strep-tamer stainings. In following experiments, 100 µM or 1 mM D-biotin was used for targeted monomerization. The overall amount of D-biotin is mutually dependent on the volume of D-biotin solutions besides the respective concentration. Notably, for 5x10^6 cells a volume of 200 µL was sufficient to remove the Strep-tamer signal for all tested Fab Strep-tamers. Further experiments conclusively confirmed that larger cell numbers required respective multiples of 200 µL of a D-biotin solution per 5x10^6 cells.

![Fig. 5.10b](image)

(Fig. 5.10b). Independently of Fab specificities, we were able to determine a threshold concentration of 100 µM D-biotin for the successful removal of Strep-tamer stainings. In following experiments, 100 µM or 1 mM D-biotin was used for targeted monomerization. The overall amount of D-biotin is mutually dependent on the volume of D-biotin solutions besides the respective concentration. Notably, for 5x10^6 cells a volume of 200 µL was sufficient to remove the Strep-tamer signal for all tested Fab Strep-tamers. Further experiments conclusively confirmed that larger cell numbers required respective multiples of 200 µL of a D-biotin solution per 5x10^6 cells.

For the subsequent step – the dissociation of monomeric Fab fragments – however, higher volumes than 200 µL might have a positive influence on Fab dissociation, which already occurs during D-biotin incubation as well. To address this, we have titrated the wash volume during D-biotin treatment in increasing amounts. Only after D-biotin was removed, slight differences became abundant: samples washed with higher volumes, revealed lower staining intensities upon re-staining with dye-conjugated Strep-Tactin (data not shown).

Since also the complete removal of D-biotin is a very crucial subsequent step after Strep-tamer disruption, which presumably also depends - similarly to Fab removal - on the wash volume, we reasoned that it would be most beneficial to create optimal conditions for removal of Fab and D-biotin in a single step while using as little D-biotin as necessary in the previous step.
Next, we aimed at analyzing the kinetics of Fab monomer dissociation during the first step-incubation with D-biotin. We re-stained CD45RO Streptamer-stained cell aliquots after varying incubation periods with 1 mM D-biotin and performed subsequent washes for D-biotin and Fab removal from the supernatant to prevent re-formation of Streptamers with unbound Strep-Tactin. We could demonstrate that incubation of at least 20 minutes is sufficient to prevent re-staining with residual Fab monomers and fresh Strep-Tactin after washing (Fig. 5.11). However, when incubation times are kept shorter (e.g. 10 minutes), small amounts of residual Fab monomers were still detected. Overall, our data indicate that it is not necessary for Streptamer disruption to provide long incubation periods (> 20 min) with D-biotin.

**Fig. 0.11:** Disruption kinetics of *Strep*-Tactin-based Fab-Streptamers with D-biotin

2x10^7 fresh PBMCs were stained with a CD45RO-specific Streptamer and were split into 4 identical aliquots of 5x10^6 cells. Each aliquot was exposed to a 1 mM D-biotin solution (PBS/0.5%BSA/1 mM D-biotin) for 10, 30, 45 or 2x10 minutes. Cells were re-stained with fresh PE-conjugated *Strep*-Tactin in the presence and absence of D-biotin (samples marked with 3 washes were considered biotin-free). All steps were conducted on wet ice (4°C). Red graphs represent control samples which were treated with PBS in place of Fab proteins.
Lastly, we aimed at determining the necessary wash volume and number of repetitive washes for the complete removal of Fab protein and D-biotin. The most time-sensitive parameter is most likely the spontaneous dissociation of Fab monomers from their target antigen. Since D-biotin does not further influence this step and an increasing number of wash steps might create a favoring equilibrium for dissociation, we thought to analyze Streptamer re-staining depending on the number of wash steps (n) rather than the total wash volume.

\[
\frac{c_n}{c_0} = \left(\frac{V_2}{V_1}\right)^n
\]

(1) number of steps n, volume of protein solution V₁, volume of wash buffer V₂, initial concentration of Fab protein c₀, final concentration of Fab protein after n washes.

**Formula 1** shows the effect of repetitive wash steps on the Fab protein concentration as a function of the number of washes. The same applies for the removal of the D-biotin or any soluble substance.

To determine the minimal number of washes necessary to remove D-biotin, we performed Strept-Tactin re-staining on Streptamer stained cells, which had undergone a different number of wash steps upon addition of D-biotin. As shown in Fig. 5.12, at least two biotin-free washes are needed to detect a Streptamer signal in flow cytometry, indicating that at this point no more D-biotin interferes with the Streptamer staining. We have previously seen how even very low concentrations of D-biotin lower the staining intensities of established Streptamer stainings. In contrast to Fab dissociation, time kinetics only play a negligibly small role in D-biotin removal. The dissociation kinetics of surface-bound Fab monomers is most likely the most critical factor for complete removal. Since dissociation kinetics are specific to each individual Fab fragments, these have to be evaluated separately for each Fab Streptamer. We have demonstrated before ([Fig. 5.11](#)) that 20 minutes were sufficient for anti-CD8-Fab monomers to spontaneously dissociate from the cell surface. In this case this is the same time frame we also proposed as optimal for D-biotin incubation in combination with subsequent washing (see above), and these different steps (multimer disruption with D-biotin, Fab dissociation and removal of D-biotin/Fab by washing) could be elegantly combined by the following protocol: one wash with D-biotin followed by two additional washes with d-biotin-free buffer with a 10 minute incubation step in each wash step. Thus, the requirements for D-biotin removal by at least two centrifugation steps as well as the requirement for at least 20 minutes dissociation time are met. Consequently, we set up experiments testing this protocol. Multiple aliquots of the same Streptamer-stained cells were incubated with D-biotin for 10 minutes and underwent one, two, or three additional washes à 10 minutes each. There is a clear difference between samples that underwent three 10-minute washes in total and those that underwent only one or two wash steps ([Fig. 5.12](#); note that the Fab Streptamer preparation used in this experiment maintained a fraction of a non-reversible component
for visualization of slight differences). In the following, all newly generated Fab Streptamers were tested for reversibility with this ‘D-biotin incubation combined with washing’ procedure and in combination with the flow cytometry-based assay. Only reagents that demonstrated full reversibility under these conditions were further used for Streptamer-based cell selection.

![Kinetics of Fab dissociation](image)

**Fig. 0.12: Kinetics of Fab dissociation depending on the number and duration of additional wash steps**

Fresh PBMCs were Streptamer-stained and allocated to multiple aliquots. All aliquots were incubated with D-biotin for 10 minutes on wet ice and subsequently underwent one, two, or three additional washes à 10 minutes each in the cold (4°C). Samples were re-stained with unbound, PE-conjugated Strep-Tactin including control re-staining with Fab-Streptamers.

### 5.2.3 Evaluation of anti-human Fab fragments for reversibility

From the above summarized results we concluded that (i) a 10-minute incubation with D-biotin is largely sufficient to fully disrupt Strep-Tactin-based Fab-Streptamers, (ii) that two additional washes with a 10-minute incubation time during each wash are sufficient for the removal of residual Fab monomers, (iii) complete removal of D-biotin requires at least two washing/centrifugation steps, when 1 mM D-biotin is used. The flow-based reversibility assay can be subsequently applied for further quality control of remaining Fab-fragments. We next compared different unmutated and mutated Fab proteins for reversibility under these proposed conditions. Freshly isolated PBMCs were stained with PE-labeled Fab-Streptamers. The cells were analyzed either before (Fig. 5.13, first column from the left) or after (second column) treatment with D-biotin. After two additional subsequent washing steps, potential remaining Fab-monomers were detected using unbound PE-labeled Strep-Tactin (third column from the left). A secondary Fab-Streptamer staining served as a control for the successful removal of D-biotin (Fig. 5.13, right column). We demonstrated complete dissociation of the wild type CD62L Fab-fragment by revealing that no substantial residual Fab protein was detected by Strep-Tactin re-staining after 3 washes. Hence, Streptamer stainings with the unmutated CD62L Fab fragment are fully reversible.
10^7 PBMCs were stained with a CD62L-specific Fab-Streptamer and subsequently exposed to D-biotin for 10 minutes on wet ice. Cells were then washed 2 times for 10 minutes each time at 4°C and subsequently re-stained with unbound, PE-conjugated Strept-Tactin or fresh CD62L Fab-Streptamer as indicated.

Next, we tested CD8 Fab Streptamer reversibility similarly. Although different donors showed varying results, we were always able to detect small amounts of residual Fab protein by Strept-Tactin re-staining indicating incomplete Fab dissociation. We hypothesized that these recombinant Fab preparations might contain a small fraction of non-reversible contaminants (e.g. by small aggregation). If this is the case, then it should be possible to accumulate this component on the cell surface by adding non-multimerized Fab-preparations. Therefore, we tested direct staining of cells with Fab Streptamers with (Multimer) and without (Fab +ST) prior pre-incubation and direct staining of cells with non-multimerized Fab protein and addition of PE-conjugated Strept-Tactin after 20 minutes (Fab Mono). The same respective protein amounts were used on identical aliquots of the same PBMCs. The pre-incubation time of Fab protein and Strept-Tactin does not affect initial Streptamer staining for CD8 (Fig. 5.14a left column). However, Strept-Tactin re-stainings differ distinctly between varying staining strategies. The Fab monomer staining with Strept-Tactin addition after 20 minutes of incubation of Fab monomers indeed accumulated the ‘irreversible’ component in the Fab preparation, whereas with conventional Streptamer staining only small amounts of ‘irreversible’ component could be detected (Fig. 5.14a third column from the left). If the ‘Fab monomer staining’ approach allows to specifically test for potential ‘irreversible’ components, the ‘irreversible’ staining phenomenon should increase with increasing monomer concentrations. And indeed, increasing amounts of Fab protein show a substantial increase of Strept-Tactin re-staining (Fig. 5.14b). Others in the laboratory subsequently improved the Fab purification to fully remove the ‘irreversible’ components. In this context, the monomer staining procedure has become the standard test to demonstrate the quality/purity of fully reversible Fab preparations.
Fig. 0.14: Different multimerization strategies result in differences in Strep-Tactin re-staining

$10^7$ fresh PBMCs were stained with a CD8 Fab-Streptamer, or incubated with unbound Fab monomers for 0 or 20 minutes before Strep-Tactin-PE was added. In the latter strategy, cells were analyzed by flow cytometry before Strep-Tactin addition as a control for unbound Fab background. Cells of all groups were subsequently exposed to 1mM D-biotin for 10 minutes on wet ice (4°C). Cells were then washed 2 times for 10 minutes at 4°C each time and re-stained with unbound, PE-conjugated Strep-Tactin or fresh CD8 Fab-Streptamer.

The monomer staining assay initiated the idea to test whether Fab-Streptamer staining could be generally improved if just the components (Fab monomer and Strep-Tactin-backbone) are added to the target cells separately (instead of adding preformed Streptamers). This way the multimerization process should preferentially take place on the surface of cells expressing the Fab-specific antigen (‘on-cell multimerization’). We tested this hypothesis and could indeed detect slightly higher staining intensities by ‘on-cell multimerization’ (Fig. 5.15). $10^6$ fresh PBMCs were stained with monomers (with or without 20 minute incubation before Strep-Tactin addition) or pre-formed Streptamers. We detected differences in staining intensities when the multimerization strategy is changed, independent of the respective Strep-Tactin-to-Fab ratio. Varying Strep-Tactin: Fab ratios resulted in dimmer or brighter staining depending on the Fab amount used, but for each ratio the pattern Fab + Strep-Tactin, 20 min > Fab + Strep-Tactin > Streptamer regarding staining intensity is maintained.

For other Fabs than CD8 as well, side-by-side comparisons of the ‘on-cell multimerization’ strategy with the conventional strategy using pre-formed Streptamers revealed differences in staining intensities of varying extent depending on the Fab specificity and even on the individual protein batch. For reversibility testing, it has become standard in the meantime to always apply the ‘on-cell multimerization’ strategy, since we found that the ‘on-cell multimerization’ pulled out more abundant Strep-Tactin re-staining in the case of inhomogenous Fab preparations.

Fig. 0.15: Multimerization strategies affect staining intensities independently of the Fab concentration

$10^6$ fresh PBMCs were stained with a pre-incubated CD45RO Fab-Streptamer (green histograms), or incubated with unbound Fab monomers for 0 (orange histogram) or 20 minutes (blue histogram) before Strep-Tactin-PE was added. From left to right: increasing amounts of Fab monomers were incubated with $10^6$ cells or used for Streptamer formation. Strep-Tactin was always used at 0.75 µg equivalent. All stainings were performed on wet ice (4°C).
We used this observation to test whether increasing the temperature during the dissociation step could help to eliminate also this component. For that reason, we tested two different temperatures selected by their relevance for clinical use. We first tested the CD8 Fab preparation containing the – at 4°C – ‘irreversible’ component using the standard reversibility assay at 4°C and room temperature (22°C) and found a dramatic difference between cold and warm conditions. Under warm conditions, the Fab dissociation was complete and no substantial re-staining could be detected (Fig. 5.16). Two donors with very different CD8 population sizes were compared and, as expected, the staining on the larger population was found to perform weaker in reversibility, as seen by means of a slightly increased staining intensity of Strep-Tactin re-staining. Under warm conditions, again, the reversibility could be rescued completely.

<table>
<thead>
<tr>
<th>donor 1</th>
<th>CD8 Fab + Strep-Tactin</th>
<th>CD8 Multimer D-biotin 1 mM</th>
<th>CD8 Multimer D-biotin 1 mM 2 washes</th>
<th>CD8 Multimer D-biotin 1 mM 2 washes</th>
<th>no Fab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>+StrepTactin</td>
<td>+StrepTactin</td>
<td>+StrepTactin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td></td>
</tr>
<tr>
<td></td>
<td>71.1</td>
<td>96.9</td>
<td>85.9</td>
<td>69.1</td>
<td>n/a</td>
</tr>
<tr>
<td># cells</td>
<td></td>
<td>26.9</td>
<td>3.1</td>
<td>14.1</td>
<td></td>
</tr>
<tr>
<td>CD8 Streptamer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4°C wet ice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>22°C room temp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>donor 2</th>
<th>CD8 Fab + Strep-Tactin</th>
<th>CD8 Multimer D-biotin 1 mM</th>
<th>CD8 Multimer D-biotin 1 mM 2 washes</th>
<th>CD8 Multimer D-biotin 1 mM 2 washes</th>
<th>no Fab</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>+StrepTactin</td>
<td>+StrepTactin</td>
<td>+StrepTactin</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50.1</td>
<td>28.8</td>
<td>29.1</td>
<td>28.1</td>
<td>n/a</td>
</tr>
<tr>
<td># cells</td>
<td></td>
<td>1.25</td>
<td>28.1</td>
<td>41.4</td>
<td></td>
</tr>
<tr>
<td>CD8 Streptamer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4°C wet ice</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>22°C room temp.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. 0.16: FACS analysis of CD8 Fab-monomer reversibility at different temperatures

10⁷ fresh PBMCs from two different donors were stained with Fab proteins and Strep-Tactin as previously described and the staining was subsequently reversed using 1 mM D-biotin in a three-step wash protocol as described. D-biotin and wash buffers were kept at either 4°C (wet ice) or 22°C (room temperature) during the process.

We next evaluated all 4 recombinant CD45RO Fab proteins that previously showed good surface staining using the reversibility test setup. Our panel of CD45RO Fabs consists of two pairs of a wildtype form and a mutated form, respectively. They differ in the light chain: one was generated by gene amplification of the UCHL1 hybridoma (p1641-42), the other was synthesized from the published sequence (p1643-44). Sequence analysis revealed variations in 7 amino acid residues thereof 6 within the constant region and 1 within the framework of the variable region. Interestingly, we could show that both wildtype Fabs performed unequally indicating that slight variations in the protein structure can have an impact on reversibility. The p1641 wt Fab exhibited a higher staining intensity upon Strep-Tactin re-staining than the p1643 wt (synthetic light chain) indicating incomplete Fab removal. The same holds true for the mutated forms. Introduction of the L11Sheavy mutation into both plasmids resulted in superior reversibility in the p1644 Fab (synthetic light chain) retaining the same pattern as the wildtype pair. In Fig. 5.17a, reversibility of both Fab pairs are shown in direct comparison using the same donor blood leukocytes. All four proteins were also tested on at least one other independent blood donor to account for inter-experimental differences (Fig. 5.17b). Although some variability can be observed between donors, most likely due to differences in individual CD45RO expression, the p1643 wt Fab and both mutated Fabs revealed better relative reversibility. Unfortunately, protein expression yielded very little protein from the mutated plasmids. Therefore, we decided to proceed with the p1634 wt Fab for selection experiments.
Fig. 0.17: Reversibility of CD45RO Fab Streptamer stainings

$10^7$ fresh PBMCs were stained with 4 different Fab proteins and Strept-Tactin as previously described and the staining was subsequently reversed at 4°C using 1 mM D-biotin in a three-step wash protocol. **a.** Representative experiment compares all 4 Fabs in Streptamer staining and reversibility. Live cells are shown. The numbers in dot plots indicate the percentage of cells within gates. **b.** Two or more repetitions of the described assessment of staining and reversibility. Dots represent the number of independent experiments using different donor PBMCs (n=3 for p1643 wt, n=2 for all others).
We have previously shown that a temperature shift from 4°C (wet ice) to 22°C (room temperature) resulted in the complete removal of Fab fragments. We hypothesized that a smaller increase in temperature might have a similar beneficial impact on the reversibility while cells can still be maintained cooled. Interestingly, an intermediate temperature of 12°C (waterbath) was insufficient for complete reversibility in the most sensitive reversibility assay applying the ‘monomer strategy’. Shifting the temperature to 22°C resulted in the complete removal of CD45RO p1643 wt. We observed substantial Strep-Tactin re-staining after the 3-wash removal regimen upon addition of 1 mM D-biotin at 12°C, while performing all removal steps at 22°C led to complete Fab dissociation.

Interestingly, remaining reagent did not negatively interfere with control Streptamer stainings (Fig. 5.18). This experiment indicates that increasing the washing temperature during Fab dissociation to room temperature should largely broaden the spectrum for Fab proteins that can be used for reversible staining and sequential positive selections. Furthermore, at higher temperatures also the sometimes contaminating ‘at 4°C irreversible’ components can be fully removed. ‘On-cell multimerization’ yielded higher staining intensities for some Fab Streptamers, but is prone to accumulate more of the contaminant to the cell surface. Obviously this problem can just be overcome by shifting the washing temperature up.

**Fig. 0.18: Temperature dependency of CD45RO Fab dissociation kinetics**

10⁷ fresh PBMCs were stained with monomeric CD45RO Fabs for 20 min before PE-labeled Strep-Tactin was added to the mix. The staining was subsequently reversed at 4°C using 1 mM D-biotin in a three-step wash protocol at 12°C (waterbath) or 22°C (RT). Living lymphocytes are shown. The numbers in histograms indicate the percentage of cells within gates.
5.3 Streptamer-based selection of \textit{ex vivo} human PBMCs using nano-sized paramagnetic microbeads

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig019.png}
\caption{Schematic overview on a sequential positive selection over three different cell surface antigens}
\end{figure}

The target population in this sequential positive enrichment procedure is defined by the simultaneous expression of all three markers. Each step represents one positive enrichment step leaving only positive cells for marker 1 in the first positive fraction after the first step. The second selection starts with only cells that are positive for marker 1 and results in a positive fraction of double positive cells (marker 1+2). In the final selection only triple positive cells are selected. This scheme reflects a strategy that can be used to enrich central memory T cells.

For the purpose of cell selection, Fab-Streptamers can be generated with \textit{Strep}-Tactin-coated magnetic beads. Depending on the specific size and surface of the beads, careful titrations of the \textit{Strep}-Tactin-to-Fab ratio had to be performed to identify optimal conditions for cell enrichment. The polysaccharide-coated beads are 50 nm -150 nm in diameter and are covalently bound to \textit{Strep}-Tactin on the surface. They are designed for the use with selection columns or the current state-of-the-art CliniMACS® clinical selection system. We have generated Fab Streptamers specific for human CD4, CD8, CD62L, CD45RO, and CD45RA based on \textit{Strep}-Tactin coated nano-sized magnetic beads.
(provided by STAGE cell therapeutics, Göttingen) to answer the question, if our Fab-based reagents can replace conventional ‘irreversible’ antibody-based selection reagents. For multimerization of Fab proteins with Strep-Tactin coated magnetic beads we mixed 2 µg of Fab protein with a 7.5 µg Strep-Tactin equivalent of magnetic bead suspension at least 45 minutes prior to use. The above-stated quantities refer to the use on $10^7$ PBMCs respectively unless indicated otherwise. We then measured cell viability by PI staining of lymphocytes and purity of the positive fraction after magnetic selection by re-staining with fluorophore-conjugated antibodies. For the recovery, positive target cells were counted before and after selection. The ratio of the number of positive target cells after selection to the target cell number before selection equals the recovery.

$$\text{recovery} = \frac{\text{cell number in positive fraction}}{\text{cell number before selection}} \times \frac{\text{purity}}{\text{relative target cell frequency}} \times 100$$

We have performed positive selections of target cell populations with relative target cell frequencies between 20% (CD8) and almost 80% (CD62L) among living lymphocytes. All selections using CD4, CD8, CD62L, and CD45RO Fab-Streptamers yielded very good viabilities, purities and recovery rates. For CD4 selection for example, the recovered positive fraction contained 99.8% CD4$^+$ living lymphocytes. Similar results were obtained for positive selections of CD8$^+$, CD62L$^+$, and CD45RO$^+$ selections. **Fig. 5.20a** illustrates all obtained results from one representative experiment for each marker. All initial relative frequencies and final purities of the positive cell fraction are shown. For CD45RA selections – an alternative to positive selection for CD45RO -, we chose to perform a negative selection. Therefore, the flow through during magnetic selection was collected. In this case the CD45RA depleted fraction is shown instead of the positive fraction from CD45RA enrichment. In **Fig. 5.20b** a summary of selection data generated using nano-sized magnetic beads is shown for each Fab including cell viability after selection, final purity (pre-gated on living lymphocytes) and recovery rates. The calculated recovery rates show a stronger variation between donors as opposed to the consistently uniform purities. Neither resulting viability and purity nor cell recovery correlate with the initial frequency of target cells. We have confirmed our observations by producing at least 2 (2-10) replicates.
Fig. 0.20: A compilation of Fab-Streptamer-based positive selections with nano-sized magnetic particles

a. $2 \times 10^7$ or $5 \times 10^7$ fresh PBMCs were prepared for column-based direct positive magnetic enrichment with Fab-Streptamers of 5 different specificities. Each dot plot represents a fraction of cells taken either before or after the selection procedure upon re-staining with fluorescent antibodies for flow cytometry. The gates indicate the percentage of cells that are positive for each marker that was used for the respective selection. CD45RA selection aimed at the CD45RA-negative fraction. b. Purities, viability and recovery are plotted for selections with all 5 Fab-Streptamers. All experiments were performed with at least 2 different donors (n=2 for CD4, n=3 for CD8; n=10 for CD62L, n=5 for CD45RO; and n=2 for CD45RA).

When multiple positive selection steps are performed, all reagents must be removed from the positive cell fraction before it can undergo a second selection step. For nano-sized magnetic bead-based Fab-Streptamers the removal of the Strep-Tactin backbone, which is covalently bound to the surface of the magnetic beads, as well as Fab monomers and excess D-biotin can be achieved by centrifugation and sequential wash steps. Small aliquots of the positive fraction can be re-stained with unbound Strep-Tactin as a control for Fab removal during the process as shown in the Strep-tamer staining section. Similarly, a second selection step can only successfully lead to selection of cells in the positive fraction when D-biotin is efficiently removed, since otherwise the contact between cells and magnetic particles would be disrupted by excess D-biotin. We have now tested the sequential positive enrichment of CD45RO$^+$/CD8$^+$/CD62L$^+$ cells based on our positive results for the reversibility of Fab-based Streptamer stainings. All three selection steps were performed with a D-biotin treatment using PBS/BSA/1 mM D-biotin and three wash steps of 10 minutes each in between selections. The first two sequential positive selection steps (CD45RO$^{1\text{st}}$, CD8$^{2\text{nd}}$) yielded a 90.5% pure CD45RO positive subpopulation for the first selection but only 25.5% purity of the second positive fraction following the second selection. Although the relative CD8 frequency has increased over the second selection (from 16.6% to 25.5%), no clear segregation of positive and negative cells was possible during the second selection. We included reagent removal controls after each selection step by taking aliquots of the positive fractions. The first selection yielded a pure subpopulation, which tested negative for residual Fab monomers. Nonetheless, the second selection did not perform as desired. The same observation holds true for the third selection for CD62L$^+$ cells. No further purification occurred after the first positive selection step although the cells tested negative for residual Fab on the cell surface after both steps. Instead, the CD45RO$^+$ cell population was dragged through all selection steps and was not lost during multiple cycles of positive enrichment (Fig. 5.21a). The results suggest that the magnetic labels could not be completely removed from the CD45RO$^+$ population and might have been incorporated in folds of the cell membrane or into the intracellular space because of their small size. Very similar results were obtained from two or three step selections using different Fabs specific for other target antigens as shown in Fig. 5.21b. Independent nanobead-based positive selection experiments over one or two parameters confirm our previous findings. Final purities of the first or second target-positive fractions are shown resulting from different combinations of antigens that were targeted. Purities obtained during the second positive selection were substantially lower in all experiments and ranged in an unacceptable area mostly below 60%.
Based on these observations, we sought to investigate potential parameters that might help obtain good purities in nanobead-based sequential positive enrichments more thoroughly. We have therefore performed sequential CD8 (1st) and CD45RO or CD62L (2nd) selections using the nanobead technology. First, we tested positive fractions again for residual Fab monomers after a single subsequently reversed positive selection step. Instead of FACS staining with unbound Strep-Tactin, we now used unbound Strep-Tactin coated magnetic nano-sized beads. Similar to the re-staining with PE- or APC-conjugated Strep-Tactin, the incubation with Strep-Tactin coated magnetic beads after D-biotin and washing should result in magnetic cell labeling if cells had still Fab monomers on their surface. We performed positive selections with CD8, CD62L and CD45RO Fabs that have previously been tested negative in PE-conjugated Strep-Tactin re-stainings and one CD45RO wt Fab that has previously shown some Strep-Tactin-PE re-staining as a control that is known to be not completely reversible. The three positive populations selected with reversible Fabs were incubated with Strep-Tactin coated magnetic beads for 20 minutes and underwent a second selection step in which bead-labeled cells are separated from unlabeled cells. Surprisingly, 22% of the positive fraction was held back in a magnetic field in the second selection (Strep-Tactin control) step. From the CD45RO positive fraction selected with a partly irreversible Fab, 38% of the positive fraction was found in the second positive fraction. A proportion of cells might fail to lose their Fab markers upon D-biotin incubation, but this effect is not likely to be entirely based on ‘irreversible’ Fab monomers (seen even for fully reversible Fabs) since no substantial re-staining with fluorescent Strep-Tactin occurred in a similar setting and a difference in retention between a completely reversible Fab (in Strep-Tactin-PE re-staining) and a partly irreversible Fab was assessed (25% vs. 38%). When we repeated the experiment with different completely reversible Fabs and found 22%-28% retention in n=3 experiments (data not shown). This could be in line we our hypothesis that Fab-bead complexes are not removed from the surface in the first place because they are trapped in the cell membrane or might even get incorporated into the cell plasma.

For previous re-stainings with PE-labeled Strep-Tactin, we have set up controls without a specific Fab protein to determine unspecific Strep-Tactin binding. It is crucial for Strep-Tactin coated nanobeads to conduct these controls as well. A selection from PBMCs with un-multimerized Strep-Tactin-beads without any Fab proteins at all resulted in a similar proportion of cells (4%; n=2) to wind up in the positive fraction of a magnetic selection step. This result rules out that attachment to the cell surface during the incubation period of Strep-Tactin coated beads alone is accountable for the failure of sequential positive enrichments. Nevertheless, a contribution of unspecific Strep-Tactin binding to the observed effect cannot be ruled out here. For that reason, we have tried to identify a sensitive target within the PBMC compartment for unspecific Strep-Tactin binding by Fab-free cell separations with Strep-Tactin coated nanobeads only. We could not find a difference between flow-through and positive fractions when both were subject to a positive enrichment step following incubation with Strep-Tactin coated nanobeads only nor was any of the fractions more or less prone to magnetic
labeling in the second selection cycle compared to the combined fractions or compared to fresh unselected cells. Taken together, we were able to determine unspecific labeling on a fraction of cells but failed to identify a Strept-Tactin-sensitive target that can be pre-cleared from the mixture of cells. We proceeded on the assumption that unspecific binding of Strept-Tactin coated nanobeads occurs and expected it to be succumbed to the Strept-Tactin-to-cell ratio. Therefore, we titrated the amount of Strept-Tactin coated beads per cell. We found increasing occurrence of unspecific clustering of cells and beads indicated by unspecific retention in a magnetic field depending on the relative amount of Strept-Tactin coated nanobeads applied. These ‘magnetically labeled’ cells were pooled and incubated with increasing amounts of Strept-Tactin coated nanobeads for a second time. Surprisingly, even when the Strept-Tactin concentration in the second step was diluted 10-fold, the number of cells in the positive fraction was still in the same range as when the Strept-Tactin was not diluted at all. We could not determine any titration effect. We conclude that magnetic particles are accumulated on the cell membrane or get trapped on the creased surface of the cells or even get internalized. This effect is in part Fab-independent and in part facilitated by multimerized conglomerates of beads with specific Fab proteins which help accumulate beads on the surface. In all experiments, cells that were retained before got carried through following selection steps because second positive fractions lack good purities but do not show substantial losses in cell numbers. D-biotin could be ruled out as a factor, because the outcome of experiments was unchanged whether cells were pre-treated with D-biotin before the first selection step or in between steps compared to a D-biotin-free control group. Taken together, unspecific binding with Strept-Tactin coated magnetic nanobeads regards about 4% of fresh human PBMCs. Assuming a maximal purity of 96% that can be achieved with this system in a single selection step, a three-step-selection would decrease the maximal possible purity to 88% assuming a steady proportion of unspecific labeling, which is already unsatisfactory for high-purity sorts of a specific subset of cells with a superior safety profile. Beyond that, our experiments have shown that in a second selection the Fab-independent unspecific labeling went up to 26% of cells of the first positive fraction, indicating that the cells which are initially selected are stably labeled with magnetic beads and are carried through the remaining selection steps. Depending on the initial cell number, then a substantial number of contaminating cells are positively selected throughout the entire process. Especially when large amounts of cells are selected in a clinical setting, the contamination rate would comprise several tens of millions of unspecific cells in a selection out of 10^9 PBMCs. We conclude that multiparameter selections on the nano-sized magnetic bead-based cell selection system are currently not feasible.
Fig. 0.21: Serial Fab-Streptamer-based positive selection with nano-sized magnetic particles over three parameters

10^6 fresh PBMCs were prepared for column-based direct positive magnetic enrichment as previously described. a. Each dot plot represents a fraction of cells taken either before or after the selection procedure upon re-staining with fluorescent antibodies for flow cytometry. The gates indicate the percentage of cells that are positive for each marker which was used for

b. 2-step positive selections with nano-sized beads

- Purity 1st pos selection
- Purity 2nd pos selection

% of target living lymphocytes

2nd step
1st step
the respective selection. Histograms depict Strept-Tactin re-staining of an aliquot from the positive fraction 1 or 2 and control PBMCs which have never been exposed to Fab proteins. b. Final purities as percentage of living lymphocytes in the positive fraction 1 or in the positive fraction 2 (after 2 cycles of positive enrichment with reagent removal in between).

5.4 Development of a pre-clinical multi-parameter purification protocol using larger magnetic microbeads

An alternative approach to the nano-sized magnetic particles is the use of larger magnetic microbeads of at least 1µm in diameter, which can be applied with column-free cell separation systems using a hand held permanent magnet. The Strept-Tactin coated larger magnetic microbeads that were used in this thesis work have been developed by Stage cell therapeutics. Such particles might be advantageous because they are less prone to internalization or trapping effects and they could substantially speed up the selection and removal process due to the increased magnetic forces conferred to a cell. Furthermore, larger beads are easier to detect and easier to remove completely from the cells. Also from a regulatory point-of-view, the removal of larger beads might be advantageous because they are easier to track and the complete removal can be better controlled. Because of their size, microscope-aided tracking and under optimal conditions even microscopy-aided counting is possible. First, we used the size-advantage of larger magnetic particles to track co-localization of target cells and Fab-conjugated magnetic microbeads throughout a positive magnetic purification step followed by D-biotin treatment. Fig. 5.22 illustrates microscopic images of all steps of a CD62L-specific selection from fresh PBMCs. Co-incubation with a CD62L-specific magnetic bead Streptamer results in formation of clusters between a fraction of the cell mixture and the magnetic particles (red circles, CD62L+ subset; Fig. 5.22a). Upon magnetic separation only cells clustered with microbeads are found in the positive fraction, whereas cells that have not clustered with magnetic beads are removed entirely by washing (Fig. 5.22b). After a 10-minute D-biotin incubation, cells and beads are both found in the positive fraction, but are now separated and no longer co-localized in clusters, indicating that cells are fully released from the magnetic beads (Fig. 5.22c).
Fig. 0.22: Microscopic tracking of positive magnetic selection and removal of magnetic microbeads

CD62L-specific microbeads were used as a selection reagent to separate CD62L+ cells from a PBMC mixture. a. The mixture of cells was incubated with CD62L specific magnetic microbeads which co-localize and cluster with the CD62L+ subpopulation of the cells. b. Unlabeled cells were washed away in a magnetic field. c. 5 mL of a 1 mM D-biotin solution was added to the positive fraction to release all clusters. d. The mixture of cells was co-incubated with only magnetic microbeads without a Fab-mediated specificity as a control for unspecific co-localization.

5.4.1 Optimal parameters for magnetic microbead selections

We now sought to identify the optimal parameters for selections using larger magnetic microbeads (termed microbeads in the following). We have used a Strep-Tactin equivalent of 7.5 µg of Strep-Tactin-coated magnetic microbeads together with 2 µg of CD8 Fab for multimerization of a CD8-specific selection reagent for the purification from a starting number of $10^7$ cells unless indicated otherwise. A selection with CD8-specific Fab Streptamers was performed during which cell fractions before and after the separation procedure were re-stained with a commercial CD8 antibody or with a PE conjugated CD8 Fab Streptamer along with a CD3 antibody. CD8 expression was higher on CD3+/CD8+ double positive cells (T cells) and resulted in the complete depletion of those cells in the negative fraction (Fig. 5.23). The Streptamer re-staining (Fig. 5.23; upper panel) was useful for us to judge the depletion rate from the negative fraction and the purity of the positive fraction in the most direct possible way. Since both re-stainings depict redundant information, the CD8-specific antibody
clone B9.11 (Fig. 5.23, lower panel) was used for all relevant re-stainings in the following. The CD8 positive cell population comprises of a high expressing T cell fraction (CD3\(^+\)) and a lower CD8 expressing CD3 negative fraction. The high expressing subset is clearly favored during the selection process resulting in a higher proportion of CD8\(^+\) T cells in the positive fraction. The differences in the flow-through (negative) fractions are even more obvious. The depletion from the negative fraction is an indirect measure of the cell recovery rate, when all cells are collected for flow cytometry analysis. The lower the count and specific frequency in the negative fraction, the higher are the recovery rates. For CD8\(^+\) T cells both purity and depletion are in the maximal possible range of close to 100%.

![Flow cytometry dot plots showing before selection, negative fraction, and positive fraction.](image)

**Fig. 0.23:** CD8-specific Streptamer selection using larger magnetic microbeads

5x10\(^7\) fresh PBMCs were magnetically labeled with CD8 Streptamers for magnetic separation using a column-free system with a simple hand-held magnet. All fractions were counted and aliquots were re-stained with either PE-conjugated CD8 Streptamer (upper panel) or the commercially available PE-conjugated antibody clone B9.11 (lower panel). Live lymphocytes are shown. The numbers in dot plots indicate the percentage of cells within gates.

As mentioned earlier, the use of different Strep-Tactin backbones makes titrations of the Strep-Tactin-to-Fab ratio inevitable. We have used the CD8-specific Fab to test selection at different Strep-Tactin-to-Fab ratios. In the range of 1.25 – 5.0 \(\mu\)g CD8 Fab per 2.5x10\(^7\) cells the respective recovery rates but not the purities showed a significant difference (**Fig. 5.24a**). To confirm this, blood from 1, 2, or 4 different donors was included in independent experiments (**Fig. 5.24b**). The next titration was conducted in order to test the influence of the incubation time on purities and recovery rates of CD8 cell selections using larger magnetic microbeads. This test has a dual purpose: on the one hand, we expect to retain more CD8\(^+\) cells when the incubation time is increased, on the other hand, we wanted to test for unspecific binding, which might occur when the incubation period is too long. Fortunately,
no unwanted cells were found in the positive fraction after 20 minutes, 40 minutes or 60 minutes of incubation (Fig. 5.24c). The recovery rates, however, did increase in correlation with the incubation time in a range from 20-60 minutes (Fig. 5.24d). This effect can be exploited for setting up selection protocols when only very little donor cells are accessible in order to increase the recovery rates if necessary. For all other sorts, however, the incubation time for each positive selection step should not exceed 30 minutes because the process of multiple selections would otherwise get too time consuming.

Fig. 0.24: Recovery rates but not purities of CD8 Streptamer selections correlate with protein amount and incubation time
2.5x10^7 fresh PBMCs were separated using different CD8 specific Streptamers with varying Strept-Tactin-to-Fab ratios. All fractions were counted to determine cell numbers and aliquots were re-stained with CD8 antibodies to determine purities. a. For the selection of 2.5x10^7 PBMCs, 1.25, 2.5 or 5.0 µg Fab protein was multimerized with a Strept-Tactin equivalent of 22.5 µg of magnetic microbeads. b. Summary of multiple experiments performed with different donor blood. Purities and recovery rates are shown depending on the Strept-Tatin-to-Fab ratio. c. Selection of CD8+ PBMCs using multimers of 5.0 µg Fab. Incubation time was 20 minutes, 40 minutes, or 60 minutes before separation in a magnetic field. d. PBMCs from two different donors are shown.

5.4.2 Sequential positive magnetic enrichment over two parameters

For magnetic bead-based Fab-Streptamers, the removal of the Strept-Tactin backbone, which is covalently bound to the magnetic beads, can easily and rapidly be done by magnetic separation with a permanent magnet after D-biotin is added for Streptamer disruption. To demonstrate that larger magnetic bead-based Streptamers are fully reversible and sequential positive enrichment is possible, we performed first positive selections using CD8 Streptamers followed by a second positive selection for CD62L positive cells. Very good purities for the intermediate positive fraction (97.7% of live
lymphocytes) and the final (second) positive fraction (97% of live lymphocytes) were obtained (Fig. 5.25). Among 22 independent replicates of sequential CD8/CD62L positive selections from different donor-PBMCs we observed only very little variation between overall purities but a larger spread between individual recovery rates (shown in right graph). When we repeated these experiments multiple times we thereby also interchanged orders of CD8 and CD62L selection steps. There was no evidence that a specific order of reagents/separation steps resulted in better overall purities. Therefore, we believe that it is advantageous to start serial positive selections with the specificity that is represented by the lowest number of positive cells within the original cell specimen, since this strategy should allow performing selections with lowest amounts of reagents and buffers.

![Sequential positive enrichment of a CD8+/CD62L+ cell subset from fresh human PBMCs](image)

**Fig. 0.25**: Sequential positive enrichment of a CD8⁺/CD62L⁺ cell subset from fresh human PBMCs

A two-parameter positive magnetic enrichment was performed on 10⁸ fresh human PBMCs. Aliquots from before the selection and each positive fraction are shown. The numbers in dot plots indicate the percentage of cells within gates. Purities and recovery rates were taken from 22 independent experiments from 2x10⁷-10⁸ initial PBMCs.

We assumed that by further evaluation of different selection parameters and conditions the overall recovery rates could be improved. Those experiments included a fine titration of the CD62L reagent. CD8⁺ cells were incubated with a CD62L-specific microbead reagent with varying Strep-Tactin-to-Fab ratios like previously described above for CD8. Similarly, higher Fab concentrations did not yield higher cell recovery rates. We detected an optimum in cell recovery at a Strep-Tactin-to-Fab ratio of 1 µg per 10⁷ pre-selected CD8⁺ cells. We have verified the cell recovery on the level of absolute cell numbers as well (Fig. 5.26). Furthermore, we titrated wash steps and wash volume without recognizing a correlation with the cell recovery rates. A larger wash volume generally resulted in higher purities but slightly lower cell recoveries.
CD62L selection out of CD8+ cells

Fig. 0.26: Different Strep-Tactin: Fab ratios influence the recovery rates but not purities of CD62L Streptamer selections

2.5x10^7 pre-selected CD8+ PBMCs were separated using different CD62L specific Streptamers with varying Strep-Tactin-to-Fab ratios. All fractions were counted to determine cell numbers and aliquots were re-stained with CD8 and CD62L antibodies to determine purities. Precisely, 1.25, 2.5, 5.0 or 10.0 µg Fab protein was multimerized with a Strep-Tactin equivalent of 2.5 µg of magnetic microbeads. Absolute cell numbers were determined (red graph and right axis) and cell recovery rates were calculated based on the initial cell number (black graph and left axis).

5.4.3 Sequential positive magnetic enrichment of central memory T cells

Ultimate goal of this thesis work was the development of a protocol enabling efficient enrichment of central memory T cells (T_{CM}), either CD8+ or CD4+. In order to do so, we started by sequential targeting of the markers CD8, CD62L and CD45RO, which should allow enrichment of CD8+ central memory T cells (T_{CM}) in a three-parameter sequential purification setup. A representative complete selection cycle is depicted in Fig. 5.27. CD8+ T cells were almost completely depleted from the negative fraction and recovered at 98.3% purity in the first step. 94.7% of all recovered CD8+ cells were CD8+/CD62L+ double positive before CD62L selection in this donor and were enriched to 99.3% purity in the CD62L selection step with some target cell loss during the second wash. The final step yielded a 89% overall purity and reached a cell recovery of 18% (referring to the absolute T_{CM} number before selection). These data show for the first time that positive enrichment of a complex cell population is possible with multiple reversible selection reagents. Since reversible MHC Streptamers are already in clinical use and GMP-conform selection protocols have been approved by regulatory authorities for this purpose, it seems feasible to transfer the serial positive enrichment procedure with Fab-Streptamers similarly to clinical applications. So far, clinical CD8+ T_{CM} enrichment has only been described by use a series of depleting antibodies such as CD4, CD14 and CD45RA in a single negative selection step followed by a positive selection step for CD62L+ cells. To our knowledge, this strategy never reached purities of CD8+ T_{CM}s any close to what we describe here for the Fab-Streptamer selections.
Fig. 0.27: Sequential positive enrichment of human central memory T cells

$5 \times 10^8$ fresh human PBMCs were incubated with anti-CD8 Fab-Streptamers conjugated with Strep-Tactin-functionalized magnetic microbeads. The CD8 positive fraction was collected and treated with 1 mM D-biotin and washed twice to remove remaining reagents. In a subsequent second selection step, CD62L positive T cells were enriched from the CD8$^+$ fraction as described for the first step. Finally, CD45RO$^+$ cells were enriched using a CD45RO specific Fab-Streptamer conjugated to Strep-Tactin-coated beads. Living lymphocytes obtained before and after each selection step are shown.
5.4.4 CD45RA depletion

As an alternative to the positive CD45RO selection step in the T<sub>CM</sub> enrichment protocol, it is also possible to enrich for the desired population by depletion of CD45RA<sup>+</sup> cells. Expression of CD45RA should in principle exclude expression of CD45RO. We have tested direct CD45RA Fab-Streptamer depletion based on magnetic microbeads from fresh human PBMCs. For re-staining we chose monoclonal antibodies for both CD45RA and CD45RO to demonstrate that CD45RA depletion can in principle substitute the CD45RO positive selection step. As shown in Fig. 5.28, CD45RA selection targeted exclusively CD45RA<sup>+</sup> cells enabling the successful recovery of CD45RO<sup>+</sup> cells. Double negative cells are neither CD8<sup>+</sup> nor CD3<sup>+</sup> cells and therefore never appear after CD8 selection (Fig. 5.29). Importantly, the recovery rates are in a similar range as recovery rates obtained from CD45RO selections (mean = 45.7%, n=5). We estimated that recovery rates from CD45RA depletion might even surmount those of CD45RO positive selections. For this reason, we were interested in a direct comparison between a CD45RO positive selection versus a CD45RA depletion following positive enrichment of CD8<sup>+</sup>/CD62L<sup>+</sup> cells to create the desired setting for T<sub>CM</sub> enrichments. Surprisingly, CD45RA depletion not only resulted in superior cell recovery rates but yielded a greater overall purity compared to CD45RO positive selection (Fig. 5.29). Here we have tested CD45RA depletion as part of a sequential enrichment protocol together with a CD8/CD62L-positive enrichment. When donor PBMCs from the same blood were split in two aliquots and depletion was either performed before or after CD8/CD62L positive selection following the same protocol with the same reagents, CD45RA depletion after CD8/CD62L positive selection resulted in a slightly better purity and recovery rate. We have confirmed this result in three independent experiments (data not shown). The new protocol design for a three-step purification of T<sub>CM</sub> using CD8/CD62L/CD45RA is based on these results.

![Fig. 0.28: A CD45RA Streptamer-based reagent for positive enrichment and depletion of human CD45RA<sup>+</sup> cells.](image)

CD45RA depletion was performed using specific Fab-Streptamers conjugated to Strep-Tactin-coated magnetic microbeads. Living lymphocytes are shown for each step of the procedure including the unwanted positive fraction of CD45RA<sup>+</sup> cells. One representative experiment from 5 independent blood donors is shown in a. n=5, gated on living lymphocytes. Viability, purity and recovery rates are shown.
Fig. 0.29: Sequential selection of memory T cells using CD45RO for positive selection or CD45RA for depletion

Pre-selected CD8⁺/CD62L⁺ cells were subjected to a CD45RO positive selection step or a CD45RA depletion step using specific Fab-Streptamers conjugated to Strep-Tactin-coated magnetic microbeads. a. Living lymphocytes of one representative experiment are shown. Numbers in dot plots indicate the relative frequency of events inside the gates. b. Two independent experiments are shown. Sequential selections including a negative depletion step (black graphs) or a positive selection step (blue graphs).

We have applied the new TCM purification protocol as shown in Fig. 5.30. One representative complete three-step selection cycle out of 6 independent experiments (all performed exactly under the same experimental conditions) for enrichment of CD8⁺ central memory T cells is shown. Very high purities were reached in the two positive enrichment steps and for CD45RA depletion in the example. The final cell product purity was 96% CD8⁺ CD45RO⁺/CD45RA⁻ CD62L⁺ T_CM. We have obtained similar high purities of T_CM in all 6 independent experiments with PBMCs derived from different donors averaging in an overall purity of 97.8% ± 1.58 of cells in the final T_CM fraction. There was no correlation between initial T_CM frequencies and overall purity of final T_CM fractions. Surprisingly, the recovery rates averaged at 29.5% ± 14.1 with higher variability between different donors. We further aimed at dissecting the contribution of each selection step to the overall cell recovery and purity. Therefore, data from two- and three-step experiments performed under the exact same conditions on different donors were analyzed. Interestingly, the variability between donors was highest for CD8 and lowest for CD62L although CD62L yielded lower recovery rates in general (Fig. 5.31). We conclude that each selection step contributes to a different extent to the overall target cell recovery in T_CM selections. We demonstrated here that reversible Fab-Streptamers can be effectively used in a serial selection procedure for robust enrichment of T_CMs to very high purities using only 3 reagents.
Sequential positive enrichment of human central memory T cells using CD8, CD62L, and CD45RA Fab-Streptamers

3x10^7 - 10^8 fresh human PBMCs were incubated with anti-CD8 Fab-Streptamers conjugated with Strep-Tactin-functionalized magnetic microbeads. The CD8 positive fraction was collected and treated with 1 mM D-biotin and washed twice to remove remaining reagents. In a subsequent second selection step, CD62L positive T cells were enriched from the CD8⁺ fraction as described for the first step. Finally, CD45RA⁻ cells were depleted using a CD45RA specific Fab-Streptamer conjugated to Strep-Tactin-coated beads. Living lymphocytes obtained before and after each selection step are shown for one representative experiment of 6 independent experiments from different donor material.

5.4.5 Sequential selection of CD8 and CD4 central memory T cells

Some approaches in adoptive T cell therapy favor the simultaneous administration of CD8 and CD4 cells and suggest a combinatorial adoptive transfer of CD8 and CD4 central memory T cells. It might be advantageous to be able to control the ratio between CD4 and CD8 T_CM in the cell product. Different strategies could allow the purification of central memory T cells expressing CD8 or CD4 with more or less control on the CD4:CD8 ratio. One is the sequential enrichment of both CD8 and CD4 central memory T cells separately. This strategy would require an additional selection step in the
process or a substantial loss in cell numbers when PBMCs are split prior to selection. Alternatively, cells could be selected as described in the previous section by replacement of the CD8 Fab with a CD3-specific Fab, which selects both T cells, CD4 and CD8. Alternatively, CD4- and CD8-specific Fab Streptamers could be mixed and simultaneously used within a positive selection step. We have tested these strategies in the following sections. First, we hypothesized that simultaneous selections of CD4 and CD8 T<sub>CM</sub> enable the highest degree of control on the CD4:CD8 ratio of the final product. We therefore replaced CD8 Fabs in Streptamer preparation with a mixture of CD4 and CD8 Fabs. Using this mixed reagent for positive selection out of fresh PBMCs, we observed substantial differences in recovery rates for CD4 and CD8 T cells. When the individual Fab proteins were mixed at a ratio of 1:1, CD4 T cells were selected at a higher ratio compared to CD8 T cells. Thus, a shift in CD8:CD4 ratio is generated in favor of the CD4 subpopulation. In Fig. 5.32a we show an example where the CD4 proportion of all T cells shifted from initially 75% CD4 T cells to over 90% CD4 T cells after selection with a mixture of CD4- and CD8-specific Streptamers at the same ratio. We hypothesized that we could adjust the CD4:CD8 Fab ratio in the mixture so that the CD4:CD8 T cell ratio after selection matches a desired ratio (e.g. 1:1). Therefore, we tested decreasing CD4: CD8 Fab ratios from 1:1 to 1:16 and observed a linear correlation between doubling the CD8 Fab fraction in the mix and doubling the frequency of CD8 T cells in the positive fraction (Fig. 5.32b). However, as demonstrated by the results from two independent donors, in order to achieve a particular CD4:CD8 T cells ratio, one must know the initial frequency to adjust the CD4/CD8 Fab Streptamer mixture correctly. Donor #1 (Fig. 5.32b left panel) had an initial ratio of CD8: CD4-positive T cells of 0.25; in this case a CD4: CD8 Fab Streptamer ratio of 1:8 was necessary to obtain similar numbers of CD8 and CD4 T cells (1:1 ratio). Donor #2 (Fig. 5.32b right panel) had an initial ratio of CD8: CD4-positive T cells of 0.5; in this case a CD4: CD8 Fab Streptamer ratio of 1:4 was needed to obtain similar numbers of CD8 and CD4 T cells. The same correlations hold true when calculating absolute cell numbers as shown in Fig. 5.32c. These data indicate that it might be possible to predictably enrich for defined CD8 to CD4 ratios if the initial CD8 and CD4 T cell frequencies are known prior to selection.
Fig. 0.32: The outcome ratio between CD4 and CD8 T cells in selection with mixed reagents can be set to a desired value.

Streptamers with previously mixed CD4- and CD8-specific Fab fragments were made at a ratio of 2 µg Fab and 7.5 µg (bead-conjugated) Strep-Tactin per $10^7$ cells. a. We have used 1 µg CD4 Fab and 1 µg CD8 Fab for multimerization of 7.5 µg (bead-conjugated) Strep-Tactin for the selection out of $10^7$ fresh PBMCs. b. Aliquots of $10^7$ PBMCs from two independent donors were selected with different mixes. CD4: CD8 Fab ratios for each selection are indicated. c. Absolute cell numbers were determined by counting positive fractions and multiplication with frequencies in CD4 or CD8 gates.
5.5 A *Streptamer* technology-based protocol for the selection of human $T_{CM}$ in compliance with GMP-manufacturing of cell products

The next thesis goal was to develop a selection protocol that enables GMP-conform $T_{CM}$ selections in a closed system. Our laboratory recently succeeded in generating a CD3-specific Fab fragment for the selection of central memory T cells that was successfully implemented in the serial enrichment procedure. CD3/CD62L/CD45RA based $T_{CM}$ selections combine both advantages, the fast and easy three-step enrichment with the possibility to isolate CD4 and CD8 $T_{CM}$ at the same time without the need for prior analysis of donor frequencies. The $T_{CM}$ selections described in the following were performed in a closed sterile system of custom-made sets of tubing and bags provided by Stage Cell Therapeutics. All bags and connection tubes are designed for single-use and hold all necessary junctions for filling, washing, and D-biotin treatment for one selection step. Welding of tubes was performed with a Terumo Medical TSCD® II welding unit (to create a new connection) or a conventional tube welding device (to close a tube) enabling transfer of collection bags to new tubing systems for subsequent selection steps. The magnet used was the DynaMag™ CTS™ Magnet by Life Technologies and holds one selection magnet (magnet 1) and a second, smaller magnet for secure removal of any residual magnetic particles (magnet 2). Both magnets and custom made tubing sets are shown in Fig. 5.33. Up to $10^{10}$ cells are co-incubated with CD3-specific magnetic microbeads in the selection bag which is subsequently sealed in place between the connection tubes to buffer and D-biotin reservoir above and the collection bags below the selection bag. The selection bag is filled up with buffer from the reservoir by opening the blue valve for 10-20 seconds. After 1 minute on the magnet the horizontal white valve is opened to conduct buffer including unlabeled cells into the collection bag for the negative fraction (Fig. 5.33a). This wash procedure is repeated twice after the white valve is closed. Two valves can never be opened simultaneously at all times. CD3+ cells are now pooled in the negative fraction and the target cells in the selection bag are treated with D-biotin by opening the red valve for 2-5 seconds (Fig. 5.33b). Note that the green color indicates all areas that are in contact with D-biotin. Analog to the wash process, the vertical white valve is opened to release cells in D-biotin into the collection bag for the positive fraction. This step is repeated another time. In contrast to the wash steps, the target cells are now flushed into a collection bag while only unbound magnetic particles alone are retained in the magnetic fields of the two magnets. Red arrows indicate the whereabouts of target cells during positive selection during washes and removal (Fig. 5.33a+b). The following CD3 positive selections were performed followed by D-biotin treatment for reagent removal as described. After three centrifugation steps including a 10-minute incubation each time (see section 5.2) A subsequent CD62L positive selection step comprising all the exact same steps as described for CD3 selection was performed using a fresh set of tubes and bags. After removal of the CD62L reagent, a CD45RA- Fab *Streptamer*-based depletion was performed similarly without the D-
biotin steps because in this case the unlabeled fraction equals the target fraction. It is directly collected in the bag for the positive fraction (vertical white valve) to ensure that the second magnet works as a backup to catch any residual magnetic labels or unwanted labeled cells.

**Fig. 0.33: Selection procedure in a custom design bag- and tubing set for the clinical DynaMag™ CTS™**

Single use clinical plastic bag and tubing system in the set up for use with the DynaMag™ CTS™. Magnets 1 and 2 are part of the DynaMag™ CTS™. The system remains closed throughout the whole process. Connections can be altered by a clinical welding device. Selections and welding can be performed in any environment and remain sterile. Selection bags are connected to the buffer reservoir and the D-biotin reservoir above and to the collection bags for negative and positive system below. **a.** Magnetically labeled cells are in the selection bag. Unlabeled cells are washed with buffer and are collected in the negative fraction bag. For washing, the blue clip is opened for 10 seconds to fill the selection bag with buffer. Subsequently, the horizontal white clip is opened to release buffer and unlabeled cells into the negative fraction bag. The wash process is repeated twice. **b.** Magnetically labeled target cells in the selection bag are flushed with D-Biotin from the reservoir when the
red clip is opened. Incubation time is 10 min to release cells from magnetic beads. Cells are subsequently released into the collection bag for the positive fraction passing the second magnet for secure removal of any residual magnetic particles. This step is repeated one more time. Blue indicates D-biotin-free buffer, green indicates buffer containing D-biotin. *location of target cells at given timepoints.

A representative TCM purification out of 5x10^8 PBMCs is shown in Fig. 5.34a. We show our complete gating strategy applied on lymphocyte singlets and all relevant gates to determine viability and purities of each step which is represented by a row (read from top to bottom). In this example we yielded 99% pure CD3+ T cells with an overall purity of 95% for CD62L and 99% for CD45RO and a remarkable 52% recovery. The bottom row of Fig. 5.34a provides additional data showing the phenotype of all cells without any pre-gating. We conclude from this that we have minimal risk emanating from a small potential contaminant with a CD3+/CD62L-/CD45RO+ phenotype which is most likely an effector memory phenotype. Those cells have previously been characterized as short-lived cells with no evidence of mediating harmful side effects concerning their in vivo behavior upon adoptive transfer. We tested Fab dissociation by re-staining with an anti-IgG light chain antibody to detect any residual Fab fragments. In three-step serial TCM purifications we yielded average purities of 93.5% ± 3.1 from PBMCs derived from human buffycoats. To be able to compare the outcome, we have used a starting population of 5x10^8 PBMCs from each donor. The cell numbers were determined after Ficoll separation of the blood. The average recovery rate was 32.9% ± 11.2, which corresponded to an absolute cell number average of 1.4x10^7 TCM from a starting number of cells which is usually obtained from 300-500 mL of donor blood (Fig. 5.34b). Similar results were obtained from apheresis products, which provide much bigger cell numbers and are commonly used for example as a source of donor stem cells in the clinic. Our largest scale experiment was performed on 2x10^9 PBMCs. We show a summary of all TCM purification experiments from apheresis products as the starting material in Fig. 5.34c. Noteworthy, in one case a low CD62L purity was observed indicating that shedding of CD62L might have occurred to some extent. In a separate experiment in the interest of CD62L shedding under given experimental conditions we did not observe any reduction in CD62L expression over time on PBMCs obtained from buffycoat und incubated with staining probes for 6 hours on ice (spans the experimental procedure).

Furthermore, being able to perform TCM selections with a CD3-specific reagent allowed us to track if CD4 T cells are also preferentially enriched opposed to CD8 T cells when the same marker is used (cf. chapter 5.4.5). When we selected T cells with Streptamers of mixed specificity for CD4 and CD8 at the same ratio we preferentially enriched CD4+ cells over CD8+ cells. CD4 frequencies were 4 times as high as CD8 frequencies or higher depending on the initial ratio (Fig. 5.32a+b). To test if this effect depends on the markers used or if it is of a more general cell-intrinsic nature, we analyzed the CD4: CD8 ratio of positively selected CD3+ cells. We were not able to detect a shift in CD4: CD8 T cell ratios after a single step of CD3 positive enrichment (cf. Fig. 5.34 first and second row). The CD4: CD8 ration before selection (first row) is 2 and the CD4: CD8 ratio after CD3 selection is 2.2 and therefore not in the range of selection bias we saw with mixed Streptamers. However, combinatorial
expression of CD62L and CD45RO markers differs vastly between CD4 and CD8 subsets making the natural pattern of co-expression of the selection markers responsible for the high content of CD4\(^+\) T\(_{CM}\) upon CD3\(^+\)/CD62L\(^+\)/CD45RA\(^-\) purification in most donors. Taken together the generated data convey evidence that T\(_{CM}\) selections from very high starting cell numbers (2x10\(^9\) cells) are possible with outstanding overall purities and very good target cell recovery rates in a closed system that can be directly reproduced in a clean room facility for the GMP production of clinical cell products. The total procedure required approximately 6 hours processing time.
TCM selection out of $5 \times 10^8$ PBMCs

**a**

<table>
<thead>
<tr>
<th>Gating Strategy</th>
<th>Viability</th>
<th>CD8 $^+$</th>
<th>CD3 $^+$</th>
<th>CD3+CD62L $^+$</th>
<th>CD3+CD45RA $^+$</th>
<th>Recovery</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>40.9</td>
<td>93.4</td>
<td>90.7</td>
<td>7.98</td>
<td>1.88</td>
<td>5.6</td>
</tr>
<tr>
<td>NC</td>
<td>88.3</td>
<td>99.8</td>
<td>98.5</td>
<td>98.3</td>
<td>66.6</td>
<td>60.4</td>
</tr>
<tr>
<td>NC</td>
<td>92.4</td>
<td>99.9</td>
<td>99.3</td>
<td>99.4</td>
<td>80.5</td>
<td>80.5</td>
</tr>
<tr>
<td>NC</td>
<td>96.4</td>
<td>99.2</td>
<td>99.9</td>
<td>98.2</td>
<td>99.6</td>
<td>99.6</td>
</tr>
</tbody>
</table>

**b**

**Buffycoat** $5 \times 10^8$ PBMC

**c**

**Apheresis** $10^5$ - $10^8$ PBMC
Fig. 0.34: Sequential positive enrichment of human central memory T cells using CD3, CD62L, and CD45RA Fab-Streptamers in closed GMP-conform system

5x10^8 fresh human PBMCs were incubated with anti-CD3 Fab-Streptamers conjugated with Strep-Tacin-functionalized magnetic microbeads. The CD3 positive fraction was collected and treated with 1 mM D-biotin and washed twice to remove remaining reagents. In a subsequent second selection step, CD62L positive T cells were enriched from the CD3^+ fraction as described for the first step. Finally, CD45RA^+ cells were depleted using a CD45RA specific Fab-Streptamer conjugated to Strep-Tacin-coated beads. Living lymphocytes obtained before and after each selection step are shown for one representative experiment of 4 independent experiments from different donor material (a). Positive fractions and their respective gating are highlighted in green for each step. b. 4 independent experiments were performed using the CD3-based protocol for T CM enrichment. Purities for each selection step are given as well as cell recovery rates. All steps within one selection step including D-biotin treatment and removal of the magnetic beads were performed in a closed system of plastic bags and tubes designed for single use. c. Set of 3 experiments performed on apharesis material with PBMC contents of 10^8-2x10^9.

5.6 Further developments in T CM purification

A major improvement in advanced GMP production of cell therapeutics is the reduction of manufacturing time during cell processing procedures. To harness the full power of the Streptamer technology, we intended to test novel, simplified protocols in order to be able to process a maximal number of cells in a minimal amount of time and effort. Ficoll separation and centrifugation steps during washing are a major time-consuming component, especially when they are conducted in a clean room in large scales.

5.6.1 Centrifugation-free purification of central memory T cells out of PBMCs

Removal of Strep-Tacin, monomeric Fab proteins and excess D-biotin after a positive selection step are crucial for subsequent selection steps. We could show that Strep-Tacin-coated magnetic microbeads can be safely removed by magnetic attraction in the field of a strong permanent magnet. However, removal of the soluble components Fab and excess D-biotin requires repeated cycles of centrifugation and subsequent removal of the supernatant containing those components. We hypothesize that Fab monomers, if not removed, will interfere with the following selection step in such a way, that monomeric Fab will partly couple with Strep-Tacin from the second Streptamer forming new, unwanted Streptamers of the previous specificity by Fab fragment exchange. To prove this hypothesis, we have stained PBMCs with CD4-specific Streptamers in the presence or absence of CD8 Fab monomers. The Streptamer specificity is clearly lost when CD8 Fab monomers were mixed with the cells prior to staining with CD4 Streptamers. Both, CD4^+ and CD8^+ cells appear Streptamer^+. Remarkably, the full staining intensity of the CD8 control Streptamer staining (with 0.5 µg Fab/10^6 cells) was already reached when only 10% of the CD8 Fab monomers (0.05 µg Fab/10^6 cells) were used compared to a regular staining of 10^6 cells. This supports our hypothesis that Fab monomers
interfere with Streptamer staining reagents. Our results clearly show de novo formation of CD8 specific Streptamers (Fig. 5.35a). Next, we hypothesized that a clear, specific CD4 Streptamer staining can be re-established when unbound CD8 Fab proteins are neutralized in the Fab/cell mix in advance of the Streptamer incubation. For neutralization, we used a previously determined amount of 50 µg of soluble unconjugated Strep-Tactin per 10^6 cells. 10^6 fresh PBMCs together with 0.2µg CD8 Fab monomer were stained with a CD4-specific Fab-Streptamer in the presence (Fig. 5.35b left panel) or absence (Fig. 5.35b right panel) of 50 µg Strep-Tactin as a neutralization reagent. CD4 Fab Streptamer staining resulted in staining of CD4^+ and CD8^+ PBMCs when Strept-Tactin is omitted but retained specificity of the staining in the sample treated with Strept-Tactin. We conclude that addition of soluble Strep-Tactin before staining rescues the original specificity by neutralization of Fab monomers. All stainings were performed in a D-biotin free system. Neutralization of D-biotin supposedly requires larger amounts of reagents. We first tested avidin as a candidate reagent for D-biotin neutralization and calculated the necessary amount for neutralization of a 500µL D-biotin (100µM) solution and performed titrations to prove this (data not shown). Then, we performed simultaneous neutralization of CD8 Fab monomers and 100 µM D-biotin. According to our expectations, addition of Strept-Tactin alone was not sufficient to neutralize 500 µL of 100 µM D-biotin (Fig. 5.35c left panel). D-biotin was finally neutralized by addition of 100 µg avidin and Streptamer staining was enabled. Avidin alone could not rescue the specificity of the CD4 Fab-Streptamer because avidin is not able to neutralize Fab monomers due to its low affinity towards the Strep-tag (Fig. 5.35c middle). D-biotin and CD8 Fab monomers were neutralized when both neutralization reagents were added (Fig. 5.35c right panel). We conclude that it should be possible to neutralize soluble selection reagents after a positive selection step and removal of magnetic beads. We tested the neutralizing reagents avidin and Strept-Tactin in a serial positive magnetic selection. As shown in Fig. 5.35d, a CD62L Streptamer selection could successfully be performed after a positive CD8 enrichment step and subsequent removal of beads and neutralization of Fab and excess D-biotin. The removal step in between selections involved neither additional washing buffer, nor centrifugation. This is the first evidence that a serial positive magnetic enrichment can in principle be performed without centrifugation and therefore a substantial amount of time can be saved.
Fig. 0.35: Soluble Avidin and Strep-Tactin can neutralize Fab monomers and D-biotin.

a. $10^6$ fresh PBMCs were stained with a CD4-specific Fab-Streptamer in the absence or presence of 0.025 or 0.05µg CD8 Fab monomer. Controls stainings include 0.05 CD8 Fab with unbound Strep-Tactin (no CD4) and Strep-Tactin alone (background). b. $10^6$ fresh PBMCs and 0.05µg CD8 Fab monomer were stained with a CD4-specific Fab-Streptamer in the presence (left panel) or absence (right panel) of 50 µg Strep-Tactin (ST) as a neutralization reagent. CD4 Fab Streptamers staining results in staining of CD4+ and CD8+ PBMCs when Strep-Tactin is omitted. The addition of soluble Strep-Tactin before staining rescues the CD4 specificity by neutralization of Fab monomers. c. Simultaneous neutralization of CD8 Fab monomers and 100 µM D-biotin by addition of Strep-Tactin (ST) and avidin (Av). Left: 10 µg of Strep-Tactin alone was not sufficient to neutralize 500 µL of 100 µM D-biotin. Middle: D-biotin neutralization by 100 µg avidin enables staining, but specificity is not kept because avidin alone is not able to neutralize Fab monomers. Right: D-biotin and CD8 Fab monomers are neutralized. d. Serial positive enrichment of CD8/CD62L positive cells out of $2 \times 10^7$ PBMCs. CD8 selection was performed as previously described. Positive fraction was treated with 1 mL 100 µM D-biotin and 100 µg avidin and 10 µg Strep-Tactin was added per $10^6$ cells respectively. A CD62L-specific Streptamer beads were added after 20 minutes for the second positive selection.

These results further encouraged us to test an easy-to-use system for efficient removal of D-biotin and monomeric residual Fab for the use in a closed system. Preliminary experiments confirmed that Strep-Tactin alone is capable of neutralizing Fab fragments and D-biotin if the concentration is high enough. A special removal column with high contents of Strep-Tactin was provided by Stage cell therapeutics. We hypothesized that the extremely high binding capacity of cross-linked biopolymer-particles can allow the fast and complete removal of soluble reagents. A high amount of Strep-Tactin is covalently bound to matrix biopolymers of 100 µm in diameter on average. The matrix can be employed in a cell suspension flow without any trapping or hindering of cells in a continuous flow. Therefore, a
cylindrical plastic syringe was modified with 20 µm filters to hold the matrix biopolymers in a section of the cylinder volume. The design allows cells to pass the filters while all matrix beads are held back (Fig. 5.36a). The matrix is characterized by its structural properties allowing the immobilization of huge amounts of Strep-Tactin on the inside of the particles. Experiments have shown that Strep-Tactin immobilization only on the surface of the biopolymers could not provide a sufficient amount of Strep-Tactin for neutralization of both Fab monomers and D-biotin. Thus, under flow conditions a continuous stable binding of dissociated Fab-monomers and excess D-biotin mainly on the inside of the particles is necessary. Compared to the molar equivalent of Strep-Tactin needed for D-biotin neutralization, residual free Fab monomers only account for about 1% of the necessary Strep-Tactin and can therefore be neglected in calculations. We have confirmed the location of Strep-Tactin by staining with the high affinity ligand D-biotin. Co-incubation of the matrix beads with biotinylated, PE-conjugated MHC-molecules resulted in bright staining of the matrix material (Fig. 5.36b). This system in principle now allows elimination of soluble selection reagents without centrifugation. Monomeric Fabs and excess D-biotin should be completely removed from the cell suspension after each step without accumulation of Strep-Tactin-bound or unbound residual reagents after a single step which could be carried over to the next step in the selection cycle. The general setup and operating principle of the removal column are shown in Fig 5.37. After D-biotin treatment of the positive fraction, cells and soluble selection reagents are separated from magnetic particles in a magnetic field. The extremely high content of Strep-Tactin within the polymeric matrix stably binds Fab monomers and excess D-biotin while cells can flow through the matrix unimpeded. At this point it is critical to use as little D-biotin for removal of Streptamers as possible. We have shown earlier that 100 µM solutions of D-biotin were sufficient for reversing Streptamer stainings in all experiments. All calculations are therefore based on a D-biotin concentration of 100 µM.

Fig. 0.36: Removal column: centrifugation-free elimination of soluble selection reagents
Setup of a plastic column of packaged cross-linked biopolymer-particles that allows the fast and complete removal of soluble reagents in a cell suspension flow without any trapping of cells or hindering of the continuous flow. a. Column is set up by a cylindric plastic tube comprising a chamber that holds the matrix resin within a 20µm pore size mesh. Polymer particles are
100 µm in diameter on average and are shown in a microscopic image with T cells as a size reference. b. Microscopic image of fluorescence labeled Strep-Tactin (provided by Herbert Stadler).

Fig. 0.37: Principle of the complete removal of selection reagents with the novel removal column

After D-biotin treatment, cells and soluble selection reagents are separated from magnetic particles in a magnetic field. The extremely high content of Strep-Tactin within the polymeric matrix stably binds Fab monomers and excess D-biotin while cells can flow through the matrix unimpeded.

Next, we evaluated parameters linked to the experimental implementation of the removal column prototype. To determine the D-biotin binding capacity of removal columns, we tested different columns and loaded them with a total of 7 mL of a 100 µM D-biotin solution (PBS/0.5% BSA/100 µM D-biotin) each. Given the small size of the columns, based on our calculations 7 mL D-biotin is sufficient to reach the level of D-biotin saturation in the column leading to a leak of D-biotin from the matrix at some point, which is detected by the drop in MFI when Streptamer stained cells are co-incubated with aliquots taken from the flowthrough of the column. Aliquots of 0.5 mL are continuously collected from the flowthrough from the columns and each aliquot is co-incubated with CD3-Streptamer+ cells. The MFI is determined by flow cytometry. A 0.5 mL column for example can securely hold back at least 2 mL of 100 mM D-biotin and a 1 mL column can absorb at least 3.5 mL before leaking biotin into the flow as shown in detail in Fig. 5.38. We have tested three different column sizes and determined the respective D-biotin binding capacities by comparison with CD3-Streptamer+ cells co-incubated with D-biotin-free buffer as a control. Below the lower limit of MFIs measured without D-biotin, drops in MFIs are considered to be D-biotin mediated. The flow rate of a liquid through the matrix in a removal column was previously measured as a function of column height and revealed a linear relationship. We therefore expected a linear relationship between the column height which equals the column volume in this case and the D-biotin binding capacity. We found almost equal disparity between the three column sizes (vertical dashed lines). When comparing
the measured binding capacities, a linear relationship is revealed by these results. In other words, the flow rate is bisected when the column height is doubled.

![Graph showing D-biotin binding capacity](image)

**Fig. 0.38: Estimation of the D-biotin binding capacity by virtue of column size**

For each column size (represented by black, blue and green graphs), Streptamer stained PBMCs were distributed to 14 identical reaction tubes at 1x10^6 cells per sample. 7 mL of a 100 µM D-biotin solution (PBS/0.5%BSA/100 µM D-biotin) were continuously run over each column. Portions of 0.5 mL of the flow through were collected at the end of each column and incubated with the prepared Streptamer stained PBMCs. FACS analysis was performed after a 20-minute incubation period to determine the mean fluorescence intensity (MFI).

To test the performance of D-biotin and Fab monomer binding, the removal column was first implemented in the removal of a Streptamer staining. Reversibility testing was now performed under the previously defined standard conditions comprising 3 wash steps and in a side-by-side assay with implementation of the removal column without centrifugation. The following experiment includes two different Fab proteins with slightly different Fab dissociation behavior. The CD4 Fab as a reference is perfectly reversible under standard conditions while a small amount of residual CD45RO Fab for the selected clone was detectable by Strep-Tactin restaining under the given conditions. We found identical results for the CD4 Fab comparing removal column and standard protocol. We conclude that the same removal efficiency is achieved for both strategies while the application of the removal cartridge yields good results in a much shorter time (ca. 40 min saving). Further, the implementation of the removal column with its extremely high binding capacity by virtue of large amounts of Strep-Tactin clearly enhanced Fab dissociation from the cells as seen in direct comparison of Strep-Tactin re-stainings upon both strategies in the case of CD45RO (Fig. 5.39).
Fig. 0.39: Implementation of a removal column enhances Fab dissociation in a FACS-based reversibility assay

2x10^7 fresh PBMCs were stained with a CD45RO or CD4 Streptamer were split into two groups after they have been exposed to a 0.1 mM D-biotin solution (PBS/0.5%BSA/0.1 mM D-biotin) 20 minutes. One group underwent the standard wash protocol for Fab dissociation and D-biotin removal while the other group was run over a removal column. Cells of both groups were re-stained with fresh PE-conjugated Strep-Tactin or fresh Fab-Streptamer. Red graphs represent control samples which were treated with PBS in place of Fab protein in the initial staining.

Subsequently, we have performed two-step serial magnetic enrichments implementing the removal cartridge between the first and the second selection step to collect evidence that the novel matrix can help improve multi-parameter cell purification. A representative experiment is shown in Fig. 5.40. In a first selection step, CD4+ cells were separated from a mixture of fresh PBMCs. The positive fraction was treated with 0.1 µM D-biotin for 20 minutes and was run over a removal column of 4 mL Strep-Tactin resin in size. The fraction was counted and aliquots were re-stained with phenotypic antibodies and Strep-Tactin-PE as a control for reversibility. We show two-step serial enrichments from 4 independent experiments including 8 positive selection steps. Purities of second step selections are clearly as good as purities from untouched cells that have never undergone a selection and reversibility cycle before indicating that no remaining selection markers interfere with subsequent selections. The recovery rates differed between the first and the second selection but this effect is marker-dependent. According to this, the measured recovery rates were not different from the usual recovery rates obtained from single positive selection with the same markers. Good purities and substantial cell counts in the second selection indicate the absence of excess D-biotin and Fab monomers (Fig. 5.40b). This is the first evidence that the removal column can be successfully implemented in reversible multi-parameter cell selections ensuring the complete removal of selection reagents without the need for centrifugation.
Two-parameter selections using a high capacity Strep-Tactin removal column for reagent removal

5x10^7 or 10^8 fresh PBMCs were prepared for positive magnetic selection as previously described. After the first selection step, positive fractions were run on a 4 mL removal column. a. Dot plots show aliquots from before selection and positive fractions from the first and second positive selection. Cells from the 1st positive fraction were re-stained with fresh PE-conjugated Strep-Tactin for detection of any residual Fab-monomers. b. Summary of all two-parameter positive selections performed with implementation of the removal column.

Centrifugation steps in between selection cycles not only enable separation of soluble components from cellular components but also allow adjustment of the volume. The use of removal columns in a centrifugation-free system does not provide a means of reducing the volume in the positive fraction once D-biotin was added. We have compared the cell recovery rates from second selection steps with those from untouched cells that have never undergone a previous selection and reagent removal cycle and did not find any evidence for a substantial cell loss during removal with the removal column. However, to ensure maximal recovery rates in subsequent selections we wanted to dilute the target cell fraction as little as possible. We have experimentally determined the necessary wash volume as a multiple of the respective column size to recover at least 90% of all cells that were loaded on the columns. Therefore, cells were counted before and after flow through a removal cartridge and after each wash. Cell numbers varied slightly between experiments. Starting material was 10^8 cells respectively. In three independent experiments with different column sizes we determined that washing with a 2.5- or 3-fold of the matrix volume recovered 90% or more of the cells from the removal column. We did not observe any cell loss due to adhesion to the matrix material and were able to recover basically 100% of cells in all cases (Fig. 5.41).
Fig. 0.401: Cell recovery from removal columns during reagent removal

$10^8$ fresh PBMCs were run over different removal columns. Columns were washed with six aliquots of 0.5 mL wash buffer (PBS/0.5% BSA) and counted after each step.

Next, we performed a three-parameter TCM enrichment as previously described with three different removal columns after each step as a proof-of-principle for the implementation of multiple removal columns into the sequential selection process. We have performed sequential CD8+/CD62L-/CD45RA⁻ selection as previously described in more detail. After each individual enrichment step, the positive fraction was treated with D-biotin and subsequently run over a 4 mL removal column to remove Fab fragments from the previous selection and excess D-biotin. The magnet to remove magnetic particles was employed simultaneously in close proximity to the removal column. This centrifugation-free CD8⁺ TCM purification yielded a CD8 purity of 99.2% and an overall purity of 96% for all three markers (CD8/CD62L/CD45RO, Fig. 5.42).

Fig. 0.412: Implementation of multiple removal columns in a three-parameter TCM purification

$5 \times 10^8$ fresh human PBMCs were incubated with anti-CD8 Fab-Streptamers conjugated with Strep-Tactin-functionalized magnetic microbeads. The CD8 positive fraction was collected and treated with 0.1 mM D-biotin and loaded on a 4 mL resin size removal column to remove remaining reagents. The removal column was placed in close proximity to a strong permanent magnet. In a subsequent second selection step, CD62L positive T cells were enriched from the CD8⁺ fraction as described for the first step. Finally, CD45RA⁺ cells were depleted using a CD45RA specific Fab-Streptamer conjugated to Strep-Tactin-coated beads. Living lymphocytes obtained before and after the selection procedure are shown. Numbers in dot plots indicate gate frequencies.

Finally, we sought to combine multiple removal columns with the previously established TCM selection protocol using the clinically approved CTS magnet for separation. With disposable tubing sets for each selection step that were connected to reservoir and collection bags prior to the experiment we were able to perform each step in a closed-system. We performed a three-parameter TCM enrichment using the markers CD3/CD62L/CD45RA sequentially with two different 5 mL removal columns after the CD3 and CD62L positive selection step respectively. A buffycoat from a healthy volunteer yielded $4 \times 10^8$ PBMCs upon Ficoll separation with a TCM content of 10%. To depict viability, phenotype, and purity of every single positive fraction and the final fraction in the purification process we show all relevant gates and our complete gating strategy in the first 4 rows (gated on lymphocyte singlets). Here, we yielded 97.6% purity in the first positive fraction (CD3⁺ T cells). For CD62L, we obtained a purity of 98.6%. Finally, CD45RA depletion resulted in a 98.5% pure CD45RO⁺ population. We were able to recover 24.5% of TCM⁺ throughout all three steps of the enrichment process. Remarkably, the
purities for each individual marker were almost identical when no pre-gating was applied (Fig. 5.43). We conclude that an uncontaminated T_{CM} subpopulation can be obtained by serial positive enrichment even without the time-consuming conventional protocol for reagent removal by implementation of removal columns. The high purities and recovery rates indicate that the implementation of removal columns in between selection steps allows a reduction of the process duration by 90-120 minutes without losses in cell purity and yield.
Fig. 0.423: Implementation of removal columns in a three-parameter T_{CM} purification using

4x10^6 fresh human PBMCs from a buffycoat were incubated with anti-CD3 Fab-Streptamers conjugated with Strep-Tactin-functionalized magnetic microbeads. The CD3 positive fraction was collected and treated with 0.1 mM D-biotin for 10 min prior to loading the fraction on a 5-mL high capacity ST removal column to remove remaining reagents. In a subsequent second selection step, CD62L positive T cells were enriched from the CD3^+ fraction as described for the first step. Finally, CD45RA^+ cells were depleted using a CD45RA specific Fab-Streptamer conjugated to Strep-Tactin-coated beads. Living lymphocytes obtained before and after each selection step are shown. Positive fractions and their respective gating are highlighted in green for each step. Each row depicts cells which have undergone none, one, two, or three selection cycles (top to bottom).

5.6.2 Transfer of the Streptamer-based TCM purification protocol to an affinity-based non-magnetic cell selection technology

To circumvent time intensive wash and centrifugation steps for isolation as well as for removal of monomeric Streptamer components (D-biotin, MHC-/Fab-monomers) we implemented high capacity Strep-Tactin biopolymers into the removal process to capture residual selection reagents. We further aimed at a faster and easier magnet-free column-based selection technology using Strep-Tactin-coated biopolymer matrices for positive enrichment of cells through column affinity. Advantages of column-based cell selections include reduced handling complexity, more time saving during washing steps as well, incubation time on the magnet is no longer necessary, and beads can be functionalized prior to the cell selection process to omit pre-incubation time for reagents. Strep-Tactin-coated biopolymer beads are at least 100 µm in diameter therefore allowing packaging in columns that enable the unhindered flow of cells in an identical way like removal columns. The non-magnetic technology is based on biopolymer beads that can be coated with multimerized Fab protein exclusively on the surface. The technology was originally invented and developed by Dr. Herbert Stadler (STAGE cell therapeutics). Although the cell selection columns consist of a very similar matrix material like the previously described removal columns, the Strep-Tactin coupling and location are distinctly different. Images of Strep-Tactin coated polymers stained with PE-coupled, biotinylated MHC-molecules clearly show, that Strep-Tactin is exclusively located on the surface of the beads in contrast to the removal beads which carry Strep-Tactin within the material (Fig. 5.44).
Next, we showed that polymer beads with Strep-Tactin coating on the surface can specifically hold back cells on their surface which are stably bound throughout washing of the beads with PBS/BSA until disruption of the Strep-Tactin-Fab multimer by D-biotin treatment. We pre-loaded Strep-Tactin beads with 0.2 µg Strep-tagged CD4 specific Fab monomers to coat beads with Fab-Streptamers which are formed through the Strep-Tactin on the bead surface. Thereby the polymer beads were functionalized for a positive CD4 enrichment step. Fresh PBMCs were incubated with the functionalized polymer beads for 20 minutes and the beads were washed carefully (Fig. 5.45a). Next, we demonstrated that the disruption of the Strep-Tactin-Fab complex with 1 mM D-biotin works well and might follow similar kinetics as the disruption of Fab-magnetic bead complexes (Fig. 5.45b). Our data indicate that a specific subpopulation of cells is successfully immobilized by previously functionalized biopolymers. The immobilization is likely to withstand a continuous flow since cells did not detach from the large beads through careful re-suspension of the mix during washing. D-biotin addition on the other hand caused instantaneous detachment of the cells from the beads. During the extended incubation time diffuse movement of detached cells became abundant.

**Fig. 0.434: Microscopic image of large non-magnetic polymer beads with Strep-Tactin conjugation**

*Strep*-Tactin coated Polymer beads in a 1:1 suspension with PBS were stained with biotinylated, PE-conjugated MHC-multimers to visualize the local distribution of *Strep*-Tactin within beads. A transmitted-light bright-field microscopic image and a fluorescence microscopic image are shown with kind permission by Dr. Stadler.
CD4-functionalized non-magnetic polymer beads with PBMCs after 20 minutes co-incubation

Polymer beads were kept in a 1:1 dilution with PBS/BSA. 10 µl of the bead suspension was functionalized with 0.2 µg of CD4-specific Fab fragments for 5 minutes. a. After a 20-minute co-incubation with fresh PBMCs, unbound cells were washed away by repetitive dilution with 1 mL PBS/BSA and subsequent sedimentation and taking the supernatant (3 times).

b. kinetics of the release after treatment with a 1 mM D-biotin solution.

We have evaluated three different strategies to implement selection columns into a cell flow and tested under which flow conditions (flow rate, constant flow or incubation stops) most cells were specifically retained by the affinity matrix. (i) gravity flow conditions, (ii) a tube leading from the column was inserted into a peristaltic electric pump which can keep a constant flowrate, (iii) manual application of suction through a syringe attached to a tube leading from the column. We have measured the retention indirectly by analysis of the flowthrough. Cells were stained and absolute cell numbers were determined. A high depletion of target cells and therefore a low detection of positive events in the flowthrough corresponds to a good retention of target specific cells. Specificity of retention was determined upon D-biotin treatment and subsequent release of the cells by re-staining and determination of the respective target cell purity. Gravity flow rates were too fast for stable retention of all cells and since the flow rate depends on the packaging of the matrix beads it was preferable to use a pump or manual suction at flow rates for a constant flow. We found flow rates of about 250 µL per minute for optimal cell retention. Next, we intended to determine the maximal retention capacity.
of a bead matrix of 0.5 mL in size under optimized flow conditions. We have counted CD8\(^+\) cells that have been retained by and subsequently released from 50 \(\mu\)L of functionalized biopolymer beads from a surplus of PBMCs. At the time when samples collected from the column flowthrough contained the same CD8 frequency as before the 50 \(\mu\)L column had retained \(10^7\) CD8\(^+\) cells from the suspension. We were then interested in the number of cells in the positive fraction that can be held back by a 500 \(\mu\)L selection column while the target cell loss does not surpass 5%. We found that 2 mL of cell suspension containing a maximum of \(5 \times 10^8\) cells can be securely loaded on a functionalized 500 \(\mu\)L selection column in order to achieve a depletion of target cells from the flowthrough of at least 95%.

In summary, biopolymer-based selection columns can be conjugated with Fabs by simple loading of a diluted protein solution without the need for pre-incubation of Fab fragments and beads. To determine the necessary column length for selection, the number of cells as well as the concentration of the cell suspension are important parameters. The length and width of a column determine the flow rate under gravity conditions. Since this is subject to severe variation, a constant flow rate is striven for. Optimal loading conditions prevail at flow rates of up to 250\(\mu\)L/min while target cells are stably bound at flow rates up to 4 mL/min. A faster flow rate can cause detachment of target cells during wash steps. For columns ranging from 500\(\mu\)L to 5 mL resin volume wash steps require a 10-fold of the respective resin volume. For the elution with a 0.1 \(\mu\)M D-biotin solution the same parameters apply. Flow rates should never exceed 4mL/min to prevent cell damage due to spontaneous detachment from the resin.

**5.6.3 Whole blood purification process without the need for prior density gradient centrifugation**

For the following experiments, we took fresh whole blood from healthy volunteers for CD8 positive selections on Fab-functionalized biopolymer columns. The blood was layered onto the columns at once or in portions of \(~3\) mL depending on the blood volume applied. When overlaid with 1-2 mL of buffer, it is clearly visible that almost no red blood cells remain on the selection column in the flow through. Only a slight shade of red remains on the column after flow through before the wash with buffer (wash). The column right before elution of the positive fraction is perfectly white (Fig. 5.46). A potential source for contamination with red blood cells and other unwanted populations is the seam between two plastic parts (indicated by black arrow). In some experiments, contaminating cells have disengaged from rough seams during elution. In these cases, CD8 purities were comparably poorer probably because CD8\(^+\) cells were outnumbered by contaminating red blood cells. For this reason, purities after a single positive selection step from whole blood were stated based on living T cells (pregated on CD3+ living lymphocytes). However, not every experiment suffered from contamination. We conclude that the underlying reasons are attributed to the quality of the plastic surface in welded areas.

A representative CD8 positive selection from 10mL of whole blood is shown in Fig. 5.46. From a very small initial CD8 frequency of 0.35% of all blood cells a 96.1% pure CD8\(^+\) fraction was purified in a
single step with no substantial contamination. In this example the CD8 purities raised to a comparable value of 97% indicating that the contamination with non-nucleated blood cells was neglectable (Fig. 5.47a). In conclusion, excellent purities and viability of CD8+ cells can be achieved from whole blood in a direct positive selection using selection columns. Similar results were obtained regardless of the initial number of cells (either 1 mL or 10 mL of whole blood). In six independent experiments we yielded average recovery rates of 39.6±9.2 exceeding those of single selection out of PBMCs by far when the recovery rate during Ficoll separation is also considered (Fig. 5.47b). As a rule of thumb, 50%-80% of PBMCs are lost during the density gradient centrifugation procedure. Recovery rates of a conventional single CD8+ selection therefore averaged at 10-25% when taking into account these losses occurring during Ficoll separation. Separation from isolated PBMCs yielded even better recoveries.

Fig. 0.456: Column-based positive selection process from undiluted whole blood

A 15 mL conical tube was modified using a mesh of 20 µm pore size to hold 1 mL of biopolymer resin. The column is then functionalized using 4 µg of CD8 Fab protein in 500µl of PBS/0.5% BSA. 10 mL of whole blood from a healthy volunteer were carefully layered on the previously functionalized CD8 selection column (first picture from the left). A semi-continuous flow of max. 500 µl/min was applied by manual suction through a conventional syringe. Wash buffer was applied in two steps à 5 mL each. During the first step the discoloration indicated that non-nucleated cells were not trapped within the selection matrix (second picture from the left). A completely washed column was free of contaminating red blood cells except for rough welding seams (third picture from the left). D-biotin treatment was applied to elute CD8+ cells from the matrix (elution).
Fig. 0.47: Column-based positive CD8 Streptamer selections from whole blood

Two different column sizes were used for the selection from 1 mL or 10 mL freshly drawn whole blood. For 10 mL whole blood, columns were prepared with 1 mL resin and loaded with 4 µg CD8 Fab. For 1 mL whole blood, columns were prepared with 400 µL resin and loaded with 2 µg CD8 Fab. a. A representative selection was performed, and samples from each fraction were taken (except 1st flowthrough), and re-stained with antibodies for flow cytometry. b. Summary of CD8 positive selections from whole blood performed on Fab-loaded Strep-Tactin columns (n=6).
6. Discussion

This thesis work is focused on the development of a pre-GMP protocol for the positive selection of human central memory T cells (T\textsubscript{CM}) using the novel Strep\textsuperscript{amer}-based reversible cell isolation technology. The central memory T cell subset has previously been associated with several traits which can positively influence the clinical outcome of adoptive T cell transfer. Therefore, many experts in the field of cellular therapy have proposed that clinical purification not only of different cell lineages (e.g. T cells, B cells, NK cells) but also defined cell subsets (e.g. memory subsets like central memory T cells and/or naïve T cells) might be advantageous. Obtaining optimal purities in the enrichment process is believed to be crucial to enhance the efficacy of adoptive T cell therapy. This challenge has been embraced by a number of research groups who developed novel cell purification techniques over the past years. Efforts in this area are complicated by fact that they have to get approved by regulatory authorities before they can be tested in clinical applications. If selection reagents (often conjugated paramagnetic beads or fluorochromes) stay on the purified cell population and get co-transferred into patients, laborious toxicity and immunogenicity studies have to be performed during the process of clinical approval. We present here a protocol for the selection of central memory T cells that can overcome some of these hurdles. We evaluated cell separation reagents that enable serial positive enrichment and demonstrated that serial magnetic enrichment works robustly over three parameters yielding very high purities and recovery rates. Thereby, the final cell product is free of any staining reagents. Based on this procedure, we established a GMP-compliant process and scaled the process up for the use in patients.

6.1 Advantages of central memory T cells for adoptive T cell therapy

The role of distinct T cell subsets with respect to overall efficacy as well as safety of adoptively transferred T cells is still controversially discussed. In terms of adoptive T cell therapy against tumors, the memory compartment has been thoroughly investigated throughout the past years. The central memory T cell subset has been associated with stem cell-like characteristics, which might be important for the subsequent clinical outcome of adoptive T cell transfer including longevity, the ability to migrate to lymph nodes, the generation of different effector and memory T cell subsets, an excellent proliferative capacity and a good safety profile. T\textsubscript{CM} are long-lived antigen experienced cells with a high differentiation plasticity. Indeed, it has been shown that a single central memory T cell can reconstitute all T cell compartments except the naïve compartment. In several studies in mice, non-
human primates and humans, preparing a therapeutic T cell product comprised of cells from the central memory phenotype was shown to provide high in vivo persistence and functionality of the transferred T cells [1-4].

In most published clinical adoptive immunotherapy studies in which T cells are used to treat cancer or viral infections, the subset composition of transferred cells was not determined when cells were administered to patients, despite the knowledge that the phenotypic composition of the T cell pool in individual donors is highly variable (interindividual differences between donors) and can similarly differ in therapeutic cell products. Nonetheless, phenotypic features were retrospectively analyzed in some cases in attempts to correlate clinical outcome with intrinsic cell attributes of the infused T cells. In studies with tumor infiltrating lymphocytes for example, the retrospective analysis of phenotypic markers demonstrated that relative frequencies of CD62L+ T cells correlated beneficially with the regression of late-stage cancers. Genetically modified naïve and central memory T cells (both CD62L+) contributed especially well to an objective anti-tumor response in allogeneic transfers. For therapy of latent viral diseases, the central memory compartment is a defined subset that harbors specific T cells that are reactive towards viral antigens. T cells specific for antigens of latent viruses can confer direct protection against re-activation by the particular pathogen in the recipient upon adoptive transfer. Antigen specificity against a defined epitope can also be exploited by using the respective peptide vaccine as a booster to activate and expand them in vivo in the recipient (for example CMV or EBV antigens).

Selection of a pure central memory T cell subset can improve adoptive T cell therapy since the heterogeneous and often highly variable compositions of currently used clinical cell products very likely interferes with the efficacy of T cell therapies. This could for example be due to regulatory T cells that could dampen the effects of central memory T cells or the competition for cytokines from exhausted cell subsets (T_EMRA) cells that may act as a cytokine sink but be less able to mediate therapeutic activity [5]. Therefore it might be advantageous to eliminate some subsets from a therapeutic cell product while other cell intrinsic properties which determine the ability of self-renewal and long-term persistence should be positively selected.

Central memory T cells share some characteristic traits with naïve T cells. For instance, the naïve T cell subset also harbors broad differentiation plasticity and is considered a suitable subset candidate for immune reconstitution as well. It has been shown for the adoptive T cell therapy of cancer that engineered T cells recombinantly expressing tumor-reactive TCR or CARs mediated a more complete and durable tumor regression when derived from naïve than memory T cells [6-8]. The cells that were investigated in these studies underwent quite extensive in vitro manipulation. Therefore, it is possible that other transduction or expansion methods could give different results.

On the other hand, in contrast to central memory T cells, naïve T cells usually carry the greatest TCR diversity and the potential reactivity profile is very broad. In allogeneic transfer, naïve T cells have therefore a particularly high risk for allo-recognition of healthy tissue in the recipient (Graft-versus-
host-Disease) [9, 10]. Antigen-experienced T cells might have some advantages compared to naïve T cells. For instance, in allogeneic settings antigen-experienced memory cells are likely to possess a superior safety profile because they carry TCRs, which should mainly be directed against non-self antigens that were for example previously presented in the context of infection.

It has also been reported that aging and regimens of conventional cancer therapy (like chemotherapy and/or radiation) can impact the size and robustness of the pool of naïve T cells whilst memory T cell compartments are less affected [11].

In summary, central memory T cells might possess superior traits with respect to safety and furthermore possess the advantage of a relatively high differentiation plasticity among the memory subsets. Therefore we chose to develop reagents and procedures to isolate central memory T cells for clinical use, although by modifying the selection steps, we could in principle also obtain naïve or effector memory T cells with the reagents that we have developed. Whether ultimately a defined mixture of cells or a single purified subset are most beneficial for the treatment of patients remains to be answered in clinical trials. Clinical protocols supporting the selection of highly defined T cell subsets will provide the opportunity to address these questions in clinical settings.

### 6.2 Central memory T cell subset selection

Subpopulations, like central memory T cells, can only be detected by their complex combination of expression markers and require elaborate protocols for purification. Not all isolation techniques are suitable for targeting such complex subsets. Especially the isolation of T_{CM} is challenging, as this subpopulation occurs in the peripheral blood at a very low frequency of 1.5-2% of PBMCs [12]. The first clinical protocol to enrich T_{CM} using standard non-reversible reagents was developed by Wang et al. [13]. A vast cocktail of depleting monoclonal antibodies was applied to exclude cells that express the markers CD4, CD14, or CD45RA. To finally enrich T_{CM} from the remaining negative fraction, a positive selection step for CD62L expressing cells was conducted. The authors described their approach as a robust technique for the purification of central memory T cells that demonstrated enhanced in vivo persistence and safety in a clinical phase I/II trial. However, this protocol results in many contaminating CD62L^+ cells that are not depleted by even the large cocktail of antibodies and may have uncertain consequences in a therapeutic setting. Inspired by this work, we have developed an improved protocol using reversible markers for the serial enrichment of central memory T cells and compared our results with the previously described clinical protocol for the preparation of T_{CM}. While recovering about 25% of target cells in relation to the number of T_{CM} in the initial product, the final purities reached by the published protocol averaged 36%, which is unsatisfactory since contaminating cells might mediate unwanted toxicities like GvHD. For reasons discussed before (e.g. GvHD risk, regulatory cells, and cytokine sink), purities of at least 90% were aimed at when developing our
alternative approach. Mainly CD13⁺ basophils were identified to contaminate the T cell product in the previously published protocol. To further improve the quality of selected cells according to this strategy, it would be necessary to include even more depleting antibodies in the first step of processing. Such an adaption of the selection protocol has quite some consequences, especially since all reagents have to be manufactured in compliance with GMP regulations. This is an expensive and also a time consuming process. We demonstrate with this thesis work how to overcome such hurdles by Streptamer-based serial positive enrichment of T_{CM}. In contrast to the published method, the mean purity of recovered CD8⁺ T_{CM} was 97.8% with a 29.5% average recovery (Fig. 5.30). CD3⁺ T_{CM} selections yielded 93.5% purity (mean) and recovered on average 32.9% of the initial number of T_{CM} (Fig. 5.34). CD13⁺ basophils were never detected in our TCM products (data not shown). However, some observations could not be vastly improved by application of a Streptamer-based isolation protocol for T_{CM}. An important issue is that the recovery rates differed between donors using both the recently published depletion- and the Streptamer-based protocol. This could be due to interindividual differences in the expression of the markers used for selections. Since only CD62L was used for positive selection in the protocol from Wang et al., differences in CD62L expression are most likely involved to provoke scattering in recovery rates. However, we have detected variation in recovery rates to some extent for all markers (Fig. 5.31). This indicates that the detected differences in recovery are not restricted to the CD62L selection step but represent more the sum of combined variations during selection for all three surface markers. Possibly, the expression of target molecules per cell influences the selection efficacy. This interpretation is supported by the observation that we often preferentially purified cells expressing the target molecule at a higher level. Segregation by gates between high and low expressing CD8 T cells for example revealed that losses during the wash (incomplete depletion in the negative fraction) occurred mainly in the CD8 low expressing population. Taken together, our data show a vast improvement on the purities and a slight improvement on the recovery rates of T_{CM} for clinical use of the Fab Streptamer-based enrichment protocol compared to available alternatives.

6.3 Advantages of reversible reagents for positive selections

6.3.1 Reversible reagents improve multi-parameter positive selections

Multi-parameter positive magnetic selection was first enabled by the use of Streptamer-based selection reagents [14]. In this thesis work, we focused on purification of the clinically relevant subset of central memory T cells. However, also effector memory and naïve T cells can in principle be easily selected
in parallel during the same clinical selection process using our set of reversible reagents. By performing the positive CD62L selection step at the end, central memory (CD3⁺/CD45RO⁺/CD62L⁺) and effector memory T cells (CD3⁺/CD45RO⁺/CD62L⁻) could be separated at high purities from the same donor in parallel. Similarly, naïve (CD3⁺/CD62L⁻/CD45RA⁺) and central memory T cells (CD3⁺/CD62L⁺/CD45RA⁻) could be isolated from the same donor material by applying CD45RA or CD45RO at the end. Compared to negative selection protocols or single parameter selection, the proposed strategy provides for cost-efficient isolation of highly pure subsets. This enables direct comparison of individual subsets from the same donor material in terms of efficacy in adoptive T cell therapy in future trials.

In the case of many subsets that require multi-parameter sorting, serial positive enrichment may become a cost-efficient way to achieve superior purities and recovery rates. The Streptamer technology is very flexible and can be applied for a theoretically infinite number of combinations of different surface antigens. This strategy can be translated very rapidly into clinical processing facilities and can be combined with already approved cell processing devices, as shown here for the CTS platform.

During this thesis work, an alternative clinical-scale selection protocols over two positive parameters has been suggested for naïve and central memory T cells [15]. Here, the selection approach relies on the combination of two different non-reversible magnetic selection strategies. The first positive selection step is conducted with standard nano-sized magnetic ‘microbeads’ and the subsequent step is performed with larger (3.5 µm in diameter) beads with a standard permanent magnet, thus eliminating interference with the previously applied smaller beads through a stronger magnetic field. Limitations of this approach are costs that are related to the approval of GMP-grade non-reversible reagents and the limit to only two positive enrichment steps due to the size range of suitable magnetic particles. Combination of this technology with reversible Streptamers is possible, since we have shown that CD3-, CD4-, CD8-, CD62L-, or CD45RA-specific Fab Streptamers perform well with nano-sized particles (Fig. 5.20). Combining both strategies should improve the process duration because reagent removal is only necessary between positive steps that are conducted with same-sized magnetic particles.

Multi-parameter analysis and selection of cells are usually associated with flow cytometry. Indeed, FACS sorting is another potential clinical approach towards multi-parameter cell isolation. Its great advantage over magnetic sorting is the possibility of simultaneous sorting over multiple parameters. This can vastly reduce processing times for initial cell numbers roughly below 10⁸. Great efforts are made in developing clinical cell sorters, but the complex technical equipment make it more difficult to develop a protocol that is generally approved by regulatory authorities. Highly advanced hardware and disposable tubing sets are necessary and currently it is still not possible to conduct a sterile selection process at low costs. The disadvantages of the open system in FACS sorters, like aerosol generation, are especially challenging. Aerosols are a potential hazard for personnel who work with human
material. The safety assessment of fluorescent labels, when applied together with the selected cells into patients, is another unsolved issue (see below). Becton Dickinson´s Influx is an example for a first cell sorter that can be implemented into GMP cell processing platforms. Novel technologies, like cell sorters based on microfluidics, promise to circumvent aerosol production and are more likely to ensure occupational safety. FACS sorting in general can also vastly benefit from the Fab-Streptamer technology. We have shown that Fab Streptamers specific for CD4, CD8, CD3, CD62L or CD45RA and CD45RO multimerized with a fluorescent Strep-Tactin backbone perform identical to the conventional fluorescent monoclonal antibodies (Fig. 5.1, 5.2, 5.4, 5.6 and 5.7). Therefore, our marker set for the positive selection of central memory T cells can easily be combined with FACS-based cell isolation techniques. This was recently successfully tested in our group (Stemberger et al., unpublished data). The use of fully reversible fluorochrome-conjugated Fab-Streptamers for clinical FACS sorting could especially overcome toxicity concern regarding the use of fluorochromes during the selection process.

6.3.2 Circumventing problems caused by remaining sort markers

For clinical applications it is important that uncompromised biological function of transferred cells is ensured. It is known for a long time that remaining sort markers, such as antibody conjugates, can cause cell damage and even unwanted side effects upon infusion. The co-infusion of selection markers such as monoclonal antibodies is a potential source for toxic side effects. Positive enrichment of cell populations leaves the purified cells usually with a non-reversibly bound selection marker. Depending on the target and its functions, there are several mechanisms how the cell function might be impaired. First, cell selection markers can cause premature activation or receptor blockade in some cases leading to alterations of the cell’s effector functions. Direct comparison of conventionally labeled cells with Streptamer-labeled cells that are subsequently reversed and untouched control cells in the case of CD3 have convincingly shown that CD3 binding caused activation in vitro only in the group with the conventional irreversible marker (unpublished data).

Further, remaining surface markers can hinder successful engraftment or clinical effects when the cells are directly transferred or compromise cell expansion ex vivo. In the case of murine CD62L, the irreversible antibody used for sorting vastly compromised engraftment of T cells [16]. If sorted cells are expanded in vitro prior to adoptive transfer, the positive selection marker should get diluted in cell culture and therefore should not interfere with engraftment.

Finally, receptor blockade might occur if targets are associated with receptor functions. This is relevant for selection of regulatory T cell, which are a defined candidate subset of T cells that have therapeutic potential for GVHD and autoimmunity, and are defined as CD4+, CD25+ and CD127-. For regulatory T cells, it is almost impossible to envision a protocol for effective purification by negative selection and the CD25 (IL2 receptor alpha) marker is necessary for the positive selection of the
regulatory T cell subset. Blocking CD25 with non-reversible selection reagents can interfere with IL-2 binding to the receptor resulting in a lack of proliferation and survival of these cells. Potential immunogenicity of antibody reagents used for cell selection is in principle independent of the target and its functions. To circumvent potential complications, it is essential to use humanized monoclonal antibodies to prevent immunogenicity. Nevertheless, non-reversible selection markers that are co-transferred with the cell product into patients have to undergo cost-intensive testing before receiving approval from the authorities. The reversible Streptamer technology is a versatile tool to circumvent the need for toxicity and immunogenicity testing, provided it can be demonstrated that these reagents can be fully removed from the selected cells and therefore, are not co-transferred into patients. Indeed, first Fab-based Streptamers recently received the legal approval for clinical use and were classified as minimally manipulative to the sorted cell population.

6.4 Generation of Fab Streptamer reversibility

We have demonstrated full reversibility for a complete set of Fab Streptamers, which was used for the separation of central memory T cells. We found that reagent reversibility depended mainly on the wash procedure and the temperature. In some cases it was necessary to shift the temperature to room temperature during the removal phase to facilitate rapid dissociation of the Fab monomers (Fig. 5.16 and Fig. 5.18). According to our hypothesis, receptor internalization might occur at higher temperature (e.g. room temperature). Our results demonstrate that Fab reversibility needs to be determined for each new Fab individually. Our laboratory is currently developing a flow-based \( k_{\text{off}} \)-rate assay for tracking of monomer dissociation on a population level. This technology allows to accurately measure the dissociation of monomeric ligands from the surface of living cells and should be broadly applicable to measure reliable values for the dissociation kinetics of Fab proteins from the cell surface [17].

A limitation of the Fab Streptamer technology is the generation of reversible Fab monomers. If the parental Fab fragment isn’t of low enough affinity to begin with, its binding affinity has to be reduced by the introduction of amino acid exchanges within the framework or variable region. We have faced examples where it was very difficult to sufficiently reduce binding affinity by mutation. In some cases we observed a ‘non-reversible’ compound within the Fab preparations, although the majority of Fab dissociated rapidly from the cell surface (Fig. 5.14). Biochemical analyses demonstrated that heavy and light chains were not represented at a 1:1 ratio in all Fab preparations. We are currently improving vectors and protein purification to eliminate a surplus of one antibody chain. Furthermore, we have gathered data indicative of better Fab quality when two different tags are fused to the heavy and light chain respectively for protein enrichment.

To speed up the general process of reagent removal, we tested a biopolymer-based column that works under simplest gravity flow conditions and which it is able to capture excess D-biotin and Fab
monomers through its high Strep-Tactin content by affinity (Figs. 5.36-5.42). We further demonstrated that it is possible to implement such removal columns into a fully closed system for one positive enrichment step (Fig. 5.43). The subsequent enrichment step still required an opening of the sterile system. The implementation of removal columns into the CTS DynaMag-based sterile system was out of the scope of this thesis and will be continued in pre-clinical and clinical work in the future.

6.5 Optimization of positive magnetic selection with larger magnetic microbeads

Current clinical cell isolations usually rely on magnetic beads of sizes in the nanometer range (50-100 nm in diameter). These technologies all depend on specialized equipment like microcolumns for retention of the cell-bead complexes. We have demonstrated that nano-sized magnetic beads are not fully reversible under the given experimental conditions. Further, our experiments suggest that some nano-sized beads remain on the cell surface or inside the cells in a Fab-independent manner. It is known that depending on the size, particles of up to 200 nm can be rapidly internalized by mammalian cells even at very low temperatures (4°C) [18-20]. Besides that, very small particles might get trapped on the cell surface, which is not smooth but consists of folds and grooves resulting from membrane evaginations. Furthermore, small changes in the cell membrane due to its semi-fluidity might cause trapping of magnetic particles, thus interfering with potential reversibility.

As a solution to this problem, we combined the reversible StrepTamer technology with larger magnetic microbeads (micrometer range). Using this approach, we were even able to show that the duration of the purification process can be reduced due to faster immobilization in the field of a strong permanent magnet. Most of our experiments were conducted with microbeads in the micrometer range of 1-1.5 µm in diameter, which sediment in a magnetic field in less than 1 minute. They also showed outstanding purities in positive cell selections compared to other bead sizes in positive selections (Fig. 5.20, Fig. 5.23, Fig. 5.24 and Fig. 5.26). Processing time and costs are still one of the major hurdles in broader availability of cell therapy for a wide range of applications. Reducing duration and the need for specialized equipment are likely to be valuable steps towards affordable and effective T cell therapies.

As an alternative, intermediate size beads (in the nanometer range, 200-300 nm in diameter) have been introduced to the field which can be retained in close proximity to a magnet without the need for separation columns [21]. These beads combine the advantage of bigger beads with the advantages of nano-sized beads which can be separated by centrifugation and do not pellet like cells and debris. In the future, different bead sizes might contribute distinctly to individual applications.
In the case of direct transfusion of a cell product upon selection, the co-infusion of larger magnetic beads into patients is not approved by regulatory authorities. Therefore, so far only negatively sorted cell products have been used for clinical cell processing with larger beads. Reversible Streptamers for the first time allow the use of larger microbeads for clinical positive enrichment, since the bead can be fully removed after the selection process.

6.6 Clinical applications for Streptamer-based T\textsubscript{CM} purification

Clinical approaches to isolate central memory T cells so far either rely on negative selection techniques or on in vitro-stimulation and subsequent phenotyping before selection. An example is a recent study from a group that identified and expanded human T cell clones for infusion based on secretion of cytokines. T cells with a high IL-2: IFN-\(\gamma\) ratio were identified and expanded as central memory-like T cells for the transfer to patients [22]. Laborious cell culture steps that consume weeks of cell preparation in a GMP facility could be eliminated by application of the Streptamer-based selection of central memory T cells.

Similarly, for the treatment of virus infections upon allogeneic hematopoietic stem cell transplantation (HSCT), e.g. CMV, the recently approved MHC Streptamer technology successfully eliminated the need for in vitro re-stimulation with peptides by direct isolation of CMV-specific T cells [23-26]. MHC-based Streptamers have received approval for clinical use recently. Previously it was necessary to use antigen stimulation to grow out high numbers of cloned T cells with a defined specificity from polyclonal T cell populations.

Other potentially interesting target cell populations for clinical use are naïve T cells or regulatory T cells, which can be obtained in a very similar way as here described for central memory cells. Even protocols that require ex\(\)\textit{vivo} gene manipulation can be modified in a way that Streptamer selection and subsequent viral transduction of T cells can be completed, perhaps this all can be accomplished in less than 24 hours (Dr. Michael Jensen, personal communication).

In this thesis, we have made some effort to reduce the time consumption of the T\textsubscript{CM} isolation process as it would be carried out in a GMP facility. We have estimated that the process currently requiring 6-8 hours (depending on the starting number of cells) can be vastly shortened by eliminating centrifugation steps during reagent removal (see above). We could show that the implementation of a removal column after each positive selection step resulted in at least 90 minutes of saved time. It is very likely that the biopolymer-based removal columns will receive clinical approval by the national authorities soon; this could help to further reduce the overall processing time.

We were interested in purification of central memory cells, for example also as a basis for the introduction of a transgene as well as for direct primary transfer. The idea that T\textsubscript{CM} might also be a suitable subpopulation for in\textit{vivo} gene manipulation was assessed in animal studies in mice and non-
human primates [2, 3]. Even when gene-modification requires an expansion step in vitro, cells derived from central memory precursors persisted long term in vivo. It has been demonstrated by Berger et al. that cell clones expanded from central memory T cells were detectable in vivo after many months while clones generated from effector memory T cells disappeared after only two weeks. These data have been gathered from adoptive transfer experiments in macaques, an animal model very close to the human organism.

A common misconception in adoptive T cell therapy concerns the missing strict dose-response relationship as known for non-living biologicals. A very low number of T cells can already be enough to mediate efficient cell engraftment and subsequent in vivo expansion. Pre-selection of a defined cell subset with superior in vivo engraftment and survival characteristics could help to make subsequent clinical responses more effective, predictable and perhaps also safer. Since antigen-induced activation can lead to excessive proliferation, cell numbers can expand very quickly upon transfer. A recent report from our lab showed that lowest numbers of Streptamer-enriched cells led to strong expansion of functional T cells in patients upon allogeneic HSCT [27].

6.7 Clinical trial using Streptamer-enriched TCM for immune reconstitution of post HPCT patients

Immune recovery from deficiencies in B- and T-cell reconstitution after hematopoietic progenitor cell transplantation (HPCT) is a process that can take up to over one year. During this time patients have to undergo prolonged administration of antiviral medications to prevent life-threatening infections, with significant side effects. It was shown that adoptive T cell transfer is a therapeutic approach that can effectively treat reactivations with latent viruses upon HPCT [28, 29]. Our pre-GMP selection protocol of CD3+ central memory T cells was recently tested in the clean room GMP-facility TUMcells to initiate the application process for production approval. The first results from GMP-purifications demonstrate that central memory T cells can be purified to very high purities and with high yields under conditions following the good manufacturing practice (GMP) guidelines. These efforts initiated already the launch of a clinical phase I/IIa study where purified central memory T cells are given in escalating doses to assess their safety and persistence in patients upon allogeneic stem cell transplantation. The study runs under the name prophylactic application of escalating doses of donor-derived central memory T lymphocytes (TCM) after allogeneic hematopoietic progenitor cell transplantation (HPCT) to prevent infectious complications (PACT): A Prospective, first in man, open Phase I/IIa Clinical Trial. Aim is the prophylactic administration of escalating doses of Streptamer selected central memory T cells to patients following hematopoietic progenitor cell transplantation (HPCT). This is the first-in-man trial of clinical grade-purified CD3+CD62L+CD45RA-CD45RO+ central memory T cells by means of serial positive enrichment. The goal of this trial is to administer
the first T cell dose 30 days post HPCT from the donor and assess potentially occurring Graft-versus-host disease and any other side-effects related to T cell administration. In detail, the first dose received 30 days post HPCT is $5 \times 10^3 \text{ T}_\text{CM}/\text{kg}$, on day 60 $10^4 \text{ T}_\text{CM}/\text{kg}$ and on day 90 $5 \times 10^4 \text{ T}_\text{CM}/\text{kg}$. The transferred population contains CD4$^+$ and CD8$^+$ T$_{CM}$ representing the whole repertoire of long-lived antigen-experienced T cells in the donor. Depending on the prevalence in the population, donor-derived T$_{CM}$ might contain CMV-, EBV-, or Adenovirus-specific T cells. Even anti-fungal T cells specific for aspergillus have been described. These cells can work as a prophylactic strategy to protect HPCT patients from secondary infections with opportunistic pathogens, superinfections, or reactivations with latent viruses by means of immune reconstitution. Further, the persistence and expansion of transferred T cells will be monitored. Our working hypothesis is that the prophylactic application of low numbers of TCMs can significantly reduce the occurrence of infections with opportunistic pathogens upon allogeneic HSCT. This direct clinical translation of the generated data from animal models or in vitro assays will shed light on the proliferative capacity and safety profile of the T$_{CM}$ subpopulation.
7. Material and Methods

7.1 Material

7.1.1 Equipment

<table>
<thead>
<tr>
<th>Equipment</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Centrifuges</td>
<td>Centrifuge Biofuge fresc, Heraeus, Hanau, Germany</td>
</tr>
<tr>
<td></td>
<td>Sorvall® RC 26 Plus, Heraeus, Hanau, Germany</td>
</tr>
<tr>
<td></td>
<td>Multifuge 3 SR, Heraeus, Hanau, Germany</td>
</tr>
<tr>
<td>Cell isolation systems</td>
<td>MiniMACS, Miltenyi, Bergisch Gladbach, Germany</td>
</tr>
<tr>
<td></td>
<td>MidiMACS, Miltenyi, Bergisch Gladbach, Germany</td>
</tr>
<tr>
<td></td>
<td>Fab Streptamer magnetic isolation, IBA, Göttingen, Germany</td>
</tr>
<tr>
<td>Flow cytometer</td>
<td>Cyan ADP, Dako Cytomation, Fort Collins, USA</td>
</tr>
<tr>
<td></td>
<td>FACSARia cell sorter, Becton Dickinson, Heidelberg, Germany</td>
</tr>
<tr>
<td>HE33 agarose gel casting system</td>
<td>Hoefer, San Francisco, USA</td>
</tr>
<tr>
<td>Heating block Thermomixer compact</td>
<td>Eppendorf, Hamburg, Germany</td>
</tr>
<tr>
<td>Incubator Cytoperm 2</td>
<td>Heraeus, Hanau, Germany</td>
</tr>
<tr>
<td>Laminar flow hood HERA safe</td>
<td>Heraeus, Hanau, Germany</td>
</tr>
<tr>
<td>Microscopes</td>
<td>Axiovert S100, Carl Zeiss, Jena, Germany</td>
</tr>
<tr>
<td></td>
<td>Carl Zeiss, Jena, Germany</td>
</tr>
<tr>
<td></td>
<td>Confocal microscope Leica SP 5, Leica, Bensheim, Germany</td>
</tr>
<tr>
<td>MightySmall SE245 gel casting system</td>
<td>Hoefer, San Francisco, USA</td>
</tr>
<tr>
<td>NanoDrop spectrophotometer</td>
<td>NanoDrop, Baltimore, USA</td>
</tr>
<tr>
<td>Neubauer counting chamber</td>
<td>Schubert, München, Germany</td>
</tr>
<tr>
<td>Shaker Multitron Version 2</td>
<td>INFORS AG, Bottmingen, Germany</td>
</tr>
<tr>
<td>Equipment</td>
<td>Supplier</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Superflow <em>Strep</em>-Tactin columns</td>
<td>IBA, Göttingen, Germany</td>
</tr>
<tr>
<td>Thermocycler TProfessional Thermocycler</td>
<td>Biometra, Göttingen, Germany</td>
</tr>
<tr>
<td>Vacuum filtering system Stericup 0.22 µm</td>
<td>Millipore, Bedford, USA</td>
</tr>
<tr>
<td>Waterbath LAUDA ecoline 019</td>
<td>Lauda, Lauda-Königshofen, Germany</td>
</tr>
</tbody>
</table>

### 7.1.2 Chemicals and reagents

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acrylamide/Bis 30%</td>
<td>Biorad, München</td>
</tr>
<tr>
<td>Ammoniumchloride (NH₄Cl)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Ampicillin</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Biocoll Ficoll solution</td>
<td>Biochrom, Berlin, Germany</td>
</tr>
<tr>
<td>Bovine serum albumin (BSA)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Cytofix/Cytoperm</td>
<td>BD Biosciences, Heidelberg, Germany</td>
</tr>
<tr>
<td>d-Biotin</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Desthiobiotin</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Dimethyl sulfoxid (DMSO)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Dynabeads® Human T-Activator CD3/CD28</td>
<td>GibcoBRL, Karlsruhe, Germany</td>
</tr>
<tr>
<td>dNTP</td>
<td>Roche, Mannheim, Germany</td>
</tr>
<tr>
<td>EDTA</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Ethanol</td>
<td>Klinikum rechts der Isar, Munich, Germany</td>
</tr>
<tr>
<td>Ethidium-monazide-bromide (EMA)</td>
<td>Molecular Probes, Leiden, The Netherlands</td>
</tr>
<tr>
<td>Fetal calf serum (FCS)</td>
<td>Biochrom, Berlin, Germany</td>
</tr>
<tr>
<td>Gentamycin</td>
<td>GibcoBRL, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Golgi-Plug</td>
<td>BD Biosciences, Heidelberg, Germany</td>
</tr>
<tr>
<td>HCl</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>HEPES</td>
<td>GibcoBRL, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Interleukin-2, human</td>
<td>Novatis, Basel, Switzerland</td>
</tr>
<tr>
<td>Isopropanol</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>GibcoBRL, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Magnesiumsulfate (MgSO₄)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>MgCl₂</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>NaOH</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>PageRuler Protein Ladder</td>
<td>Fermentas, St. Leon-Rot</td>
</tr>
<tr>
<td>Reagent</td>
<td>Supplier</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Penicillin</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>PermWash 10x</td>
<td>BD Biosciences, Heidelberg, Germany</td>
</tr>
<tr>
<td>pET expression vectors</td>
<td>Novagen, Darmstadt, Germany</td>
</tr>
<tr>
<td>Phosphate buffered saline (PBS)</td>
<td>Biochrom, Berlin, Germany</td>
</tr>
<tr>
<td>Polybrene (Hexadimethrine bromide)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Potassiumphosphate (K$_2$PO$_4$)</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Propidiumjodide (PI)</td>
<td>Molecular Probes, Invitrogen,</td>
</tr>
<tr>
<td>RPMI 1640</td>
<td>GibcoBRL, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Sodiumchloride (NaCl)</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Strep-Tactin-APC</td>
<td>IBA, Göttingen, Germany</td>
</tr>
<tr>
<td>Strepactin-bead conjugate</td>
<td>IBA, Göttingen, Germany</td>
</tr>
<tr>
<td>Strep-Tactin-PE</td>
<td>IBA, Göttingen, Germany</td>
</tr>
<tr>
<td>Streptavidin PE</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Sucrose</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>Tris-hydrochloride (Tris-HCl)</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Triton X-100</td>
<td>Biorad, Munich, Germany</td>
</tr>
<tr>
<td>Trypan Blue</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
<tr>
<td>β-Mercaptoethanol</td>
<td>Sigma, Taufkirchen, Germany</td>
</tr>
</tbody>
</table>

### 7.1.3 Media and buffers

<table>
<thead>
<tr>
<th>Buffer /Medium</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ammoniumchloride-Tris (ACT)</td>
<td>0.17 M NH$_4$Cl</td>
</tr>
<tr>
<td></td>
<td>0.3 M Tris-HCl, pH 7.5</td>
</tr>
<tr>
<td>Cell culture medium</td>
<td>1x RPMI 1640</td>
</tr>
<tr>
<td></td>
<td>10% (w/v) FCS</td>
</tr>
<tr>
<td></td>
<td>0.025% (w/v) L-Glutamine</td>
</tr>
<tr>
<td></td>
<td>0.1% (w/v) HEPES</td>
</tr>
<tr>
<td></td>
<td>0.001% (w/v) Gentamycin</td>
</tr>
<tr>
<td></td>
<td>0.002% (w/v) Streptomycin</td>
</tr>
<tr>
<td>Complete freezing medium (CFM)</td>
<td>FCS</td>
</tr>
<tr>
<td></td>
<td>10% DMSO</td>
</tr>
</tbody>
</table>
### Buffer /Medium Composition

<table>
<thead>
<tr>
<th>Buffer /Medium</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-biotin 100 mM stock solution</td>
<td>2.4431 g d-biotin</td>
</tr>
<tr>
<td>FACS buffer</td>
<td>1x PBS</td>
</tr>
<tr>
<td></td>
<td>0.5% (w/v) BSA</td>
</tr>
<tr>
<td></td>
<td>pH 7.45</td>
</tr>
<tr>
<td>Human T cell culture medium</td>
<td>1x RPMI 1640</td>
</tr>
<tr>
<td></td>
<td>10% (w/v) human serum</td>
</tr>
<tr>
<td></td>
<td>0.025% (w/v) L-Glutamine</td>
</tr>
<tr>
<td></td>
<td>0.1% (w/v) HEPES</td>
</tr>
<tr>
<td></td>
<td>0.001% (w/v) Gentamycin</td>
</tr>
<tr>
<td></td>
<td>0.002% (w/v) Streptomycin</td>
</tr>
<tr>
<td></td>
<td>0.002% (w/v) Penicillin</td>
</tr>
<tr>
<td>Periplasmic lysis buffer (P)</td>
<td>100 mM Tris/HCl, pH 8</td>
</tr>
<tr>
<td></td>
<td>500 mM sucrose</td>
</tr>
<tr>
<td></td>
<td>1 mM EDTA</td>
</tr>
<tr>
<td>Protein purification elution buffer (E)</td>
<td>100 mM Tris/HCl</td>
</tr>
<tr>
<td></td>
<td>150 mM NaCl</td>
</tr>
<tr>
<td></td>
<td>1 mM EDTA</td>
</tr>
<tr>
<td></td>
<td>2.5 mM desthiobiotin, pH 8</td>
</tr>
<tr>
<td>Protein purification washing (W)</td>
<td>100 mM Tris/HCl, pH 8</td>
</tr>
<tr>
<td></td>
<td>150 mM NaCl</td>
</tr>
<tr>
<td></td>
<td>1 mM EDTA</td>
</tr>
</tbody>
</table>

#### 7.1.4 antibodies and conjugates

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Clone</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human CD127 PE-Cy7</td>
<td>R34.34</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD14 PE-Cy7</td>
<td>61D3</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD19 ECD</td>
<td>J3-119</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>----------------</td>
<td>--------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Reagent</td>
<td>Clone</td>
<td>Supplier</td>
</tr>
<tr>
<td>Human CD28</td>
<td>28.2</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD3 APC</td>
<td>UCHT1</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD3 eF450</td>
<td>OKT3</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD3 Orthoclone</td>
<td>OKT3</td>
<td>Janssen-Cilag, Neuss, Germany</td>
</tr>
<tr>
<td>Human CD3 Pacific Blue</td>
<td>UCHT1</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD3 PE</td>
<td>UCHT1</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD3 PE-Cy7</td>
<td>UCHT1</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD4 eF450</td>
<td>OKT4</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD4 FITC</td>
<td>X35</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD4 Pacific Orange</td>
<td>S3.5</td>
<td>Life technologies, Carlsbad, USA</td>
</tr>
<tr>
<td>Human CD45RA</td>
<td>4KB5</td>
<td>Dako, Fort Collins, USA</td>
</tr>
<tr>
<td>Human CD45RA APC</td>
<td>HI100</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD45RA PE-Cy7</td>
<td>L48</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD45RO FITC</td>
<td>UCHL1</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD45RO PE</td>
<td>UCHL1</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD49d</td>
<td>9F10</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD62L FITC</td>
<td>HI100</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human CD62L PE</td>
<td>LT-TD180</td>
<td>Exbio, Prague, Czech Republik</td>
</tr>
<tr>
<td>Human CD8 eF450</td>
<td>OKT8</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human CD8 Pacific Blue</td>
<td>B9.11</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human CD8 PE</td>
<td>RPA-T8</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human IFN-γ FITC</td>
<td>45.15</td>
<td>Beckman Coulter, Brea, USA</td>
</tr>
<tr>
<td>Human IFN-γ PE-Cy7</td>
<td>B27</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human IL-2 APC</td>
<td>MQ1-17H12</td>
<td>eBioscience, San Diego, USA</td>
</tr>
<tr>
<td>Human Ki-67 PE</td>
<td>B56</td>
<td>BD Pharmingen, San Diego, USA</td>
</tr>
<tr>
<td>Human TNF-α PE-Cy7</td>
<td>Mab11</td>
<td>eBioscience, San Diego, USA</td>
</tr>
</tbody>
</table>

### 7.1.5 Cells

PBMCs from human blood were obtained from volunteer healthy donors upon written informed consent. Usage of the blood samples was approved according to the national law by the local Institutional Review Board (Ethikkommission der Medizinischen Fakultät der Technischen Universität München).
7.1.6 Software

<table>
<thead>
<tr>
<th>Software</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adobe Illustrator</td>
<td>Adobe Systems, San Jose, USA</td>
</tr>
<tr>
<td>End Note Program</td>
<td>Microsoft, Redmond, USA</td>
</tr>
<tr>
<td>FlowJo</td>
<td>Treestar, Ashland, USA</td>
</tr>
<tr>
<td>Graph Pad Prism</td>
<td>Graph Pad Software, La Jolla, USA</td>
</tr>
<tr>
<td>Microsoft Office</td>
<td>Microsoft, Redmond, USA</td>
</tr>
<tr>
<td>Summit</td>
<td>Dako, Fort Collins, USA</td>
</tr>
</tbody>
</table>

7.2 Methods

7.2.1 Ficoll density centrifugation and determination of cell numbers

Healthy donor blood was diluted 1:1 with sterile PBS. The mix was carefully pipetted on top of 10 mL of Biocoll® Ficoll solution in a 15 mL conical plastic tube for centrifugation at 2000 rpm for 20 min at 22°C. For washing, PBMC layer was harvested and diluted in 45 mL sterile PBS and pelleted by centrifugation at 1500 rpm for 10 min.

The PBMC pellet was re-suspended in 20 mL PBS/0.5%BSA/1mM EDTA for cell counting. Cell counts were determined in a 1:10 dilution with a 0.15% Trypan Blue in PBS solution for live/dead discrimination using a Neubauer counting chamber.

At least two squares were counted: \( \text{count/square} \times 10^5 = \frac{\text{cells}}{\text{ml}} \)

The PBMC suspension was pelleted again at 1500 rpm for 10 min and taken up in 100 µl of PBS/0.5%BSA1mM EDTA per 1x10^7 PBMCs.

7.2.2 Cryopreservation of human lymphocytes and cell lines

Cell numbers were determined using a Neubauer counting chamber in a 1:10 solution of 0.15% Trypan Blue in PBS. Cells and complete freezing medium (FCS/10% DMSO) were cooled to 4 °C before the cells were pelleted by centrifugation at 1500 rpm for 8 min at 4°C. The pelleted cells were taken up in complete freezing medium to a final concentration of 2x10^7 per mL. The suspension was quickly transferred to 1 mL cryopreservation tubes and rested on wet ice. After 30 min, the tubes were frozen in a −80°C freezer. After 48 hrs, the tubes were frozen in liquid nitrogen for long-term storage.

For thawing, the tubes were immersed in a 38°C water bath under gentle agitation for 1 min. After 1 min, the content was quickly diluted in 10 mL of full RPMI medium, centrifuged at 1500 rpm for 8
min and this step was repeated once using fresh RPMI medium. According to the specific experimental requirements, the cells can be rested in supplemented RPMI (T cell medium) at a concentration of 1x10^6 cells per well in a 48-well tissue culture plate overnight.

### 7.2.3 Activation of T lymphocytes

Cells and Dynabeads® Human T-Activator CD3/CD28 Beads were prepared as described in the product directions. 750 000 cells per well were distributed in a 48-well tissue culture plate. 1.5x10^6 T-Activator beads were added to achieve the desired bead-to-cell ratio of 3:1. The plates were stored in the incubator (37°C/95%H₂O/5% CO₂). It is recommended to check the distributed cells and beads under the microscope. To remove the Beads, the content of individual wells was transferred to a tube, placed on a magnet and washed with PBS/5% BSA.

### 7.2.4 In vitro cultivation and expansion of T lymphocytes

First, T lymphocytes were washed and counted or taken from an over-night culture after resting. Autologous (recommended) or non-autologuos feeder PBMCs were thawed and the cell counts were determined. 5x10^6 PBMCs were needed for 1 T_25 tissue culture flask which yields 1-2x10^7 T cells after 14 days of cultivation. The PBMCs were washed in full RPMI and have received irradiation at 35 Gy. Further, 2.5x10^7 B-LCL cells are washed and irradiated at 50 Gy. All irradiated cells are mixed together in human T cell medium and 600 ng of OKT-3 antibody was added to the mix. The mix was topped off with 19 mL of human T cell medium and transferred steriley to a T_25 tissue culture flask. 1 mL of human T cell medium was used to dilute and transfer 50 000 T lymphocytes to the flask. The flasks were stored in the incubator (37°C/95%H₂O/5% CO₂). After 24 hrs, 20 µL of a 50U/µL (in PBS) pre-diluted solution of IL-2 was added to each flask followed by gentle shaking. On day 4 after stimulation, the content of each flask was pelleted and the cells were taken up in 20 mL of fresh T cell medium supplemented with 20 µL of a 50U/µL solution of IL-2. Every 72 hrs after that, a half medium change with supplemented medium was performed and the cells were counted and split if the counts exceeded 1x10^6 cells/mL. The protocol for rapid expansion of T lymphocytes was published by Riddell et al. [159].

### 7.2.5 Fab expression and purification

The wildtype Fab fragments were generated by gene synthesis (GeneArt) based on published sequences of the heavy and light variable regions (V_H and V_L) of the respective mAb clones. Variable
sequences were linked to the constant Fab regions and the heavy chain was fused to a OneSTrEPtag affinity tag (IBA). In a final cloning step, the Fab-Streptag fusion gene sequences were introduced into the Acceptor vector pASG-IBAwt2, adapted for periplasmatic expression of the Fab protein. Combinatorial cloning was performed using the StarGate cloning system, following the manufacturer’s recommendations (IBA). After each cloning step, sequences were verified by Sanger sequencing at the commercial provider GATC using own primers.

For Fab protein expression, the *E.coli* strain JM83 was transformed with the plasmid DNA by electroporation. After growing bacteria to an optical density at 600nm (OD$_{600}$) of 0.5-0.6 in 1L cultures, periplasmatic expression of the Fab-Streptag fusion protein was induced by adding anhydrotetracycline (AHT, 1:10,000) that activated the *tet*-promoter in the final expression vector. After three hours of protein expression, bacteria were harvested by centrifuging at 5000g at 4°C for 12 minutes. Pelleted bacteria can be stored at -80°C.

For extracting the Fab protein from the periplasma, bacteria were resuspended in buffer P and incubated at 4°C for 30 minutes. Extracted proteins were separated from solid components of the bacteria by centrifugation at 15,000rpm at 4°C for 15 minutes. To digest the DNA, the supernatant was incubated with Benzonase (1:2000-1:6000) in the presence of 100µL/10-30mL supernatant of 1M MgCl$_2$ at 4°C for 30 minutes. The digested Fab protein solution was filtered through a sterile 0.2µm filter.

For affinity purification, filtered Fab fragments were applied onto a Strept-Tactin superflo column (IBA) that had been equilibrated with 2.5mL buffer W twice. After washing the Fab proteins on the column with 1mL buffer W 5 times, the Fab fragments were eluted from the column by adding 0.8mL, 1.5mL and 1mL buffer E. Using the middle elution fraction, the buffer E is exchanged for PBS (pH 7.5) by dialysis. The protein concentration was measured at 280nm using a NanoDrop spectrometer. Additionally, the size, quantity and purity of Fab fragments were examined by using the Agilent 2100 Bioanalyzer system.

### 7.2.6 T lymphocyte-mediated kill assay (Chromium release assay)

96-well tissue culture plates were set up and run in triplicates with controls for minimum and maximum release. To determine cytolytic activity $10^4$3 target cells were labeled with $^{51}$Cr for 90 min. Excess $^{51}$Cr was removed from the supernatant by centrifugation (2washes). Co-cultures with $^{51}$Cr-labeled target cells and effectot T cells were set up and incubated for 4h at different effector/target ratios (E/T ratios). Spontaneous release was determined using target cells incubated alone and maximum release was determined by direct lysis of target cells using the detergent Triton-X. After incubation, 30 µL of the supernatant was transferred to solid scintillator-coated lumaplates and dried over night before analysis. The specific lysis was calculated as follows: % specific cytotoxicity =
[mean sample release (cpm) - mean spontaneous release (cpm)]/[mean maximal release (cpm) - mean spontaneous release (cpm)] × 100.

7.2.7 Antibody and Strep-tamer staining with subsequent FACS analysis

For phenotypic characterization of cells, a master mix of the respective monoclonal antibody-conjugates was prepared, and was added to the cell samples. During the labeling cells were kept on ice, in the dark for 20 min. Strep-tamer staining was conducted in the same way. After the incubation period, cells were centrifuged in a 96-well tissue culture plate and underwent two additional washes. All samples were analyzed with a CyanLx 9 color flow cytometer.

7.2.8 MACS sorting

MACS cell isolation was performed on Miltenyi LS-columns according to the manufacturers recommendations. In brief, paramagnetic beads-based Strep-tamers were co-incubated with freshly isolated cells for 20 min at 4°C. Cell suspension was washed once and centrifuged at 300g. MACS columns were placed on a magnet and were equilibrated with buffer (PBS/0.5% BSA/1mM EDTA). The Strep-tamer-labeled cells were transferred to the column and washed three times. Positive cells were eluted by displacement of the column from the magnet. Cells were eluted off the column under pressure.

7.2.9 Magnetic microbead sorting

Fab-Strep-tamers were prepared first by co-incubation of Fab fusion proteins with Strep-Tactin-coated magnetic microbeads. For 1x10^8 cells, 20 µg Fab was thawed and diluted in 250 µL PBS/0.5%BSA/1mM EDTA. Dilution ensures a more equal distribution of Fabs on the backbone. Diluted Fabs were mixed with 300 µL microbead suspension (pre-diluted 1:1 with 150 µL buffer). Up to 5x10^8 cells were placed in a 50 ml sort tube and the volume was adjusted to 1mL per 1x10^8 cells. The prepared reagent was added after at least 45 min pre-incubation and the mix was incubated rolling at 4°C for 30 min. Tubes were filled up to approx. 10 ml per 1x10^8 cells and placed on the magnet for at least 1 min. The supernatant was taken with a serological 10 ml pipette and collected in a 50 ml Falcon tube. Washing was repeated 4 more times. Pellets were re-suspended in 5 ml FACS buffer containing 0.1 or 1 mM D-biotin and re-suspended well, then incubated for 10 min on ice. Beads were separated from the suspension on the magnet. After 1 minute, the supernatant containing the positive cell fraction was collected in a fresh tube. The step was repeated one more time to flush any remaining cells off the magnetic beads. Cells are re-suspended in buffer without D-biotin and washed two
additional times. The positive fraction was spun down at 1500 rpm for 8 min at 4°C and the supernatant is taken off with a pump. The pellet is re-suspended pellet in the desired volume and washed on the magnet to get rid of remaining beads. The supernatant is collected and washed. It can then be used for additional selection steps.
8. Acknowledgements

This thesis work was made possible in the first place with the strong and dedicated support from Prof. Dirk Busch and Prof. Stan Riddell who gave me the exceptional opportunity to work in close collaboration in an ambitious and nourishing environment. They also granted me the opportunity to gather professional and personal experience during my most memorable stay in Prof. Riddell’s lab in Seattle where valuable and exciting insights awaited me every day. I wish to thank Prof. Busch for his continuous help for over four years and his invaluable advice. He is a devoted supervisor to whom I owe great gratitude for the countless hours of excellent teaching and the critical revision of this thesis. I’d like to thank Prof. Riddell for his enduring devotion to the project, helpful assistance, revision of the manuscript, and the many visits, meetings and almost weekly video conference calls. At all times I enjoyed his committed supervision. He provided me with answers and gave me a wider perspective on the field of my research.

The TUM Institute of advanced study is acknowledged for supporting all collaborative activities at the best.

Prof. Michael Groll deserves my gratitude for his active participation in my thesis committee and for inspiring and motivating discussions.

I want to thank my collaboration partners from IBA GmbH and Stage cell therapeutics, particularly Dr. Lothar Germeroth and Dr. Herbert Stadler for their wonderful cooperation.

A very big thank you to Dr. Christian Stemberger and Dr. Stefan Dreher for always providing me with knowledgeable advice and for the reliable support with my project. Their assistance made an essential contribution to this work.

Special thanks to Dr. Michael Hudecek for his excellent mentoring qualities and his ongoing enthusiasm. He was a great supervisor in Seattle and a good friend ever since.

Thank you, Paulina Paszkiewicz for being by my side as my colleague and friend for the past four years and for the future. Your company made many days worthwhile.

Another big thank you to Dr. Georg Dössinger whom I distracted from work with many questions related to science and beyond. Thank you for all the open-minded discussions and patience as a good friend.

I’d like to thank Claudia Tschulik, Sabine Przbilla, and Kirsten Weiß who were closely involved in experiments and helpful discussions. Thank you for your cordial cooperation.

Bianca Weißbrich, Patricia Gräf, and Fabian Mohr have contributed to this work with many insightful discussions and by keeping me company and providing me with crucial distractions. All other members of ‘Troger 30’ are acknowledged for their helpfulness and company. Thank you for a wonderful time.
I could never forget Paula Kosasih and all the other great people from the FHCRC in Seattle who taught me so much and whom I miss deeply.

Many thanks go to my lectors Dr. Georg Dössinger, Dr. Christian Stemberger, and Katrin Molter for their infinite support.

My infinite love to all my friends to whom I owe my greatest gratitude for their time and moral support at crazy times. Sabine Neumeier, Christina Daschkin, Ines Vogler, Katrin Molter, and Daniel Wiegand, you are the best friends I could wish for.

I am extremely grateful for the sublime friendship with Tobias Göpel and Alex Scherer. Words are not enough to express my feelings for you.

Finally, my dear family was unexceptionally supportive of me throughout my life. At this point I want to thank my grandparents for their loving support and for understanding my needs.

Infinite thanks to my parents for the strongest support I could possibly receive. I have spent the best times with you. Your unconditional love and encouragement are never taken for granted.

Thank You!
9. Bibliographie


[143] Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA and Restifo NP. Determinants of


